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Abstract  
Magnetic nanocarriers have attracted increasing attention for multimodal cancer therapy 
due to the possibility to deliver heat and drugs locally. The enhancement of the anti-cancer 
effect of chemotherapy with application of concurrent hyperthermia has been noticed more 
than thirty years ago. However, combining magnetic nanoparticles with drug molecules in 
the same nanoformulation has only recently emerged as a promising tool for the 
simultaneous application of hyperthermia and chemotherapy. 
 
In this work, initial experimentation was primarily focused on the synthesis of magnetic 
nanoparticles of high saturation magnetisation to develop efficient mediators of heat based 
on an iron core and a bismuth shell. However, such nanoparticles could not be obtained 
due to the impossibility to grow the bismuth shell on the iron nanoparticle surface. The rest 
of this study reports the development of a novel magnetic nanocomposites (MNCs) made 
of an iron oxide core and a pH- and thermo-responsive polymer shell, that can be used as 
both mediators of heat and drug carriers. The conjugation of the anticancer drug 
doxorubicin to the thermo-responsive MNCs via acid-cleavable imine linkers provides 
advanced features for the targeted delivery of doxorubicin via the combination of magnetic 
targeting, and dual pH- and thermo-responsive behaviour, which offers spatial and 
temporal control over the release of the drug. The nanoparticles exhibit a 
superparamagnetic behaviour with a saturation magnetization around 78 emu/g and good 
heating properties in an alternating magnetic field. Almost a complete doxorubicin release 
was obtained under acidic tumour pH and hyperthermia conditions. Finally, in vitro studies 
on human glioma and breast cancer cell lines and on a murine prostate carcinoma cell line 
confirmed that thermo-chemotherapy applied via the developed smart delivery system 
exhibits a substantial increase in cytotoxicity as compared to standalone therapies, and 
almost complete cell death was observed while applying low thermal and 
chemotherapeutic doses. 
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1.1 Magnetic nanoparticles in biomedical applications 
Nanoparticles (NPs) are defined as particles that have one or more physical dimensions 
under 100 nm. Their size is a significant advantage for their use as sub-cellular size probes 
to study biological processes at nanoscale as cells in living animals are usually between 1 
to 30 µm in diameter and cells parts and organelles are much smaller in the sub-micron 
range. This has strongly driven the development of nanotechnology into the fields of 
biology and medicine. Due to their small size, and particularly due to the increasing 
surface-to-volume ratio, the properties of a nano-sized material will differ from the ones of 
the bulk material (i.e. optic, electric, magnetic and electronic properties). Thanks to their 
inherent properties, magnetic nanoparticles (MNPs) have been developed as magnetic 
resonance imaging (MRI) contrast agents,1,2 and potential new cancer therapies such as 
magnetic fluid hyperthermia,3,4 and nanovectors for controlled drug delivery.5,6 The 
possibility to manipulate the MNPs with an external magnetic field is a significant 
advantage to target and concentrate the NPs in specific parts of the body. Recently, 
research has been leaning towards the design of MNPs that can combine several 
therapeutic functions (hyperthermia and drug delivery),7,8 or therapeutic and diagnostic 
functions (so called theranostics).9,10 Scientists have been attempting to understand the 
structure and properties relationship of NPs to harness their properties.11,12 Indeed, 
controlling the composition, size and shape of the NPs via syntheses would allow tailoring 
and tuning the desired properties.13-16 
 
Among MNPs, iron oxide are the most commonly used NPs and, have attracted great 
interest for their applications in biomedicine due to their numerous advantages.17 Indeed, 
iron oxide NPs are relatively easy to synthesize, biocompatible, non-toxic, chemically 
rather stable and superparamagnetic below a certain size (around 27 nm).18 Some iron 
oxide nanoformulations have already been approved by the US Food and Drug 
Administration (FDA). The two main forms of iron oxide are ɣ-Fe2O3 (maghemite) and 
Fe3O4 (magnetite).  
 
The main feature of this chapter is to present the recent advances in the development of 
multifunctional therapeutic nanosystems incorporating both magnetic nanoparticles and 
drugs, and their superior efficacy in treating cancer compared to either hyperthermia or 
chemotherapy as standalone therapies. The principle of magnetic fluid hyperthermia is 
also presented, along with a study of the different parameters influencing the heating 
performances of the nanoparticles. 
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1.2 Magnetic nanoparticles for hyperthermia therapy 
1.2.1 Introduction to hyperthermia 
The concept of hyperthermia was already in practice many centuries ago by Greeks, 
Egyptians and Romans to treat certain conditions including breast masses.19,20 In 3000 
BC, Indians medical practitioners used local and whole body hyperthermia. During the 19th 
century, it was observed that fever can cause tumour regression,20 and scientific study 
was performed on hyperthermia to treat cervical cancer.19 The use of hyperthermia as a 
treatment for cancer was taken more seriously in the 1970’s, and controlled clinical trials 
on induced hyperthermia began to be conducted. It was then discovered that cancer cells 
have a greater sensitivity to hyperthermia as compared to normal cells. Indeed, healthy 
tissues are able to withstand temperatures of 42 – 45 °C, in contrast to cancer cells which 
undergo apoptosis at those temperatures.21,22 Treatment at temperatures above 46 °C is 
called thermo-ablation. It leads to the necrosis of cancer cells, but may also affect healthy 
cells. Apoptosis, also called programmed cell death, is a distinct mode of cell death, 
whereby the cells in normal tissues triggered their self-destruction in response to a signal.23 
Contrary to the necrosis, there is no associated inflammation. Apoptosis also occurs 
spontaneously in cancer cells, thereby retarding the growth of the tumour, and can be 
increased when subjected to heat, irradiation or anti-cancer drugs. In contrast to apoptosis 
that is a natural process, necrosis is a form of cellular damage that results in the premature 
death of cells in body tissues and initiates an inflammatory response in the surrounding 
environment.24,25 It is almost always harmful and can even be deadly (i.e. can lead to 
septicaemia or gangrene). Thus, thermoablation in this temperature range is not desirable 
due to the potentially important side effects on healthy tissues, and hyperthermia induced 
apoptosis is preferable. 
 
While the specific mechanism of cell killing by hyperthermia is still unknown, the thermal 
energy needed for induction of cell death has been found to be close to the energy needed 
for protein denaturation, leading to the conclusion that the main cytotoxic effect of 
hyperthermia is based on the denaturation of membrane and cytoplasmatic proteins.26,27 
Membrane alteration and cytoskeletal damage such as cell rounding and blebbing, a 
typical feature of apoptosis, are some of the most apparent manifestations of thermal 
damage at the cellular level. Another important consequence of protein denaturation is the 
alteration of DNA synthesis and repair. A higher sensitivity to heat has been observed for 
cells in the mitosis phase (with damage to the mitotic apparatus),26,27 which makes cancer 
cells more susceptible to heat than normal cells as they undergo faster cell division. The 
tumour selective effect of hyperthermia is also due to the physiological differences 
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between normal and tumour tissues. Indeed, the architecture of the vasculature in tumour 
is disorganised and abnormal compared to normal tissue, one of the principal features 
being the lower vessel density (Figure 1.1).  
 
 
Figure 1. 1 Schematic representation of a normal and a tumour vasculature. Figure taken 
and modified from ref. 28.28 
 
In many cases, tumour blood flow remains greater than in the surrounding healthy tissues, 
especially in small tumours (tumour blood flow generally decreases with increasing tumour 
size).29 However, when hyperthermia is applied at temperatures over 42 °C, tumour blood 
flow tends to decrease, while in normal tissue it significantly increases. This decreased 
blood flow results in a lower heat dissipation rate, hence the temperature in a tumour will 
rise faster than in normal tissue.29,30 This difficulty in dissipating heat may cause cancer 
cells to undergo apoptosis, while normal cells are more easily maintained at physiological 
temperature.31 The disorganised structure of tumour vasculature also leads to oxygen and 
nutrient deprivation,32 and reduction of the blood flow caused by heat exposure favours 
even more regions of hypoxia, energy deprivation and acidosis.26,33 These tumour 
microenvironmental factors also make cancer cells more sensitive to hyperthermia,34 in 
addition to its direct cytotoxicity. 
 
In fact, hyperthermia may increase or decrease the tumour oxygenation depending on the 
temperature and the exposure time.35 Hyperthermia applied at temperatures lower than 
42 °C is more likely to provoke an increase in the tumour blood flow, thereby improving 
the oxygen supply. This phenomenon can be exploited to make cells more sensitive to 
radiotherapy (radiosensitivity is favored by good tissue oxygenation) or chemotherapy 
(drug delivery is increased by higher perfusion).26,36 The synergistic effect of hyperthermia 
with radiotherapy has been demonstrated in various clinical trials,37,38 and shows a better 
efficacy than either hyperthermia39 or radiotherapy alone.40 This synergism induces an 
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increase in cell death even at temperatures lower than temperatures normally applied in 
hyperthermia therapy. This thermal radiosensitisation is explained by the increased in 
blood flow, and by the fact that S-phase cells (cells undergoing DNA replication) and 
hypoxic cells (cells that survive the hypoxia and acidic environment of tumour), normally 
resistant to radiation, are highly sensitive to heat destruction.26,41,42 The synergistic effect 
of hyperthermia with chemotherapy has also been demonstrated in clinical trials.43-45 The 
increase in blood flow provoked by a heat treatment results in an increase in drug 
concentration in the tumour area, an increase intracellular drug uptake and enhanced DNA 
damage.42 Moreover, heat has been found to enhance the cytotoxic effect of many anti-
neoplastic drugs.46 Consequently, hyperthermia is often used as an adjuvant therapy with 
radio- and/or chemotherapy.36 
 
A wide range of heat sources and treatments for hyperthermia are being developed for 
clinical applications. There are three main types of hyperthermia: local hyperthermia, 
regional hyperthermia and whole-body hyperthermia. The hyperthermia technique is 
chosen depending on the location, the depth and staging of the malignancy. In whole-body 
hyperthermia, the entire body is heated up. This method is often chosen in the case of 
deep-seated and propagated metastases. The heating can be achieved through hot water 
baths, thermal chambers or infra-red radiators.47 However, as may be expected, this 
treatment may lead to major side effects given the fact that the heat is not selective. 
Therefore, careful control of the temperatures is needed. Even if temperatures of 41.8 - 
42 °C can be achieved, and the method is clinically realisable, the medical care needed to 
ensure a safe procedure in the case of whole-body hyperthermia is much greater than in 
local or regional therapy.36 This has resulted in its limited use as a standalone procedure. 
Regional hyperthermia is used to deliver heat to advanced stage tumours. Thermal 
perfusion, external applicator or arrays of multiple applicators (microwave antennas) are 
example of devices used in regional hyperthermia.47,48 Local hyperthermia is often used to 
treat localised tumours either superficially or in accessible body cavities. It is the less 
invasive technique. Local hyperthermia systems are based on applicators or antennas 
emitting mostly microwaves, ultrasounds or radio waves.47,49 Recently, a new technology 
has been developed for local hyperthermia using MNPs as mediator of heat. This 
technology is called Magnetic Fluid Hyperthermia (MFH).  
 
1.2.2 The different types of magnetism 
Magnetism is a physical phenomenon in which attractive or repulsive forces are exerted 
by an object on other objects. All materials display to some extent a magnetic behavior, 
which means they are influenced by an external magnetic field. We can distinguish two 
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different contributions to the magnetic moment of an atom: the movement of electrons 
which orbit around the nucleus, known as the orbital magnetic moment, and the spin of 
electrons which gives an intrinsic magnetic moment, called spin magnetic moment. 
Therefore, the magnetic behavior of a material strongly depends on its electronic 
configuration. In fact, the magnetic moments of atoms or ions arise from their valence 
electrons. The filled electronic shells do not contribute to the magnetic moment because 
of their zero net orbital motion and because electrons are combined into pairs, the electron 
spins offset two by two (opposite intrinsic magnetic moments). There are five types of 
magnetism behavior: diamagnetism, paramagnetism, ferromagnetism, ferrimagnetism 
and anti-ferromagnetism.  
 
Diamagnetism is a general property of atomic matter and originates from bound electrons. 
A diamagnetic material does not possess a permanent magnetic moment, but an induced 
magnetic moment which opposes the applied magnetic field. Paramagnetism is due to the 
presence of unpaired electrons. Every atom of a paramagnet has a magnetic moment. 
Because of thermal motion, those moments are randomly oriented, and therefore the 
average magnetization is equal to zero in the absence of any magnetic field. However, 
when an external magnetic field is applied, the moments of all the atoms tend to align 
themselves in the same direction as the applied field, thus amplifying it. If the temperature 
is too high, it is difficult to reach the saturation magnetization (due to the growing thermal 
motion). Paramagnetic materials do not retain any magnetization, which means the total 
magnetization drops back to zero when the external magnetic field is removed. 
Ferromagnetism is the property of certain material to become highly magnetized under the 
action of an external magnetic field, and even retain a magnetization after the removal of 
the applied field. A ferromagnet is formed of magnetic domains, known as Weiss domains, 
in which the moments of atoms are all parallel to each other to maintain a lowered-energy 
state. In the absence of any external magnetic field, the total magnetization of a 
ferromagnet is zero. However, when an external magnetic field is applied, the magnetic 
domains tend to align themselves in the same direction as the applied field. The saturation 
magnetization is reached as soon as each moment of each domain is aligned toward this 
direction. When the applied field is removed, the magnetization does not revert back to 
zero, this is the remanent magnetization. In order to reduce the magnetization to zero 
again, a magnetic field with a precise intensity needs to be applied, and is called coercivity 
(or coercive field). The magnetization curve of a ferromagnet is represented by a 
hysteresis loop. An antiferromagnet is also formed of magnetic domains, but the 
permanent magnetic moments are antiparallel per domain. Thus, the magnetization is non-
existent in the absence of an external magnetic field, and a very strong magnetic field 
would be required to align every moment in the same direction due to strong exchange 
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interactions between the magnetic moments. Therefore, the magnetization curve of an 
antiferromagnet is a straight line with a slightly positive slope. A ferrimagnet is formed of 
magnetic domains with opposing magnetic moments, but the opposing moments have 
different amplitude. Thus, a spontaneous magnetization remains, as in the case of a 
ferromagnet, and the magnetization curve of a ferrimagnet is represented by a hysteresis 
loop. It is often difficult to tell the difference between a ferromagnetic and a ferrimagnetic 
material depending only on its magnetization curve. Ferro- ferri- and antiferromagnetic 
materials all become paramagnetic above a certain temperature due to thermal motion. 
 
1.2.3 Superparamagnetism 
Superparamagnetism is a form of magnetism that occurs in ferromagnetic or ferrimagnetic 
materials, when they are in the form of sufficiently small NPs. Bulk materials basically 
contain multiple magnetic domains due to their large size. However, below a critical size 
that is dependent upon the nature of the materials itself, small enough NPs becomes 
single-domain particles, which can be regarded as one giant magnetic moment composed 
of all the magnetic moments of the atoms forming the NP. Superparamagnetic NPs are 
preferred over ferri- and ferromagnetic NPs for biomedical applications, because they do 
not retain any magnetisation once the magnetic field is removed (Figure 1.2). 
 
 
Figure 1. 2 Typical curve for a superparamagnetic material. Squares show the orientation 
of the moment of single-domain nanoparticles with increasing field strength. 
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Often, the magnetization aligns along one preferred direction, but the magnetization can 
randomly flip direction under the influence of temperature. The average time to perform 
such a flip is called the Néel relaxation time τN and is given by the following equation:50 
 
 
𝜏𝑁 = 𝜏0𝑒
(
𝐾𝑉
𝑘𝐵𝑇
)
 (1.1) 
 
τ0 is a length of time characteristic of the material. Its typical values are of a magnitude of 
10-9 to 10-10 s. kB is the Boltzmann constant, T the temperature, K the magnetic anisotropy 
energy density of the nanoparticle and V the volume of the nanoparticle. Thus, KV is the 
energy barrier the magnetization flip has to overcome by thermal energy. 
 
In the absence of external magnetic field, depending on the timescale of the experiment τ 
used to measure the magnetization, the state of the nanoparticles can be identified: if τ 
>>τN, the measurement time is much longer than the average time between two flips. This 
means that a fluctuation state is observed, with different magnetization directions, and 
therefore, the magnetization appears to be in average zero. The nanoparticles are in a 
superparamagnetic state. In this state, an external magnetic field is able to magnetize the 
nanoparticles, in the same way to a paramagnet. However, their magnetic susceptibility is 
much larger than the one of paramagnetic materials. If τ <<τN, the Néel relaxation time is 
much longer than the measurement time. This suggests the nanoparticles are in a well-
defined state, the magnetisation appears static because the measured magnetization will 
be the same as the one at the beginning of the measurement. The system is in a blocked 
state. The transition between the superparamagnetic state and the blocked state occurs 
when τ = τN. The temperature for which τ = τN is called the blocking temperature TB, which 
is dependent upon the size and the composition of the nanoparticles.51 
 
1.2.4 Magnetic hyperthermia: mechanism of heat generation 
1.2.4.1 AC hysteresis losses 
The conversion from magnetic energy to thermal energy in MNPs submitted to an AC 
magnetic field can be due to several mechanisms.  
 
In multi-domains NPs (ferri- or ferromagnetic material), the production of heat is due to 
hysteresis losses, which can be seen as the amount of energy dissipated during a 
magnetisation cycle.52,53 The magnetisation curve of a ferromagnet is represented by a 
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hysteresis loop (Figure 1.3) and the hysteresis losses can be measured by integrating the 
area of the hysteresis loop. 
 
Figure 1. 3 Hysteresis loop of a ferromagnet (squares show domain wall displacement with 
increasing field strength). The area of the hysteresis loop represents the energy dissipated 
during a magnetisation cycle. 
 
1.2.4.2 Relaxation losses 
Single-domain NPs dissipate heat through relaxation losses which fall in two modes: Néel 
relaxation and Brownian relaxation. The mechanism of relaxation depends on the size of 
the NPs but also on the nature of the magnetic material mainly because of its anisotropy 
constant.54 Néel relaxation comes from the reorientation of the magnetic moment in the 
same direction as the applied magnetic field with each field oscillation.55,56 The Néel 
relaxation time τN is given by the equation 1.1: 
 
 
𝜏𝑁 =  𝜏0exp (
𝐾𝑉
𝑘𝐵𝑇
) (1.1) 
 
Néel relaxation is strongly size-dependent. A smaller particle requiring less energy for the 
rotation of its magnetic moment, the Néel relaxation mechanism will be very important.   
 
Brownian relaxation is caused by the friction arising from the rotation of the particle itself 
in the carrier liquid.55,56 The Brownian relaxation time τB is expressed by the following 
equation: 
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𝜏𝐵 =  
3𝜂𝑉𝐻
𝑘𝐵𝑇
 (1.2) 
 
Where η is the viscosity of the liquid carrier, VH the hydrodynamic volume of the particle, 
kB the Boltzmann constant and T the temperature. The Brownian relaxation mechanism is 
size-dependent too and also strongly viscosity-dependent.57 A higher viscosity of the liquid 
medium will slow down the rotation of the particles. Néel and Brownian relaxation 
mechanisms are represented in Figure 1.4. 
 
 
Figure 1. 4 Schematic representation of the Néel versus Brownian relaxation. Néel 
relaxation: the magnetic moment rotates within each particle. Brownian relaxation: the particle 
rotates as a whole. 
 
Generally, losses by Néel relaxation prevails in small NPs while the Brownian regime 
dominates in larger NPs.55,58 In fact, the Brownian losses are not exclusively found in 
superparamagnetic NPs.52 For hyperthermia applications, it is better to have MNPs 
relaxing essentially through Néel mechanism, because when internalised in the cells, a 
change in the viscosity medium can happen and/or free rotation of the particles can be 
prevented. 
 
A combination of the two magnetic relaxation times gives the overall effective relaxation 
time τ of the particles55:  
 
𝜏 =  
𝜏𝐵𝜏𝑁
𝜏𝐵 + 𝜏𝑁
 (1.2) 
 
1.2.4.3 Quantification of heat losses 
Application of an AMF oscillating faster than the relaxation time of the MNPs induces the 
release of heat from the MNPs caused by the delay in the relaxation of the magnetic 
moment.55 The heat dissipation P is given by the following equation59: 
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 𝑃 =  µ0𝜒
"𝑓𝐻² (1.3) 
 
Where P is the heat dissipation value, µ0 is the permeability of free space, χ″ is the AC 
magnetic susceptibility (imaginary part), f is the frequency of the applied AC magnetic field, 
and H is the strength of the applied AC magnetic field. 
 
Quantification of the power dissipation of magnetic nanoparticles in an AMF is usually done 
by measuring the specific absorption rate (SAR) expressed in W/g (also referred to as 
specific loss power)55: 
 
𝑆𝐴𝑅 = 𝐶
𝛥𝑇
𝛥𝑡
 (1.4) 
 
Where C is the specific heat capacity of the sample and ΔT/Δt is the initial slope of the 
time-dependent heating curve. SAR highly depends on various parameters such as the 
size, size distribution, shape, chemical composition and surface modification, saturation 
magnetisation of the particles, frequency and amplitude of the applied magnetic field. A 
high heating potential is crucial for the clinical use of MFH, because it would require a 
smaller amount of NPs to be injected to the patient. Therefore, engineering MNPs (control 
their physical and chemical properties using synthesis) to obtain high SAR values is highly 
desirable.60-63 For example, most ferri- and ferromagnetic materials require application of 
a high magnetic field to use a full loop area, which is not realisable clinically due to 
physiological and technical restrictions. On the other hand, superparamagnetic NPs 
producing heat via Néel and Brownian relaxation mechanisms are able to generate a much 
larger quantity of heat and thus a higher SAR at lower field amplitudes. Hergt et al. 
suggested that the optimum size to get particles with a high SAR value is near the transition 
from superparamagnetic to ferromagnetic behaviour.64 Considering the equation of the 
heat dissipation value, it is clear that SAR values increase with the frequency f and the 
amplitude H of the applied field. However, to apply hyperthermia safely to patients and 
avoid any detrimental effect on healthy tissues due to electromagnetic radiation exposure, 
the Hf factor should not exceed a threshold which was experimentally estimated to equal 
5 x 109 Am-1s-1.65 
 
The comparison between SAR values obtained by different research groups can be 
challenging. Indeed, there is a lack of standardised protocol to measure the heating ability 
of the MNPs. The ideal for accurate measurement of the SAR would be an adiabatic setup, 
but because it is expensive and time-consuming, most research groups use non-adiabatic 
and often home-made setups which results in more sources of inaccuracies and increase 
variability of the SAR values.66-68 Moreover, there is no standard for the frequency and 
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amplitude of the applied field to be used during an experiment and research groups 
measure nanoparticles heating capabilities under different field conditions. Because the 
SAR value for a given sample is not an intrinsic property of the system as it is strongly 
dependant on the amplitude and frequency of the field used, comparison of SAR values 
between different systems is almost impossible. Pankhurst et al. introduced a parameter 
allowing direct comparison of the heating efficiency of superparamagnetic nanoparticles, 
the intrinsic loss power (ILP).4 The ILP is obtained by normalizing the SAR by the 
frequency and field amplitude, and is therefore independent of the magnetic field 
parameters: 
 
𝐼𝐿𝑃 =
𝑆𝐴𝑅
𝐻²𝑓
 (1.5) 
 
1.2.5 Nanoparticle delivery to the tumour 
MNPs must be delivered in a secure pathway specifically to the cancer site and should be 
retained in the tumour in order to avoid side effects and reach a sufficient concentration 
for an effective therapy whether it is for magnetic hyperthermia or for drug delivery. Three 
main approaches for the delivery of NPs can be distinguished: direct injection, systemic 
passive and active delivery. 
 
The direct injection method consists of injecting directly the magnetic fluid into the tumour. 
The intratumoural injection is the simplest way to administer the NPs. It is the most 
commonly found in in vivo studies69,70 and has even already been used in clinical trials of 
MFH.38,71 The main advantage of this technique is the ease to achieve a high and localised 
concentration of MNPs in the tumour. However, the intratumoural injection of MNPs is only 
possible in localised and superficial or easily accessible tumour, thus this approach is 
limited in the investigation of many cancers, and particularly advanced stage cancers. 
Moreover, direct injection results in a non-homogeneous MNPs distribution in the tumour, 
which makes the complete regression of the tumour difficult.72 
 
Systemic delivery is achieved by injecting MNPs intravenously that will accumulate 
preferentially in tumour tissue due to the enhanced permeability and retention (EPR) 
effect.73,74 The EPR effect was first reported by Matsumura and Maeda in 1986,75 and was 
further investigated and described in a greater extent by Maeda et al.76-81 The EPR effect 
rests on the facts that solid tumours exhibit a defective vascular architecture and that 
lymphatic clearance from the interstitium of tumour tissue is impaired. The first results in 
an enhanced vascular permeability which facilitates nutrients and oxygen supply to satisfy 
the demand of growing tumours, while the second results in the retention of 
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macromolecules in the tumour. Therefore, solid tumours possess a leaky vasculature 
compared to normal tissues, which facilitates the extravasation of NPs. Consequently, 
when NPs are injected intravenously, they can leak out of the blood vessel to deposit in 
the tumour, and are retained here for a long time due to impaired lymphatic drainage 
(Figure 1.5).  
 
Figure 1. 5 Passive targeting and EPR effect. Nanoparticles extravasate through vascular 
fenestrations of tumours and are retained there due to poor lymphatic drainage.82 
 
MNPs can also be injected in the artery supplying the blood stream to the targeted organ 
in order to improve the deposition of MNPs in the tumour. To take advantage of the EPR 
effect, the MNPs should be able to circulate long enough in the blood stream. For this 
purpose, NPs should have a hydrodynamic diameter smaller than 200 nm to avoid liver 
and spleen clearance18 and bigger than 5 nm to avoid renal clearance.83,84 The coating of 
the NPs plays an important role in the permeability and retention of the NPs in cancer cells, 
as well as in the blood retention time of the NPs. Ideally, NPs should be furtive to not be 
cleared by the reticulo-endothelial system. In a recent study, SPIONs were coated with 
two different polymers for MRI applications: alkali-treated dextran (ATD) and 
carboxymethyl dextran (CMD).85 A much higher labeling of the macrophages was obtained 
with the ADT-coated NPs. After 4 h, ADT-coated NPs exhibited a labeling efficiency 
superior to 95% (against only 20-30% for the CMD-coated NP) as a result those NPs would 
be rapidly cleared by macrophages in the reticulo-endothelial system. Protein adsorption 
onto the surface of NPs may accelerate the clearance by the reticulo-endothelial system86 
and affect the bio-reactivity of the NPs.87 A good coating can prevent or at least minimize 
proteins attachment onto the surface of NPs. An appropriate coating should also confer 
good colloidal stability of the nanoparticles in a biological medium, to avoid aggregation 
and conserve the hydrodynamic size that ensures them a long blood circulation time. The 
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passive delivery of NPs via the EPR effect results in a more global distribution of the MNPs 
in the tumour compared to an intratumoural injection and allows for the treatment of most 
type of cancers. However, the principal disadvantage of this method is the difficulty to 
reach a concentration of NPs sufficient enough for an effective treatment, yet the amount 
of NPs injected cannot always be further increased to avoid a non-negligible MNPs toxicity. 
In order to achieve higher deposition and improve tumour uptake of the NPs, they can be 
driven magnetically inside the body via an external magnet and/or can be functionalised 
with a targeting ligand for active delivery. 
 
Active delivery consists of improving the specificity of NPs by functionalising their surface 
with a targeting moiety that binds to cell receptors. It usually results in a higher NPs 
accumulation and cellular uptake in the targeted cancer cells. Among the most commonly 
used targeting agents, we can find antibodies,88,89 antibody fragments,90,91 receptor 
ligands,92,93 peptides94,95 and aptamers.96,97 The superiority of targeted MNPs in cancer 
treatments has already been proven many times. For example, in a recent study,98 iron 
oxide NPs were coated with dextran and functionalised with an anti-human epidermal 
growth factor receptor (HER2) aptamer for targeted hyperthermia. Results showed that a 
90-fold lower dose of the aptamer-functionalised NPs was necessary to produce a 60% 
decrease in the HER2-overexpressing cell viability compared to the non-tagged NPs. 
Another targeting system that can be used to improve the accumulation of MNPs into a 
tumour is the magnetic targeting, also called magnetophoresis. This technique used an 
external static magnetic field placed near the tumour to magnetically attract the NPs toward 
this area and has already shown efficacy in in vivo studies.99,100 
 
1.2.6 Magnetic nanoparticles for hyperthermia therapy 
Numerous materials have been investigated for their potential use in magnetic 
hyperthermia, such as Fe, Co, Ni metallic NPs and their oxide. Pure metals have the 
highest saturation magnetisation, but have limited use in biomedical applications due to 
their inherent toxicity and poor chemical stability (mainly their quick oxidation process). 
Research into metal ferrites has shown good chemical stability, SAR values and magnetic 
properties, making a new class of potential candidates for magnetic hyperthermia.60 The 
effects of Co or Zn dopant in metal ferrites NPs have also been investigated, showing 
improved SAR. 15 nm (Zn0.4Mn0.6)Fe2O4 NPs synthesised by thermal decomposition 
exhibited an increased anisotropy and a saturation magnetisation of 175 emu/g resulting 
in a SAR value almost four times higher than that of Feridex NPs, a FDA approved iron 
oxide nanoparticles.101 Despite the superior magnetic properties of metallic NPs, iron oxide 
NPs are still the most studied magnetic material for hyperthermia applications, due to their 
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low toxicity, good biocompatibility, ease of synthesis and surface functionalisation. The 
most used synthetic routes to make iron oxide NPs are the thermal decomposition of 
organometallic iron precursor and the co-precipitation of Fe2+ and Fe3+ aqueous salt in the 
presence of a base. Many good papers reviewing the different methods for the synthesis 
of MNPs for biomedical applications, the main parameters influencing the MNP properties 
(precursors, time and temperature of the reaction, solvent, ligand, etc) as well as MNP 
surface functionalisation can be found in the litterature.17,102-105 
 
A number of MNP properties influence their hyperthermia potential such as the 
composition, shape, coating, magnetic properties, size and size distribution. Some recent 
studies have been carried out to investigate the influence of these properties on the 
magnetic hyperthermia treatment effectiveness, and Kolhatkar et al. reviewed parameters 
that can be varied to tune the magnetic properties of NPs.106 Carrey et al. recently 
published a method to identify suitable materials for hyperthermia.107 A new approach for 
the exact calculation of the hysteresis loop is presented and models for the calculation of 
the optimum parameters of MNPs for magnetic hyperthermia, such as the optimum 
anisotropy, are provided. 
 
1.2.6.1 Influence of the size and size distribution 
Sedlacik et al. synthesised magnetite NPs by a microwave irradiation-assisted 
solvothermal method, using different nucleating agent (ammonium acetate, ammonium 
carbonate and aqueous ammonia).108 The highest saturation magnetisation was obtained 
for magnetite NPs nucleated with aqueous ammonia due to a pure cubic Fe3O4 spinel 
phase and absence of non-magnetic impurities. The lower saturation magnetisation 
obtained for the two other NPs was attributed to the presence of coexisting phases with 
different magnetic properties, such as goethite. The highest SAR value was also obtained 
for the NPs nucleated with aqueous ammonia, most likely caused by their higher saturation 
magnetisation, their smaller size and narrow size distribution compared to the particles 
obtained with the other nucleating agents. Gonzales-Weimuller et al. studied the influence 
of the size (range from 5 to 14 nm) and polydispersity on the SAR of iron oxide NPs 
subjected to an AMF (frequency = 400 kHz; amplitude = 24.5 kA/m).14 The highest SAR 
value of 447 W/g (ILP = 1.86 nHm²/kg) was obtained for the 14 nm NPs. Moreover, the 
lower the size polydispersity, the higher the SAR value, no matter the NPs size. For larger 
NPs where hysteresis losses are the main mechanism of heat, the SAR value increases 
as the NPs size decreases.109 The heating power in MgFe2O4 NPs was found to be strongly 
size-dependant, with a maximum SAR value for particle size of 10 nm.110 De la Presa et 
al. synthesised maghemite NPs of 8 nm, 11 nm, 13 nm and 14 nm by a co-precipitation 
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method, and studied the influence of NPs concentration, size, coating, liquid carrier, field 
amplitude and frequency on SAR value.111 For each NP size, the concentration of NPs 
dispersed in water does not seem to influence the SAR in the studied iron concentration 
range of 6 to 300 mg/mL. Increasing the size of the NPs resulted in an increased SAR 
value: for 8 nm to 11 nm NPs, the SAR is increased by four times, from 10 W/g to 40 W/g. 
For 11 nm to 13 nm NPs, the SAR only increased from 40 W/g to 55 W/g. The influence 
of the medium viscosity was investigated by dispersing the NPs in either water or agar. 
For the smallest NPs, the viscosity has a negligible influence on the SAR, but for the 
biggest NPs, the SAR strongly decreases when measured in the viscous media (agar). 
This is due to the fact that Néel relaxation is mainly responsible of the production of heat 
in small NPs. With bigger NPs, both Néel and Brownian relaxation take part in the heating 
process. Néel relaxation, unlike Brownian relaxation, is not influenced by the carrier 
viscosity. As a conclusion, the optimum size for a maximized viscosity-independent SAR 
value was found to be around 12 nm for maghemite NPs. 
 
1.2.6.2 Influence of the shape 
The influence of the shape on the MNPs heating properties has been less extensively 
studied than the influence of the size. Song et al. synthesised magnetite NPs by thermal 
decomposition in octadecene in the presence of oleic acid, and varied the amount of 
surfactant and refluxing time to get highly monodisperse spherical (9.5 nm) and quasi-
cubical (9.6 nm) MNPs.112 The quasi cubical MNPs displayed a highest SAR value which 
could originate from their bigger magnetic core volume and a higher crystallinity. A 
significant enhancement of heating performances is observed for multi-core flower-shaped 
maghemite NPs of 24 nm (constituted of smaller grains of 11 nm), with a SAR of 1992 
W/g.113 
 
1.2.6.3 Influence of the coating 
MNPs are usually coated with a hydrophilic ligand or polymer to improve their 
biocompatibility and their colloidal stability. Indeed, NPs aggregation would modify the NPs 
properties including their heating performances.  The choice of the ligand is important 
because it can modify the magnetic properties of the NPs. Larumbe et al. showed that a 
silica coating on magnetite NPs negatively affected the magnetic properties and the SAR 
value, due to an enhancement of the spin disorder surface effects caused by the silica 
coating.114 In a recent study, magnetite NPs with controlled particle size (9 nm, 19 nm and 
31 nm) and mPEG surface coating thickness (by varying the molecular weight: 2000 Da, 
5000 Da, and 20000 Da) were synthesised by thermal decomposition.63 The heating 
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efficiency was observed to decrease with increasing polymer chain length, excepted for 
the largest NPs. Indeed, the 31 nm NPs coated with 2000 Da mPEG agglomerate, 
because the polymer chains were too short to provide a good colloidal stability due to 
strong magnetic dipole-dipole interactions between the particles. This trend was reflected 
by the measured SAR values for each system. The highest SAR value achieved was 930 
W/g for the 19 nm NPs coated with 2000 Da mPEG and the lowest was 267 W/g for the 9 
nm NPs coated with 20000 Da mPEG. The study of chitosan-coated magnetite NPs 
showed an improved SAR compared their bare magnetite NPs counterparts.115 A bilayer 
of oleic acid has been shown to improve the hyperthermia properties of La0.7Sr0.3MnO3 
NPs,116 arising from an improved colloidal stability of the NPs suspension at physiological 
pH. All these results emphasize the importance to carefully chose and optimise the surface 
coating for a given system to yield the highest SAR possible. 
 
1.2.6.4 Materials for self-controlled hyperthermia 
It is important to control the temperature during magnetic hyperthermia treatment, in order 
to avoid overheating of the surrounding healthy tissues. However, a precise control of the 
temperature can be difficult to achieve, and therefore, magnetic materials with a maximum 
self-heating temperature are very attractive for hyperthermia applications. The Curie 
temperature (Tc) is an intrinsic property of magnetic materials. Above this temperature, 
the magnetic system becomes paramagnetic (Figure 1.6) and consequently the heating 
stops.  
 
Figure 1. 6 Schematic representation of the moments of atoms of a ferromagnet below and 
above its Curie temperature in the absence of an applied magnetic field. 
 
The Tc of a magnetic system can be modified to a certain extent with the chemical 
composition. By choosing a material with a Tc close to the hyperthermia temperature range 
and adjusting it at the desired therapeutic temperature, the heating of the tumour can be 
controlled and the temperature maintained at a constant desired value for a self-controlled 
hyperthermia treatment. For example, the Tc of Mn-ferrites can be decreased by replacing 
magnetic ions with non-magnetic Ti4+ ions (Mn1+xTixFe2O4), from 300 °C for x = 0 to 35 °C 
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for x = 0.6.117 A Tc of 46 °C was obtained for x = 0.55. Among the magnetic materials with 
a tunable Tc in the therapeutic temperature range, we can find: La1-xSrxMnO3 whose Tc 
increases with an increasing Sr content,118 Gd-substituted Zn-ferrite (ZnGdxFe2−xO4) 
whose Tc increases with an increasing Gd content and was found around 45 °C for 
x = 0.02,119 Ni1-xCrx whose Tc increases with a decreasing Cr content and was found equal 
to 44 °C for x = 5.63,120 and Mg1+xFe2-2xTixO4 whose Tc decreases with a decreasing Fe 
content and was found around 46 °C for x = 0.37.121 
 
1.2.7 Examples of in vivo applications of magnetic 
hyperthermia 
Basel et al. used specific monocytes/macrophages-like cells (Mo/Ma) to carry core/shell 
iron/iron oxide NPs directly into the tumour of mice injected with Pan02 cells to generate 
a murine model of disseminated pancreatic cancer.122 These Mo/Ma cells have been 
shown to be tumour-homing cells, they infiltrate tumour site and they specifically 
accumulate in pancreatic tumours when injected intraperitoneally. The Mo/Ma cells loaded 
with MNPs were injected intraperitoneally, and 3 days after the injection, the mice were 
subjected to 20 min of AMF exposure. The mice subjected to the hyperthermia treatment 
survived significantly longer than the other mice, with a 31% increase in lifespan.  
 
Lin et al. used Mn-Zn ferrite NPs coated with polyethyleneimine to evaluate the anti-cancer 
effect of the magnetic fluid with and without combined radiotherapy in vitro and in vivo.123 
They chose a magnetic fluid with a NP concentration of 10 g/L because the hyperthermia 
temperature stabilised around 43 °C under application of an AMF of 230 kHz and 1 kA/m. 
Tumours were grown into the right posterior limb rump of nude mice by injecting 
exponentially growing HepG2 cells. The magnetic fluid was injected intratumourally 
following a multipoint injection strategy, and the hyperthermia treatment was applied for 1 
h. The volume inhibition rate and mass inhibition rate of the tumour for the combined group 
were 87.6 % and 88.6 % respectively, against 41.0 % and 34.2 % for the radiation-alone 
group, 79.9 % and 77.9 % for the hyperthermia alone group. The in vivo experiments 
revealed a good inhibition of the tumour growth, for both hyperthermia alone and the 
combined treatment. 
 
Ferucarbotran (also called Resovist) consists of clinically approved SPIONs coated with 
carboxydextran developed for contrast-enhanced MRI of the liver. Those NPs can also be 
used for hyperthermia therapy as they are able to generate heat when submitted to an 
AMF. Araya et al. injected A549 cells, a human non-small cell lung cancer cell line, in 
 41 
 
BALB/c nu/nu athymic female nude mice and studied the anti-cancer effect of 
ferucarbotran-mediated hyperthermia.124 Ferucarbotran NPs were injected intratumourally 
and the temperature was maintained at 43 – 45 °C for 20 min by application of an AMF. 
Even if complete tumour suppression was not fully achieved, the tumour volume was 
significantly suppressed. Shetake et al. showed tumour regression in a fibrosarcoma 
tumour model after subjecting the mice to repeated magnetic hyperthermia treatment of 
10 min each using iron oxide nanoparticles.125 The tumour growth inhibition was mainly 
attributed to severe apoptosis and reduced tumour cells proliferation. In another study, 
BxPC-3-xenograft bearing mice (human pancreatic adenocarcinoma) and MDA-MB-231-
xenograft bearing mice (human breast adenocarcinoma) were subjected to a magnetic 
hyperthermia treatment of 1 h with an AMF of 435 kHz and 15.4 kA/m using two types of 
dimercaptosuccinic acid-coated iron oxide nanoparticles synthesized via different 
routes.126 A better response of breast cancer xenografts to the hyperthermia therapy 
compared to pancreatic tumours was observed. After 4 weeks, in breast MDA-MB-231 
xenografts, tumours showed a significant shrinking of their relative volumes to 85% and 
50% for the two different types of nanoparticles in relation to the tumour volumes before 
treatment.  In contrast, untreated MDA-MB-231 tumours showed linear growth over the 
same period of time, resulting in a relative tumour volume of 305%. In pancreatic BxPC-3 
xenografts, tumour growth was also significantly reduced after magnetic hyperthermia. 
The relative tumour volume at 4 weeks post magnetic hyperthermia was 204% and 244% 
compared to 507% of the untreated animal group. Interestingly, Huang and Hainfeld et al. 
reported complete regression of tumours in approximately 80% of animals using a very 
short 2 min dose treatment with an AMF of 980 kHz and 38 kA/m upon intravenous 
injection of iron oxide nanopartiches that achieved a tumour concentration of 1.9 mgFe/g in 
a subcutaneous squamous cell carcinoma mouse model.72 The tumours could be heated 
to 60 °C in 2 min, durably ablating them with millimetre precision, leaving surrounding 
tissue intact. 
 
Some clinical trials have already been performed with MNPs for hyperthermia therapy and 
have been summarized by Thiesen & Jordan in 2008127 and by Zhao et al. in 2013.128 
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1.3 Magnetic nanosystems for combined thermo-
chemotherapy 
1.3.1 Enhancement effect of the combined therapy 
The enhancement of chemotherapy effects with application of concurrent hyperthermia is 
called thermo-chemosensitisation. Several mechanisms are involved in this thermal 
enhancement, such as an increased antineoplastic drug accumulation in tumours, and an 
enhanced drug cytotoxicity (improved intracellular uptake of drugs and increase sensitivity 
of cells to drugs).129,130 The first one is due to the physiological effect of mild hyperthermia 
on tumour vasculature, including an increased blood flow, perfusion, and blood vessel pore 
size of the already leaky tumour vasculature. All these factors facilitate drug extravasation 
in tumour tissues. The mechanisms responsible for the enhanced drug cytotoxicity are not 
yet fully understood, but generally involve an improved intracellular uptake of drugs due to 
an increase cell membrane permeability, an inhibition of DNA-repair of the chemically 
induced lethal or sublethal damages, and an acceleration of the cytotoxic chemical 
reaction in the case of certain antineoplastic agents.46 Figure 1.7 summarizes the 
mechanisms behind the synergistic effect of simultaneous hyperthermia and 
chemotherapy. 
 
 
Figure 1. 7 Mechanisms responsible for the synergistic effect of the combined thermos-
chemotherapy. 
 
Several studies have demonstrated that the thermal enhancement of the cytotoxic activity 
of many anti-cancer agents is maximized at mild hyperthermia temperatures (40.5 – 
43 °C).131 Chemotherapeutic drugs can be classified into four different categories 
depending on the way heat affects their cytotoxicity132: 
• Agents exhibiting a linear increase in cytotoxicity with increasing temperature: 
alkylating antineoplastic drugs (nitrogen mustards, nitrosoureas and thiotepa), 
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platinum-based chemotherapeutic drugs (i.e. cisplatin), mitoxantrone and 
mitomycin C are part of this category. 
• Agents showing a threshold temperature effect: they do not undergo a linear 
increase but only a little change in cytotoxicity with increasing temperatures until a 
threshold of 42 °C – 43 °C. Above this threshold, a synergetic effect is observed. 
This is the case of adriamycin, bleomycin and actinomycin D.  
• Agents not presenting any change in cytotoxicity with higher temperatures: the 
antimetabolites, methotrexate, 5-fluorouracil, amsacrine, and the vinca alkaloids 
(vincristine and vinblastine) show temperature-independent action. 
• Agents that are not cytotoxic at 37 °C, but become cytotoxic with increasing 
temperatures. This type of cytotoxicity is characteristic of cysteamine, amphotericin 
B and lidocaine. 
Different studies have aimed to evaluate and identify the mechanisms behind the thermal 
enhancement of the cytotoxic activity of some chemotherapeutic drugs. The thermal 
enhancement of cisplatin and adriamycin cytotoxicity was evaluated in vitro using a human 
bladder cancer cell line.133 Mild hyperthermia alone (41 °C) and low drug concentration (20 
µg/mL of cisplatin or 4 µg/mL of adriamycin) did not have any cell killing effect. However, 
the anti-tumour effect of the combined therapy was significantly higher than either 
hyperthermia or drug alone, using the same drug concentrations and hyperthermia 
temperature. The survival rate in the case of the combined treatment was the same as that 
of a 10-fold higher concentration of cisplatin or adriamycin administered alone. These 
results indicate that the quantity of drugs used in chemotherapy for the treatment of cancer 
can be effectively reduced by combination with mild hyperthermia, thereby limiting the side 
effects of the treatment. The mechanisms of action of the two drugs are the following: 
cisplatin inhibits DNA synthesis and cell division through formation of DNA intrastrand 
crosslink adducts (DNA platination).134 Crosslinks causes DNA replication arrest and 
apoptotic cell death if the crosslink is not repaired. Adriamycin intercalates into DNA and 
inhibits the enzyme topoisomerase II resulting in DNA damage and cell death. Adriamycin 
can also generate free radicals that damage cellular membrane, DNA, proteins and lead 
to apoptotic cell death.135 Consequently, mechanisms responsible for the thermal 
cytotoxicity enhancement of both drugs are assumed to be an increase in cellular uptake 
of drug and inhibition of DNA repair of drug-induced DNA damage. 
 
Onconase is a cytotoxic ribonuclease that binds to cell surface receptors, degrades 
ribosomal RNA once internalised to the cell and inhibits protein synthesis causing 
apoptotic cell death.136,137 Onconase also suppresses proliferation, is cytotoxic to several 
tumour cell lines and is synergistic with many anti-cancer agents. The thermal 
enhancement of onconase cytotoxic effects by mild hyperthermia was evaluated in vitro 
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on human lymphoblastoid TK6 cells.138 The percentage of apoptotic cells was measured 
after treatment with onconase alone (2 or 5 µg/mL), hyperthermia alone (40 °C or 41 °C), 
for a treatment duration of 24 h or 48 h, and for the combined treatment. The results are 
presented in Table 1.1. The increased therapeutic effect of mild hyperthermia with 
onconase was observed at 41 °C and even at 40 °C, temperature at which the cells were 
not much affected. The thermal enhancement mechanism of onconase cytotoxic activity 
is not known with certainty. However, it is believed that an increased intracellular uptake 
of the drug and accelerated kinetics of ribosomal RNA degradation is responsible for the 
synergistic effect of the therapy. 
 
Table 1. 1 Percentage of apoptotic cells after 24 h and 48 h of treatment. 
Treatment duration 
Onconase 
concentration 
Temperature 
37.5 °C 40 °C 41 °C 
24h 
0 µg/mL 6% 6% 25% 
2 µg/mL 13% 39% > 50% 
5 µg/mL 15% 49% > 55% 
48h 
0 µg/mL / 7% 45% 
2 µg/mL 33% 54% 74% 
5 µg/mL 42% 77% 85% 
 
The thermal enhancement of melphalan (alkylating agent) and oxaliplatin (platinum-based 
agent) cytotoxicity were studied in vitro using spontaneous fibrosarcoma FSa-II tumour 
cells, as a function of treatment time at temperatures between 37 - 44.5 °C with a constant 
concentration of melphalan (0.25 µg/mL) or oxaliplatin (7.5 µg/mL).139 For both drugs, a 
thermal enhancement was observed, more pronounced in the case of melphalan, that 
became greater with increasing temperatures or increasing treatment time. The 
mechanism of effect of oxaliplatin has been found to be the same as cisplatin (formation 
of DNA intrastrand crosslink adducts which inhibits DNA replication and leads to cell 
death). Melphalan interacts with DNA to form interstrand crosslink adducts, also causing 
apoptotic cell death. At physiological temperatures, they observed a constant cell killing 
effect indicating that cytotoxic reactions occurred at a constant rate. With increasing 
temperatures, the reaction rate became faster. Thus, at mild hyperthermia temperatures 
(below 42 °C), the mechanisms responsible for the thermal enhancement of the drug 
cytotoxic activity seem to be mainly an increase rate of chemical reactions leading to cell 
death, the inhibition of DNA repair of drug-induced DNA damages and an enhanced 
intracellular uptake of drugs. Above 42 °C, hyperthermia has a direct killing effect on cells 
due to the denaturation of proteins induced by heat. This study also highlights the 
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importance of the thermal dose: the heating temperature and time of exposure greatly 
influence the interaction between heat and drug.  
 
Other numerous studies showed a thermal enhancement of drug cytotoxicity. For example, 
the combined treatment of hyperthermia at 43 °C for 45 min and cisplatin or etoposide 
resulted in more apoptotic cells than hyperthermia or drug alone with a lower concentration 
of drug.140 Again with cisplatin, the combined treatment was 1.7 times more effective than 
hyperthermia alone (43 °C, 60 min) and 1.4 times more effective than cisplatin alone.141 
Hyperthermia was in this case applied by means of iron oxide NPs injected intratumourally 
while cisplatin was injected intraperitoneally. BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea), 
an alkylating agent, causes DNA interstrand crosslink which lead to cell death. The 
alkylation reaction rate is accelerated by hyperthermia which results in an increased cell 
death.142 A comparative study of some of the clinically employed platinum-based 
anticancer agents (cisplatin, carboplatin and oxaliplatin) demonstrates a cytotoxic thermal 
enhancement for all of them.143 However, a true synergistic effect was observed in the 
case of cisplatin, while only an additive effect was reported for carboplatin and oxaliplatin. 
All these studies reveal that the most effective treatment is achieved when hyperthermia 
and drug are administered simultaneously, but some exceptions exist. Thus, drug 
pharmacokinetics have to be investigated to be able to benefit as much as possible from 
the improved anti-cancer effect of the treatment using a minimum amount of drugs thereby 
minimizing the toxicity. For instance, gemcitabine needs a time interval of 24 h between 
drug administration and application of hyperthermia to obtain a synergistic effect.46 
 
There is a concern about the oncogenic potential of many anti-cancer drugs. Hyperthermia 
combined with chemotherapy has the potential to reduce the risk of treatment-induced 
secondary cancer because hyperthermia lower oncogenic transformations. Indeed, 
hyperthermia converts sublethal damage induced by the drug to lethal damage and/or 
inhibits DNA repair, therefore reducing the expression of transformation. Moreover, cells 
in S-phase are particularly sensitive to heat, and transformation mainly occurred when 
cells are in S-phase. Thus, hyperthermia could reduce the frequency of transformation 
induced by chemotherapy. A study dedicated to the oncogenic potential of hyperthermia 
combined with either actinomycin D, mitomycin C or carmustine showed a reduction of the 
drug-induced transformation for a given level of cell killing compared to the administration 
of drug alone.144 A reduction of oncogenic transformations was also reported in the case 
of melphalan145 and cisplatin.145,146  
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1.3.2 Nanosystems for simultaneous hyperthermia and drug 
delivery 
Anti-cancer agents are often highly cytotoxic for both cancer and healthy tissues. The 
controlled release of drugs in a localised, targeted area is a major challenge in 
chemotherapy, as it would allow the reduction of systemic exposure therefore minimizing 
the side effects, and also lower the chemotherapeutic dose used for the therapy. This 
becomes possible using nanosystems as vehicles for drug delivery.9,147-151 The 
chemotherapeutic drug is stored and protected in the nanocarrier until it gets to the cancer 
site, where it is released. The drug is thus harmless to healthy tissues during its circulation 
in the body, and provided in high concentration at the desired location. Different 
nanoformulations incorporating both MNPs and drugs have been created for the purpose 
of thermo-chemotherapy. A growing area in drug and gene delivery is the use of stimuli-
responsive compounds, and especially thermo-sensitive polymers, to trigger the release 
of drugs.152  
 
Stimuli-responsive polymers, also called smart polymers, have the ability to change 
properties in response to a change in their environment such as the temperature, pH, light, 
magnetic field, etc.153 Thermo-responsive polymers respond to temperature: they undergo 
a conformational change at a specific temperature, called lower critical solution 
temperature (LCST) or upper critical solution temperature. The words upper or lower 
indicate whether it is an upper bound or lower bound to a temperature range of partial 
miscibility. For example, below the LCST, the polymer is in a swollen hydrophilic state, and 
transforms to a shrunken hydrophobic state above the LCST by expelling the aqueous 
content. The most studied polymer for thermo-responsive drug delivery systems is poly(N-
isopropylacrylamide) (PNIPAAm) which has a LCST of 32 °C in water. By varying the ratio 
of hydrophilic/hydrophobic co-monomer, the LCST of a given polymer can be tuned.154 
This behaviour is therefore used to remotely trigger the release of drug: by tuning the LCST 
to be in hyperthermia temperature range, a drug may be retained at physiological 
temperature, and released as a consequence of hyperthermia. The use of MNPs for local 
hyperthermia is therefore particularly relevant to this purpose. Indeed, the heat produced 
by the MNPs under application of an AMF will trigger the fast release of the drug, and 
increase the effectiveness of the treatment due to the synergistic effect of simultaneous 
hyperthermia and chemotherapy. The incorporation of MNPs also offers the possibility to 
guide the magnetic nanosystems in the body to target the tumour thanks to an external 
magnet. pH-responsive polymers are also often exploited for drug delivery applications 
because of the pH changes found in the human body. The pH in tumour environment is 
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often more acidic than pH in the blood or healthy tissue. pH-sensitive drug delivery 
systems can target the tumour site and release their payload due to the pH difference. 
 
The approach of simultaneous thermo-chemotherapy using magnetic nanosystems is 
relatively new. Kumar and Mohammad recently reviewed and proposed extending of the 
meaning of the term hyperthermia, to cover both hyperthermia therapy and magnetically 
modulated controlled drug delivery through heating.155 In this case, heat is only used as a 
trigger for drug release. In our context, hyperthermia and chemotherapy therapeutic 
functions are combined in the same nanosystem taking advantage of the great potential 
of MFH and controlled drug delivery in the treatment of cancer, and benefiting from the 
synergetic effect of the combined therapy. The most relevant organic/inorganic designs 
developed so far will be presented, focusing on the most encouraging results of pH- and/or 
thermo-sensitive systems for the triggered delivery of drugs under application of an 
external AMF. Among them, we can find core/shell NPs, liposomes, micelles, and 
polymeric carriers such as hydrogels or polymeric NPs. Figure 1.8 displays the most 
important biologically useful nanosystems for simultaneous thermo-chemotherapy, which 
are usually administered intratumourally or intravenously. 
 
 
Figure 1. 8 Type of nanosystems designed for thermo-chemotherapy commonly found in 
the literature. 
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1.3.3 The different nanosystem designs 
1.3.3.1 Liposomes 
Liposomes are spherical vesicles composed of an aqueous core surrounded by a lipid 
bilayer. They are one of the most attractive and studied system for drug delivery. 
Hydrophilic chemotherapeutic drugs can be entrapped in the aqueous compartment, while 
hydrophobic drugs can be encapsulated in the lipid membrane. Liposomes change the 
pharmacokinetics of the drug and lower its systemic delivery and toxicity. With the major 
advancement of long circulation liposomes by incorporating PEG-chains in the lipid 
bilayer,156 liposomal formulation are now able to increase the circulation time of some 
drugs in the body and enhance the drug deposition in the tumour via EPR effect.  
 
Magnetoliposomes are formed by incorporating MNPs in the liposome with the molecules 
of drug, either in the core for hydrophilic NPs157 or in the lipid membrane for NPs in a 
hydrophobic state.158 Temperature-sensitive liposomes use specific lipid and polymers to 
achieve temperature-triggered release of drugs. Under the phase transition temperature 
of the bilayer, drugs are retained inside the liposome, until they are released in tumour 
tissue or vasculature as a consequence of heat causing bilayer disruption. As thermo-
sensitive liposomes have been widely investigated for drug delivery, several well-
documented reviews can be found in the literature.159-161 Thermo-sensitive 
magnetoliposomes have shown potential efficacy for the combined treatment of cancer. 
For example, liposomes with MNPs encapsulated in the lipid bilayer and calcein as a 
model of hydrophilic drug loaded into the aqueous compartment have shown interesting 
“on-demand” release properties.162 The release can be triggered repetitively, by switching 
on and off the AMF, with almost inexistent cargo release when the AMF is turned off. This 
property is due to the reversible permeability change of the lipid bilayer rather than the 
destruction of the liposome, and is an attractive feature to control dose, location and time 
of drug release, with simultaneous magnetic hyperthermia. 
 
Kulshrestha et al. developed paclitaxel-loaded magnetoliposomes with a lipid bilayer 
formed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-rac-glycerol (PG) (9:1, w/w).163 The transition temperature of DPPC 
is 41 °C, while the one of PG is 1 °C, but adding a small amount of PG proteins to the 
DPPC lipid bilayer has shown to increase the stability of the bilayer, without lowering too 
much the transition temperature, thereby minimizing the release of drug at physiological 
temperature. Magnetite NPs and paclitaxel were encapsulated into the liposome aqueous 
compartment. At 37 °C, only 1.2% of paclitaxel was released compared to 55.6% at 43 °C 
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under application of an AMF. In vitro experiments performed on HeLa cells showed a 
decrease of cell viability by 37% after magnetic hyperthermia treatment alone at 42.5 °C 
for 30 min and by about 50% for paclitaxel-loaded magnetoliposomes without application 
of an AMF, while the combined treatment resulted in 89% cell killing. Thus, this liposomal 
formulation shows promising potential for cancer thermo-chemotherapy, because of its 
good biocompatibility, the almost non-existent drug release at 37 °C, the magnetic 
hyperthermia-triggered burst drug release and the synergistic effect of the combined 
treatment. 
 
1.3.3.2 Micelles 
Surfactants are composed of a hydrophilic head group and a hydrophobic tail. When in 
aqueous solution, they spontaneously assemble into an aggregate with the polar heads 
facing the surrounding water and a hydrophobic, water-excluding core. Hydrophobic drugs 
can therefore be encapsulated into the micelle core. Drug molecules can also be directly 
conjugated to the polymer structure via a cleavable link.164 Such as liposomes, micelles 
can extend the circulation time of the drugs in the body, enhance their accumulation via 
EPR effect in the tumour and protect them against renal and reticulo-endothelial clearance. 
Micelles can be engineered to be thermo-responsive via incorporation of a thermo-
sensitive polymer either in the head polar group or the non-polar tail. Micelles have been 
widely used as drug delivery systems, and several recent good reviews can be found on 
the subject of polymeric micelles.164-166 Micelles with a thermo-sensitive corona are usually 
used for drug delivery applications. The thermo-sensitive polymer undergoes a 
conformational change from hydrophilic state to hydrophobic state when it reaches its 
LCST, therefore destabilizing the micelle structure and allowing the release of the drug. 
The collapsed hydrophobic corona may interact with the cellular membrane resulting in an 
enhanced intracellular uptake.167 The micelles can be loaded with MNPs and drug at the 
same time, to form magnetic micelles that can be used for hyperthermia with combined 
chemotherapy. 
 
Kim et al. prepared iron oxide nanoparticle-conjugated polymeric micelles that encapsulate 
doxorubicin (DOX) and observed a significant decrease in cell proliferation under 
application of an AMF as compared to free DOX.168 An enhanced apoptosis of human 
adenocarcinoma cells was obtained for the combined therapy than either hyperthermia or 
chemotherapy applied separately. Similar results were obtained for DOX and Mn, Zn 
doped ferrite NPs encapsulated in the hydrophobic core of magnetothermally responsive 
star-block copolymeric micelles with a LCST of 43 °C for application in thermo-
chemotherapy.169 The drug was found to be quickly released at 43 °C due to the 
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deformation of the micellar structure, and an enhanced tumour growth inhibition on human 
liver hepatocellular HepG2 cells was observed under application of an AMF. 
 
1.3.3.3 Polymeric nanoformulations 
Polymeric nanoparticles are of great interest for biomedical applications due to the 
possibility to control and tune their compositions, structures and properties (i.e. shape, 
size, surface charge, functionalisation) thanks to a controlled reaction of polymerisation.170 
Several MNPs and drug molecules can be encapsulated in the same polymeric NP, to be 
used as agents for thermo-chemotherapy. From the choice of the polymers composing the 
NPs as well as the different polymers ratio, can arise new or improved properties, such as 
thermo-sensitivity, biocompatibility, etc. 
 
An interesting and very complete study developed a pH- and thermo-sensitive nanosystem 
composed of SPIONs and two anti-cancer drugs, curcumin and 5-fluorouracil (5FU), 
encapsulated in a poly(D,L-lactic-co-glycolic acid) (PLGA) shell for the combined 
therapy.171 Curcumin causes a decrease in the mitochondrial membrane potential while 
5FU inhibits the synthesis of DNA and RNA. The polymeric NPs were also functionalised 
with two targeting moieties, folate, whose receptors are highly displayed in several 
carcinomas, and transferrin, whose receptors are highly overexpressed in cancer cells to 
obtain a dual targeted, dual drug loaded MNPs-encapsulated PLGA nanovector. Three 
different cell lines were used for in vitro studies: a human breast cancer MCF-7 cell line, a 
human glial G1 cell line and a mouse fibroblast L929 cell line used to compare effects on 
healthy cells. The better targeting efficacy of the dual-targeted NPs was clearly evidenced 
by the internalization studies and cytotoxicity assays resulting in a higher specificity and 
uptake than single-targeted NPs. A synergistic effect of the two drugs was also observed 
as compared to the use of a single drug. The effect of simultaneous chemotherapy and 
magnetic hyperthermia was evaluated after 60 and 120 min of treatment. The use of non-
targeted NPs resulted in a high reduction of the cell viability for both healthy and cancer 
cells, due to the lack of specificity of the nanovector, unlike the treatment performed with 
the dual-targeted NPs that showed a drastic cytotoxic effect on cancer cells without 
significant damage to healthy cells. Thanks to the dual targeting ability, both heat and 
drugs can be targeted to cancerous tissues. The synergistic effect of the MNPs and the 
combination of the drugs was found to be highly effective in destroying cancer cells within 
a very short period of time by initiating early and late apoptosis, with remaining cell 
viabilities of 7% and 4% for MCF-7 and G1 cells 24 h after the treatment. 
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Hydrogels consists of a three-dimensional polymer network containing large quantities of 
water, but remain insoluble due to their cross-linked structure. The properties of a hydrogel 
such as its elasticity, degradation rate or swelling ratio can be tuned by modifying the 
hydrogel parameters (i.e. polymer, block lengths, cross-linker ratio, etc). Nanohydrogels 
are commonly used as drug delivery systems through entrapment of drugs in the polymer 
matrix, and release via diffusion or matrix degradation. MNPs can also be incorporated in 
the hydrogel matrix. Thermo-sensitive nanohydrogels are formed by cross-linking thermo-
sensitive polymers, and the final LCST of a nanohydrogel can be tuned by changing the 
different polymers ratio. Above the LCST, a nanohydrogel becomes hydrophobic and 
shrink, therefore expelling water and drug molecules. 
 
A concentric layered magnetic chitosan hydrogel with controlled layer numbers and layer 
thicknesses was recently synthesised via a facile alternate alkali treatment method.172 
Magnetite NPs and the chemotherapeutic drug adriamycin were incorporated into the 
hydrogel matrix. The drug release behaviour was estimated by switching ON and OFF a 
low frequency AMF. An increased rate of drug release was observed when the AMF is ON. 
In this study, magnetic hyperthermia is not believed to be the trigger of the drug release, 
but rather a volume shrinkage of the hydrogel due to the magnetisation of the MNPs, which 
promote drug release by expelling the drug out of the hydrogel. 
 
Jaiswal et al. developed a dual pH- and temperature-responsive nanohydrogels by 
incorporating magnetite NPs and DOX into a polymeric matrix based on poly(N-
isopropylacrylamide)-chitosan, with a LCST optimised around 42 °C.173 pH and 
temperature enhance release was observed under acid environment (pH 4.6) and 
hyperthermia temperature (42 °C). The combined treatment using the drug-loaded 
magnetic nanohydrogels on human breast MCF-7 cells and cervical carcinoma HeLa cells 
yielded up to 85% cell death, which was significantly higher than cell death achieved by 
hyperthermia alone. Jaiswal et al. also developed a DOX-loaded thermo-responsive 
hydrogel with embedded iron oxide nanoparticles.174 In vitro studies on bladder cancer T-
24 cells revealed a synergistic of the combined therapy due to enhanced apoptosis and 
that more than 80% cells were found dead in just 6 h post field exposure, and 95 % after 
24 h. Interestingly, in vivo biodistribution showed a preferential accumulation of the 
hydrogel in the lungs, which pave the way for lung cancer treatment as well. 
 
1.3.3.4 Core/shell nanoparticles 
Core/shell NPs are particularly relevant for combined modalities of cancer therapy.  The 
metallic core can endow the NPs with the desired magnetic properties for hyperthermia 
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applications, while the organic shell can provide drug loading capabilities. Moreover, the 
coating can also provide an increased colloidal stability, chemical stability (i.e. prevents 
any further oxidation), biocompatibility and reduced toxicity. The polymer can be grafted 
onto the MNP surface by two different approaches.175 In the first one, called “grafting to” 
or “grafting onto”, an end-functionalised polymer is used with suitable terminal groups to 
directly bind to the MNP surface. In the second approach, called “grafting from”, the 
polymerisation proceeds from the surface thanks to an initiator molecule preliminary fixed 
on the MNP surface. Finally, simpler but less reliable, the polymer can be attached to the 
MNP surface by non-covalent interactions, such as electrostatic or van der Waals 
interactions. For drug delivery purposes, the drug can be physically loaded into the 
polymer shell or the drug can be covalently loaded through formation of a chemical bond 
between the drug and the polymer/ligand forming the shell of the MNPs. In the latter, the 
drug release mechanism often involves heat or pH inducing bond cleavage. In either case, 
it has been demonstrated in vitro that DOX has a higher cytotoxicity toward cancer cells 
when it is conjugated to iron oxide NPs covalently or electrostatically compared to free 
DOX, most likely due to a higher cellular uptake through endocytosis compared to passive 
diffusion.176 
 
1.3.3.4.1 Physical drug loading 
Physical drug loading is generally obtained by hydrophobic/electrostatic interactions and 
is generally quite simple to realise. For an efficient nanovectors, a high drug loading 
efficiency and a rapid “on demand” release is desirable while drug leakage through the 
polymer layer should be avoided. A recent study has shown promising results with a pH-
responsive system in the drug release behaviour and cell killing effect with the combined 
therapy in the treatment of ovarian cancer.177 Iron oxide NPs were coated with three 
different layers, forming a reservoir for drug loading capability: oleic acid, 1-octadecene, 
poly(maleic anhydride-alt-1-octadecene) (PMAO) and poly(ethylene-imine) (PEI). DOX 
was then encapsulated into the MNPs polymeric shell and the MNPs were further modified 
with a PEG layer for improved colloidal stability and increased blood circulation time. 
Finally, the MNPs were functionalised with a targeting ligand to human ovarian cancer 
cells: Luteinizing Hormone–Releasing Hormone (LHRH) peptide. This system will be 
called LHRH-PEG-DOX-IONP. Only 17.6% of DOX was released at pH 7.4, while 91.1% 
was released at pH 5.5, with a burst release within the first 2 h (44.7%). Indeed, DOX is 
loaded through electrostatic interactions with the negatively charged carboxyl groups of 
the amphiphilic polymer. The release of DOX is accelerated at acidic pH because it 
reduces the interaction with protonated carboxylic groups. It also increases the solubility 
of DOX in aqueous solution due to the protonation of the primary amine of DOX molecules. 
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This drug release behaviour enables a limited release of drug in the blood stream, while a 
quick release can be obtained at cancer sites. In order to assess the efficacy of the 
combined treatment in vitro on A2780/AD human ovarian carcinoma cell line, 15 µg Fe/mL 
of LHRH-PEG-DOX-IONPs were loaded with 1 µg/mL of DOX and subjected to an AMF 
for mild hyperthermia conditions (40 °C). The effect of chemotherapy and mild 
hyperthermia alone resulted in 27% and 72% cell death, respectively, while the combined 
treatment had a 95% cell killing effect. Thus, the combined treatment shows a superior 
efficacy than either chemotherapy or mild hyperthermia as stand-alone therapy and is 
preferable in many ways because of the lower temperature and drug concentration used, 
thereby minimizing side effects and damage to healthy tissues. Electrostatic interactions 
were also used to load DOX into MgFe2O4 magnetic nanoassemblies coated with PEG-
diacid.178 A loading efficiency of 80% was achieved and 75–80% of DOX was released 
under acidic pH compared to only 20-25% at physiological pH. The synergistic effect of 
DOX combined with hyperthermia was once more observed, with up to 90% cell death, 
against 45% and 65% cell death for magnetic hyperthermia or chemotherapy alone, 
respectively. 
 
Barick et al. developed pH-responsive peptide mimic shell cross-linked magnetic 
nanocarriers (PMNCs) for combination therapy.179 Magnetite NPs were functionalised with 
glycine and the free amine groups are utilised for further conjugation with the peptide L-
arginine to obtain PMNCs with both amine and carboxylic terminal groups. The NPs were 
coated with a peptide, because peptides can enhance the cellular uptake, have low toxicity 
and are pH-responsive. The pH of zero-point charge of PMNCs was estimated at 5.4, 
meaning that the surface is charged positively at pH < 5.4 and negatively at pH > 5.4. The 
reversal of the surface charge can be exploited for the purpose of drug delivery: the drug, 
loaded in the shell, is retained via electrostatic interactions, and released upon the change 
of surface charge. DOX is used as a model of cationic chemotherapeutic agent, to study 
the drug loading and release behaviour at pH 4, 5 and 7.3. The DOX release studies show 
an increase in the release rate with a decreasing pH: only 7% of DOX was released at pH 
7.3 while the release was complete at pH 4. The time needed for the release of 50% of 
DOX was found to be around 30 min and 45 min at pH 4 and 5, respectively. The potential 
of the DOX-loaded PMNCs was investigated on HeLa cells for the combined therapy, after 
only 10 min of AMF exposure and a DOX concentration of 4 µM. The chemotherapy 
treatment alone (free DOX or DOX-loaded PMNCS) resulted in a cell viability decreased 
by 10%, and hyperthermia alone (PMNCs subjected to AMF) had a 13% decreased effect 
on the cell viability. The cell killing effect was higher in the case of the combined therapy, 
as a 28% decrease in cell viability was observed. This system is interesting for the 
combined therapy giving the results obtained with a short time of AMF exposure. 
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Moreover, it exhibits a quasi-nonexistent drug leakage through the peptide mimic shell and 
the amine and carboxylic terminal groups of the nanocarriers leave many possibilities for 
the conjugation with targeting moieties. 
 
While efficient, the use of pH-sensitive drug delivery systems only offers spatial control but 
does not allow for the remote control of the drug release. Thermo-sensitive drug delivery 
vehicles can be used for hyperthermia-triggered drug release, which offer spatial and 
temporal control over the drug release but also offer the possibility of an “ON-OFF” release 
by switching ON and OFF the AMF. For example, magnetite NPs coated with N-
isopropylacrylamide-co-acrylamide (P(NIPAAm-co-Am)) with a LCST of about 40 °C show 
almost complete drug release after three AMF on–off cycles (frequency = 60 kHz; 
amplitude = 6.5 kA/m).180 
 
1.3.3.4.2 Covalent drug loading 
The advantage of conjugated drug to the MNP surface via a labile bond is that no leakage 
of drug through the polymer shell is possible. This design involves the cleavage of the 
bond used to conjugate the drug to the MNP in response to a stimulus. The drug can 
therefore be magnetically guided at the right location and activated at the right time, limiting 
systemic effects in a great extent. For the purpose of thermo-chemotherapy, heat labile 
bonds are particularly relevant, because the heat produced by the MNPs subjected to an 
AMF induces bond cleavage. For example, in the following study, the authors have 
designed a magnetic nanocarrier for thermo-chemotherapy composed of an iron oxide 
core functionalised with a ligand containing a furan ring that serves as a thermo-sensitive 
linker for a biologically active molecule through reversible Diels-Alder chemistry.181 The 
retro-Diels-Alder (rDA) reaction generally occurs at temperatures around 90 – 110 °C. 
These temperatures are too high for biological purpose, but recent studies have shown 
the existence of local heating effect in the vicinity of MNPs leading to high temperatures at 
the NPs surface.182-184 This phenomenon can be exploited to kill more effectively cancer 
cells without a significant increase of temperature in the biological medium, or in the case 
of this study, trigger the drug release by initiating a reaction occurring a high temperature. 
Indeed, the ligand has been designed to provide the cleavable bond close to the NPs 
surface, allowing the exploitation of the local heating phenomenon. The study shows that 
indeed, upon application of an AMF, the rDA reaction occurs, leading to the release of the 
conjugated molecule, and thereby this design offers possibility for thermo-chemotherapy 
applications. 
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Azo-bonds are commonly used as thermally-labile linkages.184,185 Azo-functionalised PEG-
coated core/shell iron oxide/silica nanoparticles exhibited on demand release of the 
covalently binded drug model upon activation of an AMF due to azo bond breakage with 
an elevation of temperature.186 Riedinger et al. developed a drug release system in which 
DOX is covalently linked to PEGylated iron oxide nanoparticle through thermo-labile azo-
ligands.187 The distance between the molecules of DOX and the iron oxide nanoparticle 
surface was varied by using PEG spacers of different molecular weights. Results showed 
that upon application of an AMF, the release of the drug is distance-dependent, due to the 
local heating effects at the surface of the nanoparticles, which rapidly decay with 
increasing distance. 
DNA melting as a result of temperature increase has also been exploited for drug delivery 
purposes. Examples include a nanoparticle capping system based on double stranded 
DNA that has been used as thermally sensitive gatekeepers: progressive DNA melting 
upon application of an AMF leads to subsequent release of the drug188; and a nucleic-acid 
duplex as a heat-labile linker that releases a drug from dextran-coated iron oxide 
nanoparticles trapped in a matrigel plug as in vitro model of tumour tissue.189 With a nucleic 
acid strand covalently linked to the nanoparticle, dye-labelled single stranded DNA self-
assembles on the particle’s surface forming a tuneable, heat-labile linker.  
 
Acid labile bonds are also widely used for drug delivery applications, as the pH in tumour 
environment is more acidic than in the blood or healthy tissue. A recent study used an acid 
labile imine bond to conjugate doxorubicin to magnetite NPs.190 The mechanism by which 
the drug is released was assumed to be: the MNPs are taken up by the cancer cell through 
endocytosis, and the drug is released in acid lysosomes due to bond cleavage in acidic 
conditions. Other acid cleavable bonds have been used recently for drug delivery purpose 
and could be used for the combined therapy, such as hydrazone bonds to conjugate DOX 
to magnetite NPs191,192 or nanocrystal clusters193 or else ester bonds to conjugate 
paclitaxel to iron oxide NPs.194 Finally, another possible cleavable bond that can be used 
for drug delivery is redox labile bond such as disulfide bonds.195 Indeed, due to the 
elevated level of reductive glutathione in many tumours cells, the tumour intracellular 
environment enables redox bond cleavage thus releasing the drug. Acid and redox 
cleavable bond for use in drug delivery applications have another important advantage. It 
has been noticed that a high amount of glutathione is often associated to 
chemotherapeutic drugs-resistant cancer.196 By releasing drugs intracellularly drug 
resistance can be, in a certain extent, overcome.197 
 
If the drug used also have a targeting ability, no cleavage of the bond conjugating the drug 
molecules to the MNPs is necessary. This is the case with the drug methotrexate (MTX) 
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which has been used in a recent study for thermo-chemotherapy.198 MTX was conjugated 
to poly(ethyleneimine)-coated magnetite NPs through an amide bond. MTX is used for its 
targeting ability on folate receptor, over-expressed in many types of cancers, and its 
therapeutic effect. The cellular uptake shows a more efficient and selective internalisation 
of MTX-MNPs in the cell cytoplasm as compared to non-conjugated MNPs. The relative 
cell viabilities for magnetic hyperthermia at 43 °C, chemotherapy alone and the combined 
treatment were estimated at 87.6%, 64.5% and 13.3%, respectively. A true synergistic 
effect between hyperthermia and MTX is observed demonstrating the efficiency of the 
MTX-MNP design for targeted thermo-chemotherapy applications. 
 
 
 
1.3.4 Examples of in vivo applications of thermo-
chemotherapy using magnetic nanoparticles 
To our knowledge, there has been no clinical trial performed on drug-loaded MNPs-based 
nanosystems for simultaneous thermo-chemotherapy. However, the fate and 
effectiveness of different magnetic carriers have been tested in vivo. In vivo experiments 
are important because the overall effects can be observed on a living subject and it is 
therefore the best way to get close from the conditions found in a human body (solid 
tumour, complicated tumour microenvironment, etc) which can interfere in a great extent 
with the fate of the nano-systems (i.e. drug pharmacokinetic, NPs distribution pattern, etc). 
 
Yoo et al. introduced resistance-free apoptosis-inducing magnetic nanoparticles (RAIN) 
based on Zn0.4Fe2.6O4 MNPs for simultaneous hyperthermia therapy and release of 
geldanamycin (GM).199 GM is a heat shock protein (HSP) inhibitors and is used to prevent 
thermoresistance. Thermoresistance is the development of resistance to the cytotoxic 
effects of heat after consecutive hyperthermia treatments that arises from the synthesis of 
HSPs as a response of thermal stress.200 Indeed, the presence of HSPs has been 
correlated with the natural adaptation to heat of a living organism. GM is conjugated to the 
MNPs via a heat labile azo linker, and complete release occurs as a consequence of 
magnetic hyperthermia after 60 min of exposure at 43 °C while no release is observed at 
37 °C. In vitro studies on MDA-MB-231 breast cancer cells revealed a 100% cell killing 
efficiency after 70 min of treatment with the RAIN, against only 25% after 80 min of 
treatment for magnetic hyperthermia alone. A strong expression of HSPs was observed 
after the heat treatment, while after exposure to RAIN hyperthermia, the expression of 
HSP was comparable to the control. Finally, MDA-MB-231 cells were transplanted into the 
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right hind legs of nude mice and 50 µg of RAIN were directly injected into the tumour. 
Hyperthermia at 43 °C was maintained for 30 min and while magnetic hyperthermia was 
not sufficient to inhibit the tumour growth, RAIN hyperthermia was found to completely 
suppress the tumour 8 days after single AMF exposure. In vitro and in vivo tests confirmed 
that HSPs are responsible for thermoresistance and that inhibition of HSPs is critical for 
hyperthermia induces apoptosis. 
 
Li et al. developed truncated octahedral magnetite NPs coated with poly(styrene-alt-maleic 
acid) and further functionalised with PEG and poly-A polynucleotide.201 PEG chains are 
used to bind a cancer cell targeting moiety: the anti-human epidermal growth factor 
receptor type 2 (anti-HER2) monoclonal antibody, while the polynucleotide has the ability 
to absorb the chemotherapeutic drug 5-fluorouracil (5-FU) by forming a hydrogen bond 
between the adenine group of the polynucleotide and 5-FU. The targeted nanosystem 
exhibited an enhanced cellular uptake in vitro on MBT-2 cells, a mouse bladder cancer cell 
line which over-expresses HER2 antigen, compared to the non-targeted one. MBT-2 cells 
were transplanted in C3H/HeN mice to induce bladder cancer in mice. NPs were injected 
intratumourally to assess the efficacy of the combined therapy on small size (< 50 mm3) 
and large size (> 50 mm3) tumours, and 2 h later tumours were exposed to an AMF for 15 
min. In the case of small tumours, hyperthermia alone as well as the combined treatment 
led to almost total tumour regression. However, for large tumours, hyperthermia alone was 
not sufficient to significantly inhibit tumour growth, and only hyperthermia with combined 
chemotherapy resulted in a significant anti-cancer effect. The efficacy of the combined 
treatment was also evaluated using the systemic delivery method through tail-vein 
injection. NPs were injected once per day for four consecutive days and the hyperthermia 
treatment was applied 24 h after the NPs had been injected. The combined treatment 
resulted in a prominent cancer regression compared to either hyperthermia or 5-FU alone. 
Interestingly, after hyperthermia treatment, a relocation of the NPs from other organs to 
the tumour was observed, probably due to the change in tumour vasculature in response 
to hyperthermia, which facilitates NPs extravasation. This information is highly valuable in 
maximizing the therapeutic effect and minimizing the side effects of the treatment. It also 
suggests that a pre-hyperthermia treatment could be applied before injection of the NPs 
to increase their accumulation at the cancer site. 
 
Many recent in vivo studies using thermosensitive magnetoliposomes for thermo-
chemotherapy applications also demonstrated prominent tumour growth inhibition and 
superior survival rate over chemotherapy or magnetic hyperthermia alone.202-204 205 
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1.4 Fundamentals of RAFT polymerisation 
1.4.1 Introduction to reversible deactivation radical 
polymerisation 
Free radical polymerization is a chain polymerization in which the active centers are 
radicals. It is one of the most widely used polymerization techniques. However, irreversible 
chain transfer and chain termination reactions (bimolecular radical-radical termination 
reactions) are inherent to any conventional radical polymerization. 
 
According to the International Union of Pure and Applied Chemistry (IUPAC), living 
polymerization is a chain polymerization from which irreversible chain transfer and chain 
termination are absent. The rate of chain initiation is much faster than the rate of chain 
propagation, so that the number of kinetic-chain carriers or active centers is essentially 
constant throughout the reaction.206,207 As a result, the polymer chains grow at a constant 
rate and reach a similar length (narrow molar mass distribution). 
Reversible addition-fragmentation chain transfer (RAFT) polymerization is one of the 
several techniques of reversible deactivation radical polymerizations (RDRP), others 
mainly being atom transfer radical polymerization (ATRP) and nitroxide-mediated 
polymerization (NMP). RDRP are modern methods of radical polymerization in which 
certain additives react reversibly with the radicals and the rate of chain initiation is much 
faster than the rate of chain propagation. RDRP therefore present much similarities with 
living polymerizations, but cannot actually be classified as such, because, even if 
minimized compared to conventional radical polymerization, they still display irreversible 
chain transfer and chain termination reactions. Many terms have been loosely used to call 
the RDRP, such as living radical polymerization, living free radical polymerization, 
controlled radical polymerization and controlled/living radical polymerization. The use of 
these names has been discouraged by IUPAC.208 The term “living” cannot be used as 
some terminations inevitably take place. The use of “controlled” is acceptable but the type 
of control must be defined (i.e. control over a certain kinetic feature or structural aspect).207 
Therefore, the term RDRP is recommended.  
 
RDRP reactions all have in common the limitation of irreversible termination reactions and 
chain transfer, intrinsic to conventional radical polymerization, combined with a 
simultaneous or quasi-simultaneous initiation of all the chains. RAFT polymerization, such 
as other RDRP, allows one to design functional polymers of controlled and complex 
architecture (linear block copolymers,209,210 star block copolymers,211-213 brush 
polymers,214,215 etc), pre-chosen molecular weight and low polydispersity (narrow molar 
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mass distribution), properties which are challenging to obtain via conventional free radical 
polymerization processes. 
 
In order to extend the lifetime of the propagating polymer chains, RDRP process is based 
on a reversible activation/deactivation equilibrium between a low concentration of active 
species (propagating polymer radicals) and a predominant amount of dormant species 
(unable to propagate or terminate).209,216  
In NMP, this equilibrium is built on a reversible termination reaction between a growing 
polymer radical Pn• and a free nitroxide N• to form a macroalkoxyamine P-N (Figure 
1.9).217,218 The propagating polymer radical and the nitroxide can be regenerated by 
homolysis of the P-N species at high temperature (often > 70 °C). However, the equilibrium 
strongly favours the dormant species and therefore irreversible termination reactions are 
strongly lessened by preferential reaction of the polymer chain Pn• with the nitroxide radical 
N• (deactivation), but also with monomer M (propagation) rather than the radical-radical 
termination reactions. 
 
Figure 1. 9 The reversible activation/deactivation equilibrium in NMP. 
 
In ATRP, the dormant species is a macromolecular alkyl halide Pn-X, and the growing 
polymer radicals Pn• are generated via a reversible redox process catalyzed by a transition 
metal complex in its lower oxidation state Mtm/L, where Mtm is the transition metal complex 
in oxidation state m and L is a ligand (Figure 1.10).218-220 Likewise, the equilibrium strongly 
favours the dormant species. Various transition metals can be used for the ATRP redox 
catalytic process such as Cu, Ru, Fe, Co, Mn, Ni, etc.221 
 
 
Figure 1. 10 The reversible activation/deactivation equilibrium in ATRP. 
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The RAFT polymerization mechanism differs from the one of ATRP and NMP. It rests upon 
a reversible degenerative chain-transfer process where the dormant species Pn-X and Pm-
X equilibrate with the growing polymer radicals Pn• and Pm• (Figure 1.11).209,218,222 
 
Figure 1. 11 The reversible degenerative chain transfer equilibrium in RAFT 
polymerization. 
 
1.4.2 Generalities about RAFT polymerisation 
The RAFT polymerization technique was discovered and first reported in 1998 by the 
Commonwealth Scientific and Industrial Research Organisation (CSIRO) of Australia.223,224 
CSIRO then published four other papers about RAFT polymerization in the two next 
consecutive years.225-228 Around the same period (in 1999), a French group reported a 
polymerization technique as Macromolecular Design by Interchange of Xanthate 
(MADIX).229,230 MADIX, such as RAFT polymerization, also works through an addition-
fragmentation chain transfer mechanism and refers in fact to a specific RAFT 
polymerization: the one promoted by xanthates, also referred as dithiocarbonates. 
 
RAFT polymerization is in fact nearly identical to a conventional radical polymerization, 
with the primary difference being the addition of a chain transfer agent. Therefore, it is not 
more difficult to conduct a RAFT polymerization than a radical polymerization. The same 
apparatus, temperatures, initiators and solvents are applicable.231 As a consequence, 
RAFT polymerization retains many of the strengths derived from the inherent versatility of 
radical polymerization,232 such as its compatibility with a wide range of polymerizable 
functional monomers, reaction media and temperatures, a relative ease of use and a high 
tolerance to diverse functional end groups.231 Temperatures reported for RAFT 
polymerization ranged from ambient to 180 °C.233 The really fast exchange reactions in 
RAFT polymerizations lead to well-controlled systems. RAFT polymerization expands the 
possibility to obtain polymers with targeted and controlled molecular weight and chain 
architectures i.e. block, brushes, stars and gradient copolymers.234,235 Among all the RDRP 
methods, RAFT is most likely the most versatile and useful polymerization technique 
thanks to its high tolerance to a wide variety of reaction conditions, which have resulted in 
its increasing utilization and therefore publications about RAFT polymerization.236 For 
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example, Renzo Paulus et al. reported the initiator-free RAFT polymerization of methyl 
methacrylate at high temperature in a microwave reactor.237 Additionally, it is possible to 
conduct RAFT polymerization in a wide variety of solvents, including water, and biologically 
friendly conditions.238,239 RAFT polymerization has also shown itself to be a particularly 
useful technique for the synthesis of water soluble co-polymer both in organic media or 
directly in aqueous media.240 Thanks to its versatility, RAFT polymerization can be adapted 
to produce polymers in a sustainable manner. For instance, RAFT polymerization does 
not require the use of metal catalysts, and can be performed at room temperature, which 
is also useful for many biological applications.222,241 
 
1.4.3 Mechanism and kinetics of RAFT polymerisation 
The mechanism of RAFT polymerization is based on a reversible addition-fragmentation 
chain transfer process promoted by a thiocarbonylthio compound (ZC(=S)S-; see for 
example compound 1) usually called RAFT agent or chain transfer agent (CTA).  
 
 1 
 
The R group initiates the growth of the polymeric chains, while the Z group activates the 
thiocarbonyl bond to give appropriate reactivity towards radical addition.  
 
As degenerative chain transfer does not create radicals, an external source of radicals, 
usually an azo initiator, must be added at the beginning of the reaction, such as 2,2-
azobis(2-methylpropionitrile) (AIBN) or 4,4-azobis(4-cyanovaleric acid)(ACVA). 
 
The mechanism of RAFT polymerization can be described in 5 steps: initiation, pre-
equilibrium, re-initiation, main equilibrium and termination.224 The mechanism is presented 
in Figure 1.12. 
• Initiation: The initiation is the first step of the polymerization. An initiator derived radical 
(I•) is created, which then react with a molecule of monomer (M) to form a propagating 
polymeric radical of length 1. This polymeric radical propagates with monomer (M) to 
give a propagating polymeric radical of length n (Pn•). 
 
• Pre-equilibrium: The polymeric radical Pn• produced in the initiation step reacts with 
the RAFT agent 1 to give the intermediate adduct radical 2. As RAFT agents have high 
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chain transfer constants, in most cases, only a couple of monomers will add to the 
initiator derived radical in the initiation step before adding to a RAFT agent.240 The 
intermediate adduct radical 2 then fragments to yield the polymeric thiocarbonylthio 
compound 3 (macro-RAFT agent) and a new reinitiating radical R•, but may also 
fragment back to the original polymeric radical Pn• and the RAFT agent. The latter 
reaction is not desired and fragmentation of 2 to give 3 and R• can be favoured by 
choosing an appropriate CTA for the monomer being polymerized (i.e. R must be a 
better leaving group than Pn).  
 
• Re-initiation: The radical R• derived from the leaving group R re-initiates 
polymerization by adding to the monomer M, initiating a new propagating polymeric 
radical Pm•. R• must be able to re-initiate polymerization efficiently to avoid any rate 
retardation. To achieve narrow molecular weight distribution, the pre-equilibrium and 
re-initiation steps must be completed relatively early in the reactions (RAFT agent and 
R• fully consumed) so that all the polymeric chains enter the main equilibrium at the 
same time.209,236 
 
 
Figure 1. 12 Mechanism of RAFT polymerisation.224 
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• Main equilibrium: The main RAFT equilibrium is the most important stage of a RAFT 
polymerization. This step involves the propagation of polymer chains by adding 
monomer molecules, and the formation and fragmentation of the intermediate radical 
4 via a process of rapid degenerative transfer of the thiocarbonylthio end group 
between the active polymeric chains Pn• and Pm•. In an ideal RAFT polymerization, 
due to the rapid equilibrium between the propagating polymeric radicals and the 
dormant thiocarbonylthio compound 4, only a few monomer molecules are added to a 
chain in each addition-fragmentation cycle and probabilities for polymer chain growth 
are shared equally among all the existing chains that have not yet undergone 
termination, resulting in low polydispersity index (narrow molecular weight 
distribution).242 
 
• Termination: While termination reactions are limited as compared to conventional 
radical polymerizations due to the rapid process of addition-fragmentation of the main 
RAFT equilibrium, terminations reaction still occurs, either by bimolecular combination 
or disproportionation. Dead polymer chains are unable to undergo further 
polymerization or chain extension and will therefore remain as impurities in the formed 
polymer (unless they can be removed via a purification process). 
 
1.4.4 Choice of the RAFT agent 
Although RAFT polymerization can be used to polymerize a wide range of polymer, 
choosing the CTA carefully and appropriately depending on the synthetic conditions and 
especially depending on the monomer, is crucial to achieve optimal control over a RAFT 
polymerization.243,244 As mentioned in section 4.3.1.4, RAFT agents are thiocarbonylthio 
compounds of formula 1 containing two distinct groups: R a leaving group, and Z an 
activating group.  
To achieve a well-controlled polymerization, the following requirements must be met: 
• The C=S bond must be reactive towards radical addition. 
• The fragmentation of the intermediate adduct radicals must be fast. 
• The fragmentation must be favored towards the formation of the new reinitiating 
radical R• (kβ > -kadd). 
• The radical R• must be able to reinitiates the polymerization efficiently. 
 
There are a wide variety of RAFT agents depending on the chemical nature of R and Z. 
In particular, four principal families of RAFT agents having different reactivity can be 
distinguished depending on the Z group. Indeed, the Z group governs the general reactivity 
of the thiocarbonylthio bond, and must be chosen to promote its reactivity towards radical 
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addition in order to increase the chance of propagating chains to add to the RAFT agent. 
In terms of molecular orbital energy, the Z group affects the energy level of the lowest 
unoccupied molecular orbital of the RAFT agent, therefore determining if radical addition 
is promoted.228,232 For example, if Z allows for the delocalization of π electrons of the C=S 
bond, such as a phenyl group, radical addition is favored. Electron-withdrawing groups 
also favored radical addition while electron-donating group have the opposite effect.244 
Starting from the most active CTA, we find the dithioesters (see for example compound 5 
– carbon adjacent to the thiocarbonylthio moiety), the trithiocarbonates (see for example 
compound 6 – sulfur adjacent to the thiocarbonylthio moiety), the xanthates (see for 
example compound 7 – oxygen adjacent to the thiocarbonylthio moiety) and the 
dithiocarbamates (see for example compound 8 – nitrogen adjacent to the thiocarbonylthio 
moiety). 
 
 
The Z group also plays an important role in the stabilization of the intermediate radicals. 
However, this stabilization must be minimized as over-stabilization can result in slow 
fragmentation of the intermediate radicals causing retardation of the polymerization 
reaction and higher probability of irreversible termination reactions. 
 
The role of the R group is very important in the pre-equilibrium and re-initiation steps. 
Indeed, R must be a good homolytic leaving group, to effectively fragment from the 
intermediate radical and form the radical R•, which in turn, must be able to re-initiate 
polymerization rapidly. For that purpose, R must be a better leaving group than Pn (kβ > -
kadd), or in other words, the stability of the radical R• must be better than the stability of Pn•, 
but the reactivity of R• must still be good enough to re-initiate the polymerization effectively. 
Steric factors, radical stability and polar factors greatly influence the leaving group ability 
of the R group, as more sterically hindered, more stable and more electrophilic radicals 
are better leaving groups.228,243 The leaving group ability of Pn is mainly dependent on the 
structure of the monomer being polymerized, with –kadd decreasing in the following order: 
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methacrylate ~ methacrylamide >> styrenic ~ acrylate ~ acrylamide > vinyl amide > vinyl 
ester.209  
 
The chain transfer coefficient Ctr, given by the relative ratio of the rate constant for chain 
transfer (ktr) to that for propagation (kp), defines the reactivity of a RAFT agent for a given 
monomer. As RAFT polymerization involves addition-fragmentation mechanisms, the rate 
constant for chain transfer ktr is dependent on both the rate constant for addition of the 
radical to the CTA (kadd) and the rate constant for fragmentation of the intermediate radical 
(kβ) as shown in equation 1.8 and 1.9:245 
 
 𝑘𝑡𝑟 =  𝑘𝑎𝑑𝑑𝜙 (1.8) 
 
 
𝜙 =  
𝑘𝛽
𝑘−𝑎𝑑𝑑 + 𝑘𝛽
 (1.9) 
 
ϕ is a partition coefficient which expresses the preference of the intermediate adduct 
radical to return to the starting materials or fragment to products. Ideally, R should be a 
better leaving group than Pn, i.e. ϕ should be > 0.5. 
 
Chain transfer coefficients Ctr of several CTA have been found to vary significantly 
depending on the monomer being polymerized and its Z and R groups (from < 0.01 to > 
1000).228 Theoretically, to yield polymers with narrow molecular mass distribution (PDI < 
1.2) and obtained a linear increase of the average molar mass with the conversion, a Ctr 
of at least 10 is required.245 
 
Depending on their reactivity, radically polymerizable monomers can generally be 
classified into two broad groups: “more activated monomers” (MAMs) and “less activated 
monomer” (LAMs). MAMs usually have their vinyl group conjugated to a carbonyl group, 
such as methyl methacrylates, methyl acrylates and acrylamides, or conjugated to an 
aromatic ring, i.e. styrenes. LAMs typically have their double bond adjacent to an oxygen 
or nitrogen lone pair, e.g. vinyl acetate or N-vinylpyrrolidone, or to a saturated carbon, such 
as diallyldimethylammonium chloride.232,245 MAMs are less active in radical addition than 
LAMs (lower kp and lower kadd). The selection of the RAFT agent is dictated by the type of 
monomer being polymerized. Active CTAs such as dithiobenzoates usually lead to well-
controlled polymerization of MAMs. However, active CTAs tend to inhibit polymerization of 
LAMs as propagation of the chains is extremely hindered by the high rate of addition of 
the propagating radicals to the CTA, and very slow fragmentation of the intermediate 
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radical due to the poor leaving group ability of poly(LAM). As a consequence, less active 
CTAs are used in the polymerization of LAMs, such as xanthates and dithiocarbamates. 
 
General guidelines for the selection of the R and Z groups depending on the monomer 
used, adapted from previous publications, are shown in Figure 1.13. 
 
Figure 1. 13 Guidelines for the selection of the RAFT agent Z and R groups in function of 
the monomer being polymerized. Dashed lines indicate partial control over polymerization. 
Figure adapted from earlier reviews.235,246,247 Abbreviations: MMA: methyl methacrylate, 
HPMAM: N-(2-hydroxypropyl) methacrylamide, St: styrene, MA: methyl acrylate, AM: 
acrylamide, AN: acrylonitrile, Vac: vinyl acetate, NVP: N-vinylpyrrolidone and NVC: N-
vinylcarbazole. 
 
1.4.5 Control of the molecular weight 
The quality of control of RAFT polymerization depends on certain parameters (among 
these parameters is the chain transfer constant Ctr of the RAFT agent, already mentioned 
in section 4.3.1.4). The ratio of initial concentration of monomer to RAFT agent 
([monomer]0/[RAFT]0) determines the average degree of polymerization DPn at full 
conversion, defined as the average number of monomer unit per polymer chain. The ratio 
of initial concentration of initiator to RAFT agent ([I]0/[RAFT]0) affects the chain end 
functionalities. At one chain end, the proportion of chains being initiated with the initiator-
derived radical rather than the R group of the CTA, and on the other chain end, the 
proportion of functional thiocarbonylthio dormant chains to dead chains. This ratio must 
therefore be minimized in order to have a larger amount of dormant chains rather than 
dead chains during the polymerization. A high ratio of RAFT agent to initiator concentration 
can suppress the unwanted side termination reactions. However, the initiator 
concentration must still be high enough to obtain an acceptable polymerization kinetics. If 
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initiator-derived chains are significant, the theoretical number average molecular weight 
(Mnth in g/mol) of a RAFT synthesized polymer can be calculated as follow:248 
 
 
𝑀𝑛
𝑡ℎ =
[𝑚𝑜𝑛𝑜𝑚𝑒𝑟]0
[𝑅𝐴𝐹𝑇]0 + 𝑑𝑓([𝐼]0 − [𝐼]𝑡)
∗ 𝑥 ∗ 𝑀𝑚𝑜𝑛𝑜𝑚𝑒𝑟 + 𝑀𝑅𝐴𝐹𝑇 (1.10) 
 
Where [monomer]0 is the initial concentration in monomer (mol/L), [RAFT]0 is the initial 
concentration in RAFT agent (mol/L), [I]0 - [I]t is the concentration of initiator consumed 
(mol/L), d is the number of chains formed from radical-radical termination (d ≈ 1.67 in MMA 
polymerization), f is the initiator efficiency, x is the monomer conversion (%), Mmonomer is 
the molecular weight of the monomer (g/mol) and MRAFT is the molecular weight of the 
RAFT agent (g/mol). 
 
Assuming that the initiator decomposition kinetic constant kd is known, then the initiator 
consumption can be defined as: 
 
 [𝐼]0 − [𝐼]𝑡 = [𝐼]0(1 − 𝑒𝑥𝑝
(1−𝑘𝑑𝑡)) (1.11) 
 
For a well-controlled RAFT polymerization, the fraction of initiator-derived chains is low, 
and as such, can be neglected. The theoretical average number molecular weight can then 
be expressed with the more commonly used following equation: 
 
 
𝑀𝑛
𝑡ℎ =  
[𝑚𝑜𝑛𝑜𝑚𝑒𝑟]0
[𝑅𝐴𝐹𝑇]0
∗ 𝑥 ∗ 𝑀𝑚𝑜𝑛𝑜𝑚𝑒𝑟 + 𝑀𝑅𝐴𝐹𝑇 (1.12) 
 
The molecular weight of the RAFT agent can be neglected too as it is low as compared to 
the other term of the equation.248 
 
The average number molecular weight increases linearly with the conversion, and the 
obtained polymer has a low polydispersity index and carries a thiocarbonylthio moiety at 
its end chain, making possible a further chain extension (i.e. for the synthesis of block 
copolymer). 
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1.5 Conclusion 
In this chapter, the role of magnetic nanoparticles and more particularly iron oxide 
nanoparticles for magnetic hyperthermia and thermo-chemotherapy application in the 
treatment of cancer has been reviewed.  
 
Water colloidal dispersion of MNPs have yet shown great potential for use as heat-
mediator agents, and efforts in the field have led to promising preclinical and clinical 
studies. However, MFH is still far from achieving its full clinical potential. Most of the 
research on magnetic nanoparticles-mediated hyperthermia therapy have been directed 
toward MNPs exhibiting good biocompatibility and improved SAR value. However, as the 
SAR increases with increasing frequency and amplitude of the applied field, one needs to 
pay careful attention as a too strong AMF may generate eddy currents and cause non-
specific heating that can damage both healthy and cancer tissues.  
 
Magnetic hyperthermia combined with drug delivery does not require working 
temperatures as high as those used for hyperthermia therapy alone. Indeed, as discussed 
in this chapter, the thermal enhancement of drug cytotoxicity is maximized at mild 
hyperthermia temperatures. Moreover, it has been proven many times through in vitro as 
well as in vivo studies that the combination therapy is far more effective than either 
hyperthermia or chemotherapy alone. As the combination of hyperthermia and 
chemotherapy in a same MNP-based nanotherapeutic system is relatively new, there are 
still some obstacles to tackle before clinical trials can be carried out. A high drug loading 
should be achieved and drug diffusion from the nanocarriers should be suppressed to limit 
systemic delivery. The pharmacokinetics and pharmacodynamics of the nanosystem need 
to be studied for a better comprehension and a possible increase in the treatment efficacy. 
However, thermo-chemotherapy by means of a magnetic nanosystem gathers all the 
numerous advantages of MFH over traditional hyperthermia and controlled drug release 
over traditional chemotherapy. Better anti-cancer effects at lower drug therapeutic dose 
and lower temperatures are achieved with the combined therapy. The possibility to trigger 
the drug release in cancer site owing to the use of pH- or thermo-sensitive nanocarriers is 
a particularly attractive feature to control the spatiotemporal release of the drug. 
 
This chapter has established the basics and fundamentals needed to understand the 
motivation behind and the aim of the work presented in this thesis. 
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1.6 Thesis outline 
This thesis reports the development of a doxorubicin-loaded dual pH- and thermo-
responsive magnetic nanocarrier for application in thermo-chemotherapy of cancer and is 
divided among seven chapters. The first chapter deals with the introduction and wide 
literature review of multifunctional therapeutic nanosystems incorporating both magnetic 
nanoparticles and drugs, and their superior efficacy in treating cancer compared to either 
hyperthermia or chemotherapy as standalone therapies. The principle of magnetic fluid 
hyperthermia is also presented, along with a study of the different parameters influencing 
the heating performances of the nanoparticles. This first chapter also elaborates the 
necessary background of the field, including the mechanisms responsible for the 
synergistic effect of the combined thermo-chemotherapy. The following chapter (chapter 
2) explains the principles and fundamentals of the different characterisation techniques 
used in this work. Chapter 3 describes initial experimentations primarily focused on the 
synthesis of core@shell iron@bismuth nanoparticles of high magnetic moment. These 
nanoparticles would have been used as the magnetic core of the nanocarrier, however, 
despite numerous trials, such nanoparticles could not be obtained. Iron oxide 
nanoparticles were chosen as a substitute and the synthesis of the nanoparticles and 
polymer, the functionalisation, drug loading and release studies are presented in chapter 
4. The potential of the developed magnetic delivery system for thermo-chemotherapy 
applications was investigated in chapter 5 using two different cancer cell lines, and 
compared to either magnetic hyperthermia or chemotherapy as standalone treatment. The 
delivery system was found to be a really promising tool in the treatment of cancer, and 
further in vitro studies using the bioluminescence imaging method were performed in 
chapter 6. Chapter 7 concludes the entire work of this thesis. 
 
Part of the work described in this thesis has been published or presented at different 
national and international conferences. These are listed in Appendix I. 
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CHAPTER 2 
CHARACTERISATION TECHNIQUES 
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2.1 Introduction 
Before any material can be used for biomedical applications, it is required to fully characterise 
it to analyse and understand its behaviour and properties. The following chapter focuses on 
explaining the basics and principles of all the techniques used in this work to characterise the 
different materials and nanosystems. 
 
 
2.2 X-ray powder diffraction 
2.2.1 Principle 
X-ray diffraction (XRD) is a physico-chemical analysis technique used to determine the 
crystalline structure of a material in the form of a powder. A crystal structure is a highly 
ordered structure and is defined by the periodic three-dimensional repetition of an atomic 
pattern with interatomic distances in the Angstrom order. 
 
X-rays are electromagnetic radiations constituted of photons with frequency within 1016 - 
1019 Hz (equivalent to a wavelength in the Angstrom order). X-ray photons are generally 
generated during electronic transitions involving the ionisation of an electron in the inner 
shells of an atom. Three main ways can be distinguished in the generation of X-rays:  
➢ Bombarding a metallic anode (often constituted of copper or molybdenum) with a 
beam of electron extracted from a metallic filament (generally tungsten) electrically 
heated, and accelerated with an electric voltage. 
➢ The disintegration of certain radioactive sources generates X-rays. 
➢ Exposing a material to an X-ray beam to generate a secondary fluorescent X-ray 
beam. 
 
In XRD, the X-ray beam is generated by the first method, where electrons of sufficient 
energy collide with a metallic material. When the electrons hit the anode, X-rays can be 
created by two different mechanisms: (1) the braking of the electrons provoked when 
deflected by the electric field of the atom nucleus gives rise to a continuum spectrum of 
radiation, known as Bremsstrahlung, and (2) the electrons have enough energy to eject 
core electrons from the inner shell (K-shell) of a metal atom composing the anode. The 
unstable energy states are compensated by the dropping of electrons from higher energy 
levels to fill up the vacancy and the difference in energy may be emitted as an X-ray 
photon, leading to an emission spectrum of fluorescent X-rays. The second mechanism is 
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wanted in XRD and the wavelength of the X-ray beam will therefore depend upon the metal 
composing the anode and upon the electronic shell the outer electron drops from.249 
 
The XRD technique requires the bombardment of a powder sample with a beam 
constituted of monochromatic and parallel X-rays. A monochromatic X-ray beam is needed 
to obtain an experimental pattern from a unique wavelength. Filtering, by foils or crystal 
monochromators, is used to produce monochromatic X-rays needed for diffraction. 
Interatomic distances and X-ray wavelengths are in the same order of magnitude. 
Therefore, a crystal can scatter X-rays, but the interaction between the X-rays and the 
matter depends upon the crystalline structure of the sample. The scattering of X-rays from 
atoms produces a diffraction pattern, which contains information about the atomic 
arrangement within the crystal. The scattered waves cancel one another in most directions, 
and constructive interferences are obtained only in a few specific directions determined by 
Bragg’s law: 
 
 𝑛𝜆 = 2𝑑ℎ𝑘𝑙 sin 𝜃 (2.6) 
 
Where n is a positive integer number, λ is the X-rays wavelength, dhkl is the distance 
between diffracting planes and θ is the incident angle. For X-rays hitting parallel planes of 
atoms, the path length difference between these X-rays must be a multiple of their 
wavelength, and as can be seen from Figure 2.1, it’s a multiple of 2𝑑ℎ𝑘𝑙 sin 𝜃. 
 
Figure 2. 1 Diffraction of X-rays from an ordered arrange of atoms. 
 
 
In order to satisfy Bragg’s law, a material of specific crystalline structure will always give 
rise, for a given X-ray wavelength and incident angle, to diffraction peaks in the same 
direction. The characteristic set of d-spacings generated in a typical X-ray scan can be 
considered to provide a unique fingerprint of the mineral or minerals present in the sample. 
A diffraction pattern is therefore characteristic of a given crystalline structure and reference 
powder data files (PdF) allow for the identification of the crystalline phase. 
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2.2.1 Instrumentation 
The most commonly found geometric arrangement for X-ray powder diffractomers is 
known as the Bragg-Brentano parafocusing system.250 It is built around a goniometer of 
fixed radius requiring that the source-to-sample distance be constant and equal to the 
sample-to-detector distance as can be seen in Figure 2.2. This geometry offers the 
advantages of high-resolution and high beam-intensity analysis at the cost of very precise 
alignment requirements. 
 
Figure 2. 2 Schematic representation of a powder diffractometer with Bragg-Brentano 
parafocusing geometry, where F is the X-ray source, DS is the incident-beam divergence-
limiting slit, SS is the Soller slit assembly, S is the sample, RS is the diffracted-beam 
receiving slit, C is the monochromator crystal AS is the anti-scatter slit.251 
 
Typically, the X-ray beam issued from the source F passes through the divergence slit DS 
and the Soller slit SS1 to illuminate the sample. The incident- and diffracted-beam slits 
move on a circle that is centred on the sample. Divergent X-rays hitting the sample at 
different points on its surface are diffracted. The diffracted X-rays are refocused at the 
receiving slit RS on the focusing circle before reaching the detector. The diffracted X-ray 
photons are translated into voltage pulses. Because the scanning speed of the goniometer 
is known, each angle 2θ can be related to its intensity and a plot of the angle 2θ versus 
intensity can be obtained, called a diffraction pattern or diffractogram. This geometric 
arrangement provides the best combination of intensity, peak shape, and angular 
resolution for the widest number of samples. The divergence slits are used to limit the 
divergence of the incident X-ray beam. Narrow divergence slits produce sharper peaks but 
is achieved at the expense of intensity loss as the intensity of the X-ray beam and the 
length of the X-ray beam hitting the sample and is reduced. 
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2.2.2 Sample preparation and analysis 
For the work in UK, XRD diffraction patterns were obtained using an X-ray diffractometer 
PanAlytical with a cobalt metallic anode (λ = 1.789010 Å) in 20°-100° 2θ range for IONPs 
and in 20°-120° 2θ range for core@shell Fe@Bi NPs. Samples were prepared by flattening 
the dry powder on a zero background silicon wafer. Patterns fitting and corrections were 
carried out with PANalytical X’Pert HighScore Plus software. 
For the work in Japan, XRD diffraction patterns were obtained using a Rigaku Miniflex600 
with a copper metallic anode (λ = 1.540593 Å). 
 
The study and interpretation of an obtained diffractogram mainly focuses on the position, 
the intensity and the full width at half maximum of the peaks. The diffraction pattern for a 
crystalline sample is characteristic of its crystalline structure, and comparison with PdF 
files allows for identification of the material(s) that compose the sample. 
 
 
2.3 Superconducting quantum interference device – 
vibrating sample magnetometer 
2.3.1 Principle 
A superconducting quantum interference device (SQUID) is a magnetometer which allows 
for the measurement of weak magnetic fields. A SQUID is generally composed of two 
parallel Josephson junctions in a superconducting solenoid (Figure 2.3). The apparition of 
a current between two superconducting materials separated by a thin layer of an insulating 
material is called the Josephson effect. The superconducting current is carried by pairs of 
bound electrons, known as Cooper pairs, which travel across the junction by quantum 
tunnelling effect. If a superconducting ring is placed in a magnetic field, the magnetic flux 
penetrating the ring is quantised in units,252 and this magnetic flux quantum is equal to 2.07 
Tm².253 The great sensitivity of SQUID devices is associated with measuring changes in 
magnetic field associated with one flux quantum. The ratio between the magnetic flux and 
the flux quantum determines the outcome of interference effects in SQUID devices. This 
interference allows highly sensitive measurements of magnetic flux and thus of magnetic 
field and magnetic moment linked to the flux quantum. If a constant predetermined current 
is maintained in the superconducting solenoid, the measured voltage oscillates with the 
changes in phase at the two junctions, which depends upon the change in the magnetic 
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flux. The flux change that has occurred is evaluated by monitoring the oscillations of the 
voltage. 
 
Figure 2. 3 Superconducting solenoid with two Josephson junctions in a SQUID flux 
sensor. 
 
A SQUID device is ultra-sensitive for the detection of really small variations of the magnetic 
flux and it is therefore possible to measure really weak magnetic fields, but the 
measurement is really slow. The most common commercial use of SQUID devices is in in 
magnetic property measurement systems (MPMS). 
 
A vibrating sample magnetometer (VSM) allows for the quick measurement of a sample 
magnetic behaviour but is not as sensible as a SQUID. Generally, the sample is positioned 
in the vicinity of pickup coils and subjected to a magnetic field. The voltage induced in the 
pickup loop is measured as the sample is vibrating sinusoidally. The vibration amplitude 
of the sample is dependent on its magnetic moment and thus, the measured change in 
voltage can be transformed into magnetic moment using a palladium calibration standard 
material with a known magnetic moment.  
 
A hybrid SQUID-VSM combines the high sensitivity of a SQUID and the high speed of 
measurement of a conventional VSM and therefore allows for rapid measurement of weak 
magnetic fields. 
 
2.3.2 Measurements 
Magnetic measurements were performed with a MPMS Quantum Design hybrid SQUID-
VSM. Its superconducting solenoid is made of niobium-titanium alloy. 
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Before starting any measurement, samples were demagnetised in order to start the 
measurement with a randomly oriented sample and suppress any memory effect. 
 
2.3.2.1 Magnetisation curves 
Magnetisation curves or M(H) hysteresis curves of magnetic nanoparticles were measured 
at 300 K and 5 K with applied magnetic field ranging from -7 T to 7 T. 
 
2.3.2.2 Zero field cooled/field cooled curves 
Zero field cooled/field cooled (ZFC/FC) curves were measured with an applied field of 100 
Oe between 5 K and 400 K. In a first step, the sample is cooled at 5 K without any applied 
magnetic field. Then, data are recorded while heating at 5 K/min with application of a 100 
Oe field, this is the ZFC curve. For the FC curve, data are recorded while cooling back to 
5 K at 5 K/min with an applied field of 100 Oe. 
 
2.3.3 Data correction 
In order to get accurate values of magnetisation and coercive field, post measurement 
processing is necessary due to “errors” caused by flux pinning sites in the superconducting 
magnet. Indeed, superconductors repel magnetic field but at large applied field, field lines 
each carrying a flux quantum can enter the magnet and these pinned sites remain in the 
magnet even after removal of the field.254,255 As a consequence, these pinned sites lead to 
magnet remanence and a superparamagnetic sample may appear hysteretic. The pinned 
sites and associated magnetic remanence are dependent on the superconducting magnet 
architecture. It is therefore different for each magnet and can be corrected. This 
remanence is reported as an offset of the magnetic field and can be calculated using a 
highly paramagnetic salt such as dysprosium oxide (Dy2O3). As M = χH, the magnetic 
moment follows a linear relationship, where χ, the magnetic susceptibility, is the slope of 
the curve. Consequently, any deviations from the linear behaviour are due to the magnet 
history.  
For both M(H) and ZFC/FC curves, running a demagnetization sequence with a small 
applied field to compensate magnet remanence prior to measurement is necessary to 
achieve a true zero field. For M(H) curves, post processing is required to correct the 
recorded data using the calibration curve recorded for Dy2O3 and extract accurate values 
of the remanent magnetisation as well as of the coercive field. 
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2.4 Transmission electron microscopy 
2.4.1 Principle 
Transmission electron microscopy (TEM) is an imaging technique where an electron beam 
is steered onto a really thin sample. The electrons interact with the sample as they pass 
through. The image, whose resolution can reach 0.08 nm, is created from the interaction 
of the transmitted electrons through the sample. Thanks to a system of magnetic lenses, 
the sample image is projected onto a fluorescent screen or charge coupled device (CCD) 
camera, which transforms the electronic image into an optical image.  
 
2.4.2 Instrumentation 
The sample is situated between the condenser and the objective lenses. The beam of 
electrons can be generated by either a thermionic or a field-emission electron gun. In order 
to increase the mean free path of the electrons, the microscope is generally evacuated to 
low pressure. In the case of a field-emission source, the electrons are generated by 
applying an important difference of potential on a W needle tip. In the case of a thermionic 
source, a metallic filament (composed of W or LaB6) with a V shape is heated to a high 
temperature to accelerate the movement of electrons. A small number of electrons reach 
the tip of the V with a so high velocity that they are ejected from the metal. The V shape 
ensures that the electrons are emitted from a small area. The electrons then pass through 
a Wehnelt, an electrode that serves as a convergent electrostatic lens for focusing and 
control of the electron beam. It is set to a negative voltage relative to the filament and to 
condense the beam of electrons. The electrons travel across an anode, and are 
accelerated towards the sample due to the high difference of potential that is applied. 
Then, the electron beam passes through a system of magnetic lenses. Firstly, the 
condenser lenses which control the region of the sample being illuminated, and allows for 
the manipulation and focusing of the beam on the sample. Secondly, the objective lenses 
which enables the magnification of the image. The image is then magnified again by mean 
of the intermediate and projecting lenses before reaching the detector and the image is 
finally projected on a fluorescent screen or a CDD camera (Figure 2.4). 
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Figure 2. 4 Schematic representation of a TEM and its components. Image taken from 
https://global.britannica.com/technology/transmission-electron-microscope 
 
2.4.3 Sample imaging 
TEM was used to observe the size, size distribution, shape and in a certain extent the 
aggregation state of the nanoparticles. Samples were prepared by putting a drop of the 
nanoparticle suspension on the surface of a carbon-coated copper grid and air-dried. 
 
For the work in UK, the TEM images of the inorganic NPs were acquired with a JEOL JEM-
1200EX, with a thermionic electron gun (W filament) working at a voltage of 120 kV. The 
microscope also combined a Gatan Orius SC200B CCD camera giving the opportunity for 
real time capture images. This system allows for image resolution of 0.3 nm. 
For the work in Japan, a Hitachi H-7650 transmission electron microscope with a 
thermionic electron gun operated at an acceleration voltage of 100 kV was used to acquire 
images of the NPs. This system allows for image resolution of 0.1 nm. 
 
 
2.5 Dynamic light scattering 
Dynamic Light Scattering (DLS) is a spectroscopic analysis technique, which allow for the 
determination of the hydrodynamic size of small particles in a liquid suspension. DLS uses 
a laser as a source of light. When the light interacts with particles animated by Brownian 
motion, the light is scattered in all directions. The measurement of fluctuations in the 
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scattering intensity over time at a given angle gives information about the velocity of the 
particles, related to their diffusion coefficient D. The particles size can then be calculated 
thanks to the Stokes-Einstein equation: 
 
 
𝐷𝐻 =
𝑘𝑇
3𝜋𝜂𝐷
 (2.2) 
 
Where DH is the hydrodynamic diameter of the particles, k is the Boltzmann’s constant, T 
is the temperature, η is the liquid carrier viscosity, and D is the diffusion coefficient. 
 
The hydrodynamic diameter of the nanoparticles was measured using a dynamic light 
scattering Malvern Nanosizer ZS instrument with a He-Ne laser at a wavelength of 633 
nm. For hydrodynamic diameter measurements, samples were prepared by diluting a drop 
of nanoparticle aqueous suspension in milli-Q water into a disposable cuvette. 
 
 
2.6 Attenuated total reflectance- Fourier transformed 
infra-red spectroscopy (ATR-FTIR) 
Fourier transformed infra-red (FTIR) spectroscopy is a technique, which allow for the 
identification of the molecular structure of a sample. FTIR is based on the measurement 
of how well electromagnetic radiations whose wavelengths lie in the mid infrared region 
(4000-400 cm-1) are absorbed by a solid, liquid, or gas sample. Rather than illuminating a 
sample with a monochromatic beam of light, this technique shines a beam containing many 
wavelengths of light at once, and measures how much of that beam is absorbed by the 
sample. Next, the beam is modified to contain a different combination of wavelengths, 
giving a second data point. This process is repeated many times. Afterward, a computer 
takes all this data and works backward to deduce what the absorption is at each 
wavelength. The name “Fourier transform infrared spectroscopy” originates from the fact 
that a Fourier transform is required to convert the raw data into the actual spectrum.  
 
Infrared spectroscopy relies on the fact that molecules possess specific frequencies at 
which they vibrate. If the frequency of a radiation matches the vibration frequency of a 
molecule, this molecule absorbs the energy of the radiation and a diminution of the 
transmitted or reflected intensity is recorded. The absorbed frequencies are resonant 
frequencies and are characteristic of the molecule structure. However, for a vibrational 
mode to be IR active, meaning for a molecule to show infrared absorptions it must possess 
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a specific feature, i.e. the electric dipole moment of the molecule must change during the 
vibration. The dipole moment of a molecule changes as the bond expands and contracts. 
An example of an IR inactive molecule is a homonuclear diatomic molecule because its 
dipole moment remains zero no matter the length of the bond. Thus, not all the vibrations 
necessarily result in absorption: it depends on the geometry and symmetry of the molecule. 
Each vibration involves all the atoms of the molecule, but the vibration tends to be more 
accentuated on a specific region or functional group of the molecule. The position of the 
vibration bands strongly depends on the strength of the bond and the mass of the atoms. 
As a consequence, a sample of a given chemical structure and composition will provide a 
spectrum in which the position of absorption bands is characteristic of the nature, 
proportion, and orientation of the chemical bonds. The intensity of the absorption band is 
related to the concentration of the functional group responsible of the absorption. 
 
Attenuated total reflectance (ATR) sampling is often used in conjunction with IR 
spectroscopy, because it makes possible the analysis of sample in the liquid or solid state 
without any further preparation. ATR uses a crystal with a high refractive index, so that the 
infra-red beam which is directed onto the crystal is totally reflected, leading to the formation 
of an evanescent IR wave within the crystal that extends into the sample. The evanescent 
waves are attenuated in the IR region and are therefore absorbed by the sample.  
 
Solid samples must be pressed onto the ATR crystal with an appropriate force thanks to a 
tip to improve the penetration of the evanescent wave (and prevent air region in the case 
of a powder) while the surface tension of the liquid is generally enough to ensure a direct 
contact with the crystal. 
 
In this work, FTIR absorption spectra were recorded with a Perkin Elmer Spectrum 100 
spectrometer. 
 
 
2.7 Thermogravimetric analysis 
Thermogravimetric analysis (TGA) is a technique of thermal analysis, which consists in 
measuring the changes in chemical and physical properties of a material as a function of 
time with constant temperature applied, or as a function of temperature using a constant 
heating rate. Information about physical phenomena such as second-phase transitions can 
be provided, or about chemical phenomena such as oxidation or decomposition of the 
compound. 
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In our case TGA analysis is used to determine the percentage of organic compound in our 
NPs by measuring the weight loss of a sample of known initial mass (as the organic part 
burns at lower temperatures than the inorganic one). The TGA instrument continuously 
records the mass of the sample as it is being heated. Components decomposed with 
increasing temperatures resulting in a mass change, and therefore the weight percentage 
of each component can be calculated. TGA analysis requires very precise measurement 
of the mass and temperature. The instrument is generally composed of a hermetic sample 
chamber which can be purged with inert gas if necessary (i.e. to prevent oxidation), a 
programmable furnace, and a precision balance. The sample is placed in a pan, either 
made of aluminium for measurements at temperatures below 600 °C, or made of platinum 
for measurement at temperatures above 600 °C, that is positioned on the balance. 
 
Samples under the form of a dry powder were placed on an aluminium pan and heated 
from 25 °C to 500 °C at a rate of 10 °C /min under N2 atmosphere on a Seiko EXSTAR600 
TG/DTA 6200 instrument. Prior to the measurement, powders were heated to 100 °C for 
30 min to remove water that could be present in the sample. 
 
 
2.8 Magnetic Alternative Current Hyperthermia (MACH) 
System 
In UK, the heating potential of the synthesised MNPs for hyperthermia therapy has been 
assessed using an in-house patented magnetic alternative current hyperthermia (MACH) 
system.256 The MACH system is able to generate an alternating magnetic field of frequency 
in the MHz region and high field amplitude. The magnetic field is dependent on the 
capacitor and the coil combination configuration, being capable to generate magnetic 
fields up to 20 kA.m-1 (250 Oe) with a 100 kHz - 2 MHz frequency range. 
 
The MACH system is composed of a 6-turn coil (inductor) and a capacitor that creates a 
resonance circuit allowing for the generation of very large magnetic field (Figure 2.5). 
Voltage from the sense coil is fed back into a control circuit that creates a pulse of current 
at the right frequency and at specific time points to prevent the current intensity to drop. A 
chiller is used as a cooling system to limit heating effects. 
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Figure 2. 5 Photos of the MACH system. 
 
A 6-turn coil was employed to measure the heating performances of MNPs in suspension 
and for in vitro experiments. The 6-turn coil provides a homogeneous field distribution at 
the center of the coil. Glass vials with a volume of 1 mL were used as containers and 
positioned in the middle of the coil with the help of a support that fix the position of the vial 
and help for experiment reproducibility. The same volume of MNP or cell suspension (0.5 
mL) was adopted for all the experiments. The increase in temperature over time was 
measured with fibers optic probes centered in the suspension.  
 
 
For the work in France, a DM3 system manufactured by nanoScale Biomagnetics was 
used (Figure 2.6). The DM3 system has 4 working frequencies of 146, 217, 344.5 and 
473.5 kHz and capable to generate magnetic fields up to 20 kA.m-1. It is mainly designed 
for in vivo experiments, but can be used for the characterisation of magnetic nanoparticle 
suspensions and for in vitro experiments by positioning the vial or the petri dish at the 
center of the coil. The increase in temperature over time was measured with fibers optic 
probes centered in the suspension.  
 
Figure 2. 6 Photos of the DM3 setup. 
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2.9 UV-visible spectroscopy 
UV-visible spectroscopy is a spectroscopy technique based on the measurement of the 
absorption of photons whose wavelengths are within the ultraviolet (200 – 400 nm) or the 
visible ranges (400 – 750 nm). When a material is exposed to light in this region of the 
electromagnetic spectrum, molecules or ions are susceptible to undergo one or several 
electronic transitions. Valence electrons on the ground state are excited and passed to a 
state of higher energy. This transition involves π-electrons and generally occurs between 
a bonding orbital (highest occupied molecular orbital) and an empty anti-bonding orbital 
(lowest unoccupied molecular orbital). In most cases, samples are analyzed in solution. 
 
A UV-visible spectrophotometer is usually composed of a light source, a monochromator 
to separate the different wavelengths, and a detector. The instrument measures the 
intensity of the light transmitted through a sample (I) as compared to the intensity of the 
light transmitted through a reference containing the same solvent as the one used for the 
sample to be analyzed (I0). The ratio I/I0 (in %) is called transmittance (T). The absorbance 
(A) is then expressed as follows: 
 
 𝐴 =  − log(𝑇) (2.3) 
 
The UV-Vis spectroscopy technique is often used as a quantitative technique to measure 
the concentration of a given compound in solution by using the Beer-Lambert’s law: 
 
 
𝐴 =  − log (
𝐼
𝐼0
) = 𝜀𝑙𝑐 (2.4) 
 
Where l is the path length (cm), c is the concentration of the absorbing compound (mol.L-
1) and ε is the molar absorptivity or extinction coefficient (in L.mol-1.cm-1). ε is a constant 
for a given species and wavelength. As for a given wavelength the product εl is a constant, 
it can be determined by plotting a calibration curve made from solutions of known 
concentration of the absorbing specie. It is then easy to determine the concentration of 
that compound in solution. 
 
A JASCO V-630 spectrophotometer was used to determine the absorbance/concentration 
of DOX in aqueous solution. Absorption spectra were recorded between 350 nm and 600 
nm. 
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The LCST of the polymer in aqueous solution was determined using a JASCO V-630 
spectrophotometer equipped with an EYELA NCB-1200 temperature controller. The 
solution was heated from 25 °C to 47 °C whilst the transmittance was recorded at 540 nm. 
The LCST value was interpreted as the temperature at which the solution transmittance 
reached 80%. 
A SpectraMax M2e multi-mode microplate reader was used to determine the 
absorbance/cell viability during the in vitro cytotoxicity studies of the nanosystems realised 
by MTT assay. 
 
 
2.10 Nuclear magnetic resonance spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a technique based on the NMR 
phenomenon and exploits the magnetic properties of some atomic nuclei. NMR 
spectroscopy can provide information about the molecular structure and purity of a 
compound. NMR is a physical phenomenon that describes a property of some atomic 
nuclei having a nuclear spin placed in a magnetic field. When they are subjected to a radio-
frequency pulse, they can absorb the energy of the electromagnetic radiation and then re-
emit it during the relaxation. This only works if the pulse is applied at a very specific 
frequency called the resonance frequency.257 This resonance frequency is different for 
each isotope as it depends upon the magnetic properties of the isotope of the atoms and 
is directly proportional to the strength of the applied magnetic field. Only nuclei having a 
non-zero nuclear spin can give rise to the NMR phenomenon. The most commonly studied 
nuclei are 1H and 13C, although nuclei from isotopes of many other elements have been 
studied by NMR spectroscopy as well. 
 
Many nuclei are magnetic, meaning that they will interact with a magnetic field. This 
interaction can be expressed as a magnetic moment. The larger the magnetic moment, 
the stronger is the interaction. When a magnetic nucleus is placed in a magnetic field, the 
response of the nuclear magnetic moment (due to the spin) is to retain its orientation with 
respect to the magnetic field, and to rotate around it. This is known as precession (Figure 
2.7). The magnetic moment describes a cone with an angle that is dependent upon its 
initial position when the magnetic field was applied. 
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Figure 2. 7 Precession of the magnetic moment. 
 
This precession movement is called Larmor precession and its angular frequency depends 
upon two factors, the gyromagnetic ratio γ and the strength of the magnetic field B: 
 
 𝜔𝐿 = −𝛾𝐵 (2.5) 
 
ωL, the precession frequency of the nuclear magnetic moment otherwise known as the 
Larmor frequency, is the resonance frequency of the nucleus. Typical values for it are on 
the order of MHz. In a standard magnetic field strength of 11.7 T, the magnetization of the 
1H nucleus precesses at a Larmor frequency of 500 MHz (and a spectrometer with this 
field strength would therefore be referred to as “a 500”). The gyromagnetic ratio γ is literally 
the ratio between the “gyroscopic” (precessional) frequency and the magnetic field 
strength. This is a fundamental quantity that is fixed for each nuclear isotope. 
 
NMR spectroscopy, in its most basic form, is the measurement of the precession frequency 
of nuclear magnetism. A bulk system composed of many nuclei will, through longitudinal 
relaxation, develop a net magnetization parallel to the external magnetic field (along the z-
axis). In an NMR experiment, this magnetization is tipped into the x-y plane using an 
electromagnetic pulse and its precession frequency is measured. 
 
NMR spectroscopy can provide detailed information on the structure and dynamics of a 
sample down to a molecular level. It is non-destructive and can be applied to almost any 
type of sample (gases, liquids, solids, heterogeneous, viscous…). Specific nuclei can be 
targeted, allowing local characterization of specific regions of a molecule. The information 
that NMR can potentially provide includes local coordination environments, molecular 
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structures, bond lengths and angles, motional rates, geometries and activation energies, 
2D and 3D images (magnetic resonance imaging) and diffusion coefficients. 
1H NMR spectroscopy was used to monitor the polymerization reaction advancement and 
analyse the polymer composition. 1H NMR spectra were recorded on a Bruker Avance III 
400 MHz NMR spectrometer using chloroform-d as a solvent. 
 
 
2.11 Gel permeation chromatography 
Gel permeation chromatography (GPC) is a type of size exclusion chromatography (SEC). 
SEC is a method of chromatography in liquid phase allowing for the separation of 
macromolecules on the basis of hydrodynamic size. It is a widely used technique for the 
analysis of polymers as it can provide important information concerning the 
characterization of the polymer such as the polydispersity index and the average molecular 
weight in number, weight and size. Depending on the nature of the two phases, we can 
distinguish the GPC and the gel filtration chromatography. 
 
 
Figure 2. 8 Schematic illustration of the principle of size exclusion chromatography. Figure 
taken from http://cnx.org/contents/uieDnVBC@21.1:28CLlnd_@2/Size-Exclusion-
Chromatography- 
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Unlike the methods of affinity chromatography which depends on the chemical affinity of 
the compound with the substrate, the main physical phenomenon GPC makes use of is 
the hydrodynamic volume of macromolecules in solution. The stationary phase of a GPC 
is made of porous beads packed in a column. Depending on their sizes, the molecules 
constituting the analyte may more or less enter the pores of the stationary phase. Thus, 
the smaller analytes can penetrate the pores more easily and are retained longer, 
increasing their retention time, while the bigger ones can barely or cannot penetrate the 
pores and are therefore eluted faster (Figure 2.8).  
 
Every column has a specific range of molecular weights that can be separated: too large 
macromolecules will not be retained and elute with the free volume (volume outside of the 
beads) while too small molecules will be completely retained and elute at the end of the 
injection with the eluent. Macromolecules having a molecular weight in between those two 
limits can be separated. This is known as the fractional range. Data analysis outside this 
fractional range does not provide any information. In order to obtain the average molecular 
weight of a polymer, calibration of the GPC with standard polymers of known average 
molecular weight and low polydispersity is necessary. Commonly used polymers for the 
calibration of the GPC are polystyrene or poly(methyl methacrylate) standards. 
 
A GPC instrument is similar to any liquid chromatography equipment. It is composed of a 
solvent reservoir, a pump that constantly delivers fresh eluent to the column at a precise 
and constant rate, an injector, a column and one or multiple detectors. The eluent should 
be a good solvent of the polymer as samples are dissolved in it prior to injection. 
 
Number average molecular weight (Mn) and polydispersity (PDI = Mw/Mn) of the 
synthesized polymers measured by SEC were performed on a Shimazdu Prominence 
high-performance liquid chromatograph equipped with a LC-20AD liquid chromatograph, 
a RID-10A refractive index detector, a CTO-20A column oven and a DGU-20A3 degasser. 
Tetrahydrofuran (THF, stabilizer free) was used as the mobile phase. Samples were 
prepared by dissolving 5 mg of vacuum-dried polymer in 2 mL of THF. THF was constantly 
delivered to the column with a uniform flow of 1 mL/min. The molecular weights of the 
polymers were determined by a conventional calibration using polystyrene standards 
ranging from 5.8 x 102 g/mol to 2.0 x 104 g/mol. 
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2.12 Flow cytometry 
Flow cytometry is a widely used technique for characterizing and analyzing particles in 
suspension, i.e. cells, bacteria or chromosomes. Typically, particles of size comprised 
between 0.2 μm to 150 μm are suitable for flow cytometry analysis. Flow cytometry can 
give information about biophysical properties of a sample, such as granularity or internal 
complexity, size and fluorescence intensity. Cytometers samples must be in the form of 
liquid suspensions as the properties of single particles are simultaneously measured as 
they flow in a fluid stream through a laser beam. 
 
A BD Accuri C6 flow cytometer (BD Bioscences, UK) was used in this work to perform flow 
cytometry analyses on cells in suspension. 
 
A flow cytometer is constituted of three main parts. The first part is the fluidic system, which 
transports the particles via a flow of sheath fluid into a flow chamber (also called flow cell), 
where a beam of light will interact with the particles. Based on laminar flow principles, the 
design of the flow cell is made so that the fluid stream carrying the particles is focused in 
the center of the laser beam and only one particle at a time pass through the laser beam, 
allowing for interrogation of single particles. This process is known as hydrodynamic 
focusing. The scattered light and the fluorescence emitted as particles move through the 
laser beam are measured and analyzed. The optic subsystem is made of excitation 
components and collection components. The excitation optics consist of the laser, prisms 
and lenses used to shape and focus the laser beam to the interrogation point. The optic 
collection components consist of lenses positioned appropriately to collect the forwarded 
scattered, side scattered and fluorescence light. Finally, the electronic part of a flow 
cytometer is composed of detectors (photodiodes and photomultiplier tubes) which convert 
the light intensity measured into electronic signals. More information about this technique 
can be found in the comprehensive book about flow cytometry published by H. M. 
Shapiro.258 
 
2.12.1 Light scattering 
When a particle passes through a beam of light, light scattering occurs. In a cell, the degree 
of light scattering is dependent upon its physical properties, such as its size, shape, 
nucleus, internal complexity and granularity. Depending on the direction the light is 
scattered, two types of scattered light can be distinguished: forward scattered light (FSC) 
and side scattered light (SSC) (Figure 2.9). 
 
 89 
 
 
Figure 2. 9 Light scattering of a cell passing through a beam of light. 
 
The scattered light in the forward direction is based on the size or surface area of the cell 
and the difference between the refractive indexes of the cell and the sheath fluid. 
Increasing size and difference between the refractive index both increases the generation 
of FSC. FSC is mainly due to diffracted light. The SSC is mainly dependent upon the cell 
granularity. The more granular a cell is the more SSC is generated. SSC is mainly due to 
refracted and reflected light, and is collected perpendicular (at approximatively 90°) to the 
laser beam. Correlated measurement of FSC and SSC can allow for differentiation of cell 
types in a sample of heterogeneous cell composition. Furthermore, it can also be used to 
study the cell uptake and internalization of nanoparticles or drugs as the SSC increases 
with the degree of loading. 
 
2.12.2 Fluorescence 
Fluorescence is the emission of light induced by the excitation of a molecule, generally by 
absorption of a photon, i.e. by absorption of light, immediately followed by a spontaneous 
emission. Indeed, this absorption of light energy promotes a valence electron in the ground 
state to an excited state of higher energy. The electron quickly relaxes back to its ground 
state emitting the excess energy as a photon of light, called fluorescence. 
Every fluorescent compound, also called fluorophore or fluorochrome, has a characteristic 
absorption spectrum, which is the range of wavelengths that excites the fluorophore, and 
a characteristic emission spectrum, which is the range of wavelengths that can be re-
emitted by the fluorophore. In most cases, the energy of the emitted photon is lower and 
therefore the emitted light has a longer wavelength than the absorbed radiation. 
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The labelling of cell with a fluorescent compound, known as cell staining, can be used for 
identification and cell sorting. An argon ion laser with blue emission at 488 nm is commonly 
used in flow cytometry, because it can excite more than one fluorophore. The Accuri C6 
flow cytometer is equipped with a blue laser (emission at 488 nm) and a red laser (emission 
at 640 nm). Examples of common fluorochromes used in flow cytometry that can be 
excited at a wavelength of 488 nm are fluorescein isothiocyanate (FITC), phycoerythrin 
(PE), propidium iodide (PI) and allophycocyanin (APC). The detectors for fluorescent light 
can be made specific to a particular fluorophore by positioning optic filters, which only let 
through a narrow range of wavelengths in front of the detectors. More than one fluorophore 
can be used simultaneously to stain the cells as long as they can be excited at the same 
wavelength and their main peak emission are far apart enough to be measured by different 
detectors. With the C6 Accuri flow cytometer, four channels are used for the detection of 
emission: FL1 533/30 nm filter (i.e. FITC), FL2 585/40 nm filter (i.e. PE/PI), FL3 > 670 nm 
filter (i.e. PerCP/PerCP-Cy5.5/PE-Cy7) and FL4 675/25 nm filter (i.e. APC). The numbers 
give the characteristic of the range of wavelength that can reach the detector, for example, 
530/30: 530 ± 15 nm. Cell staining can help in the investigation of cell events, for example, 
AnnexinV-FITC/PI are used for the study of cell death and cell viability, for the detection of 
early apoptosis and late apoptosis/necrosis. 
 
When more than one fluorophores are used at the same time, their emission spectra may 
overlap, and can be detected by the detection filter for other fluorophores. For example, 
the emission spectra of FITC overlap with the one for PI. As a consequence, due to the 
spillover of FITC fluorescence into PI bandpass filter, the PI population will appear positive. 
This can be corrected by a process of fluorescence compensation, which ensures that the 
fluorescence detected in a particular detector derives from the fluorophore that is being 
measured. 
 
 
2.13 Inductively coupled plasma atomic emission 
spectroscopy 
Inductively coupled plasma atomic emission spectroscopy (ICP-AES) is an analytical 
technique which allows for the quasi-simultaneous detection and quantification of all 
metals present in a sample at the parts per million range. In this method, the sample is 
placed in an argon or helium plasma at very high temperatures (6000 - 8000 K) to generate 
ions and excited atoms. Samples can be in the solid or liquid state. Generally, solid 
samples are previously dissolved in an acid to form a solution. The solution is injected into 
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the centre of the plasma flame via a nebulizer that transforms the sample into a fine spray. 
The molecules constituting the samples are broken up into simple atoms and will in turn 
be ionised as they collide with the charged ions and electrons composing the plasma. The 
ICP-AES is based on the fact that when the released electrons resulting from the ionisation 
of the sample recombine, a photon is emitted in the UV/visible range, and this wavelength 
is characteristic of the element involved. The light emitted by the plasma is analysed and 
separated into its different wavelengths via one or several monochromators or a 
polychromator, and finally the intensity is measured thanks to photomultiplier tubes or a 
CCD. The intensity of the radiation is proportional to the concentration of the ions in the 
sample. Consequently, the concentration of the desired element can be easily determined 
by referring to a calibration curve previously obtained by measuring intensities of solutions 
of known concentration of this same element under the same conditions. 
 
A Varian 720 axial ICP-AES has been used to determine the total iron content in the 
synthesized iron oxide nanoparticles. Samples were prepared by digesting 1.2 mg of dry 
nanoparticle powder in 0.2 mL of nitric acid and diluted with 14.8 mL of milli-Q water. The 
final concentration of nanoparticles in solution is 80 ppm, therefore we know that the final 
iron concentration will be between 0 – 80 ppm. This information indicates what range of 
concentration the calibration curve must cover. Solutions of known concentrations were 
used to obtain a calibration curve using an ICP iron standard solution of 10000 ppm. 
Appropriate dilutions were made to obtain the desired concentration, using the same total 
volume and same volume of acid as for the samples. 
 
 
2.14 Optical microscopy 
An optical microscope uses visible light and a set of lenses composed of an objective and 
a condenser to magnify images of really small sample. Optical microscopes are commonly 
used in biology for the observation of cells and tissues. 
 
A Leica DMI6000 B automated inverted microscope was used for imaging of biological 
samples. For fluorescence microscopy, a light source of wavelength 633 nm was used. 
Captured images were processed and analysed with Leica Application Suite X software. 
 
An inverted microscope is upside down compared to a conventional optical microscope. 
Its light source and condenser are pointing down and are located above the stage where 
the sample is positioned, while the objective and turret are pointing up and are located 
below the stage. As a consequence, one is looking at a sample from below with an inverted 
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microscope. It is widely used to observe living cells and organisms as it is large enough to 
fit large containers such as a flask which allows the specimen to be under natural 
conditions while in other types of microscopes the sample is under glass slide. 
 
2.14.1 Bright field microscopy 
Bright field microscopy is the oldest and simplest optical microscopy technique. The 
sample is illuminated with white light. The light transmitted through the sample forms the 
image, and the contrast is the result of transmitted light being absorbed in more or less 
dense areas of the sample. For biological samples, this technique usually has a low 
resolution and contrast. Contrast can be enhanced by staining the samples, for examples, 
histological samples of cells loaded with iron oxide nanoparticles can be stained with 
Prussian blue and nuclear fast red. Prussian blue stains the iron in blue while nuclear fast 
red stain the cell nucleus in pink (Figure 2.10).259 
 
Figure 2. 10 Images acquired with an inverted microscope using the bright field imaging 
technique. A) U-87 cells and B) MCF-7 cells counterstained with nuclear fast red. C) U-87 cells 
and B) MCF-7 cells loaded with iron oxide nanoparticles stained with Prussian blue and 
counterstained with nuclear fast red. 
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2.14.2 Fluorescence microscopy 
Fluorescence microscopy is a type of optical microscopy that uses the fluorescence 
phenomenon, that is the absorption and subsequent re-emission of light by a compound. 
A higher intensity light source as compared to conventional optical microscopy needs to 
be used to excite the fluorescent species in the sample of interest. In most cases, labelling 
of the sample with fluorescent stains is necessary to make it fluorescent. Study of cellular 
processes and imaging of structural components can be performed via labelling specific 
cell compartments or molecules. Fluorescence microscopy even allows users to determine 
the distribution of a single molecule species, its amount and its localization inside a cell. 
Colocalisation and interaction studies can be performed, and ion concentrations as well 
as intra- and intercellular processes like endocytosis and exocytosis can be observed. For 
example, DRAQ5 is a far-red DNA stain that is commonly used to counterstain the nuclei 
or measure DNA content. LysoTracker Green is a green stain commonly used to label 
acidic compartments in cells such as lysosomes. The intrinsic fluorescence of a sample or 
compound can also be used. For instance, the drug doxorubicin is fluorescent and 
therefore allows for the study of its localisation in cells. 
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CHAPTER 3  
SYNTHESIS OF CORE@SHELL Fe@Bi 
NANOPARTICLES FOR HYPERTHERMIA 
APPLICATIONS 
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3.1 Introduction 
In this project, efficient mediators of heat based on an iron core and a bismuth shell were 
aimed to be developped. Indeed, one of the major challenge in magnetic hyperthermia and 
thermo-chemotherapy is to obtain NPs with good heating abilities, as it would allow the 
reduction of the magnetic nanoparticles quantity to be injected in the patient. Pure iron 
NPs have a much greater heating potential than iron oxide NPs, due to their higher 
saturation magnetisation and magnetic anisotropy. However, such NPs are really difficult 
to obtain because of the quick oxidation process of iron. Iron is a hard magnetic material, 
which means it has a large hysteresis loop. Therefore, the NPs must have a 
superparamagnetic or quasi-superparamagnetic behaviour so that a high magnetisation 
can be reached at low applied field to be used safely for hyperthermia therapy. This project 
focused on the synthesis of new NPs based on pure iron in an attempt to get MNPs with 
high saturation magnetisation and low coercive field to get exceptional heating potential 
for hyperthermia therapy. Moreover, iron oxide is already well-known for its application as 
contrast agent for MRI. Because the saturation magnetisation of iron oxide is much lower 
compared to pure iron, the use of pure iron NPs would provide a better contrast at lower 
quantities.260 Bismuth has been chosen as a coating to protect iron against oxidation. Such 
as gold, bismuth is rather chemically inert and can be used as CT-imaging agent. It has 
been preferred over gold, because it possesses a larger X-ray attenuation coefficient, has 
low toxicity and is less expensive.261,262 
 
If the development of such NPs is successful, they would find applications not only in 
hyperthermia therapy but also in CT-imaging due to the bismuth coating and as MRI 
contrast agent due to the iron core. For that purpose, different synthetic routes by 
sequential reduction of iron and bismuth were investigated. These NPs could then be 
functionalised with a biocompatible polymer and used for thermo-chemotherapy 
applications. 
  
 
3.2 Materials and methods 
3.2.1 Reagents 
Hexadecylamine (C16H35N, HDA, 90%), hydrochloric acid (HCl, 37%), oleylamine 
(C18H37N, OAm, 70%), 1-octadecene (C18H36, 90%), 1-decanethiol (C10H22S, 96%), iron 
pentacarbonyl (Fe(CO)5, >95%) and bismuth trichloride (BiCl3, >98%) were purchased 
from Sigma Aldrich, Japan. Ethanol (EtOH, 99.5%) was obtained from Nacalai tesque, 
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Japan. Iron pentacarbonyl (Fe(CO)5, >95%) and hexane (C6H14, >96%) were obtained 
from Kanto Chemicals, Japan. All the reagents were used as purchased without any further 
purification. 
 
3.2.2 Preparation of the Bi-DT complex 
Bismuth-decanethiol (Bi-DT) complex was synthesized using a molar ratio of 1:4 or 1:12 
(Table 3.1). Briefly, BiCl3 was added to a mixture of decanethiol and octadecene (2 mL), 
and stirred under argon (Ar) atmosphere until full dissolution of the solid occured. The 
formation of the complex could be confirmed by a change in colour of the solution, from 
colourless to yellow. 
 
Table 3. 1 Quantities of BiCl3 and DT used for the preparation of the Bi-DT complexes. 
BiCl3:DT molar ratio mBiCl3 (mg) nBiCl3 (mmol) VDT (mL) nDT (mmol) 
1:4 79 0.25 0.212 1 
1:12 79 0.25 0.636 3 
 
3.2.3 Synthesis of core@shell Fe@Bi nanoparticles 
The iron core was synthesised by following a slightly modified previously reported 
procedure.263 In a typical synthesis, oleylamine (OAm, 0.16 mL, 0.5 mmol), 
hexadecylammonium chloride (HDA-HCl, 0.139 g, 0.5 mmol) and 1-octadecene (10 mL) 
were mixed in a 50 mL three-neck flask and degassed for 30 min at 120 °C under an Ar 
flux and vigorous magnetic stirring. Addition of Fe(CO)5 (0.35 mL, 2.5 mmol) was 
performed at 180°C and the solution was kept at this temperature for 30 min. Then, the Bi-
DT complex was added to the flask either in one go or at a constant rate of addition (Table 
3.2) using a syringe pump (KD Scientific Inc., KDS100). After addition of the Bi-DT 
complex, the temperature was maintained at temperature T for a time t (Table 3.2). 
 
The NPs were collected with hexane and ethanol, and washed by centrifugation with 5 mL 
of hexane and 15 mL of ethanol (8500 rpm, 3 times, 10 min) and redispersed in hexane 
for further use. A small amount of NPs was dried under an Ar flux to obtain a dry powder. 
 
In addition to those syntheses, core@shell Fe@Fe3O4 NPs and Bi NPs were also 
synthesized following the same protocol for comparison. 
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Table 3. 2 Experimental conditions used for the synthesis of the core@shell Fe@Bi 
nanoparticles. 
Sample BiCl3:DT (molar 
ratio) 
Rate of injection Bi-DT 
complex (mL/hr) 
T (°C) t (min) 
AH31 1:4 / 180 30 
AH38 1:4 / 180 60 
AH37 1:12 / 180 60 
AH43 1:4 30 180 30 
AH45 1:4 15 180 30 
AH48 1:4 10 180 30 
AH49 1:4 10 160 30 
 
 
3.2.4 Synthesis of core@shell Fe@Fe3O4 nanoparticles 
The synthesis of core@shell Fe@Fe3O4 NPs was performed by following a slightly 
modified previously reported procedure.263 In a typical synthesis, OAm (0.16 mL, 0.5 
mmol), HDA-HCl (0.139 g, 0.5 mmol) and 1-octadecene (10 mL) were mixed in a 50 mL 
three-necks round bottom flask and degassed for 30 min at 120 °C under an Ar flux and 
vigorous magnetic stirring. Precursor Fe(CO)5 (0.35 mL, 2.5 mmol) was added at 180 °C 
and the solution was kept at this temperature for 30 min. 
The NPs were collected with hexane and ethanol, washed by centrifugation with 5 mL of 
hexane and 15 mL of ethanol (8500 rpm, 3 times, 10 min) and redispersed in hexane for 
further use. A small amount of NPs was dried under an Ar flux to obtain a dry powder. 
 
3.2.5 Synthesis of Bi nanoparticles 
The synthesis of Bi nanoparticles was carried out as follows: OAm (0.16 mL, 0.5 mmol), 
HDA-HCl (0.139 g, 0.5 mmol) and 1-octadecene (10 mL) were mixed in a 50 mL three-
necks round bottom flask and degassed for 30 min at 120 °C under an Ar flux and vigorous 
magnetic stirring. The Bi-DT complex was added at 180°C and the solution was kept at 
this temperature for 60 min. 
The NPs were collected with hexane and ethanol, washed by centrifugation with 5 mL of 
hexane and 15 mL of ethanol (8500 rpm, 3 times, 10 min) and redispersed in hexane for 
further use. A small amount of NPs was dried under an Ar flux to obtained a dry powder. 
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3.3 Results and discussion 
 
3.3.1 Initial considerations 
Thermal decomposition of Fe(CO)5 at 180 °C in the presence of hexadecylammonium 
chloride and oleylamine in octadecene under inert atmosphere has been shown to give 
highly crystalline iron NPs.263 Preliminary experiments were performed at UCL using this 
approach to synthesize the iron core. Formation of the bismuth coating was attempted by 
reduction of bismuth tribromide using triethylsilane: 
 
BiBr3 + 3Et3SiH  Bi(0) + 3/2H2 + 3Et3SiBr 
 
Interpreting the results (not shown) was challenging but after careful analysis, the most 
likely conclusion was that the Bi NPs were growing independently of the Fe seeds instead 
of coating them. This hypothesis is consistent with the important lattice mismatch between 
Fe and Bi calculated from XRD patterns. Moreover, Fe and Bi crystallize in completely 
different system, i.e. α-Fe crystallizes in a cubic structure with a lattice parameter a = 
2.8444 Å, while Bi crystallizes in a rhombohedral structure with lattice parameters a = b = 
4.5460 Å and c = 11.8600 Å. This significant mismatch in lattice parameters makes the 
heteroepitaxial growth of Bi on the Fe seeds impossible. However, despite numerous trials 
with different synthetic conditions, it seemed that the non-epitaxial growth of Bi on the Fe 
substrates was not happening either. 
 
After arriving at JAIST, and discussing the synthetic scheme with Prof. Maenosono, we 
decided not to continue with this synthetic scheme and to change the method used to form 
the Bi coating. 
 
The thermal decomposition of Fe(CO)5 at 180 °C in presence of HDA-HCl and OAm in 
octadecene under inert atmosphere was kept for the synthesis of the iron core. However, 
we decided to use a Bi complex formed from BiCl3 and decanethiol (called Bi-DT complex) 
in octadecene for the formation of the Bi coating. Indeed, having a precursor in the liquid 
form was more convenient to add during the synthesis performed under vacuum as 
compared to the solid precursor BiBr3. We chose a Bi-DT complex because it has been 
shown by Prof. Maenosono’s group that decanethiol makes stable complexes with the Bi 
cation, which then can be effectively reduced to Bi metal while being protected from 
creating BiOCl crystals. This is not the case for Bi-oleylamine or Bi-oleic acid complexes.264 
Moreover, from the literature, it was found that Bi has a strong affinity with thiols, which 
could help in the stabilization of the particles.265 
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3.3.2 Synthesis of core@shell Fe@Fe3O4 nanoparticles 
Fe@Fe3O4 nanoparticles were synthesized following the same protocol as for the 
synthesis of Fe@Bi NPs, but without adding the Bi-DT complex. This is really important to 
see what type of Fe NPs are obtained following this synthetic route and so that differences 
between the obtained nanoparticles with and without bismuth can be identified more easily.  
 
The TEM images show spherical core@shell NPs (Figure 3.1). The core was composed 
of iron, and the shell of iron oxide. The iron oxide shell was most likely formed when the 
NPs were exposed to air at the end of the synthesis. The Fe@Fe3O4 NPs were 
agglomerated, but calculations from the NPs present on the edges of the agglomerates, 
showed an average nanoparticle size of 16.6 ± 3.0 nm (n = 100), with an average core 
size of 10.9 ± 2.4 nm. 
 
 
Figure 3. 1 TEM micrographs of Fe@Fe3O4 nanoparticles A) at low magnification and B) 
higher magnification. 
 
The XRD pattern of the Fe@Fe3O4 NPs matched with cubic α-Fe (Figure 3.2). There was 
no peak characteristic of an iron oxide phase, meaning that the shell of the NPs was 
formed of amorphous or really small grain domain size iron oxide. From the XRD pattern, 
a crystallite size of 11.5 ± 0.2 nm was calculated for the iron peaks, which was in good 
agreement with the core size calculated from the TEM images. 
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Figure 3. 2 XRD pattern of the Fe@Fe3O4 NPs. Peaks were indexed according to the 
reference patterns for iron (pdf ref. 00-006-0696) and magnetite (pdf ref. 00-019-0629). 
 
 
The magnetic properties of the Fe@Fe3O4 NPs were evaluated at 300 K on the dry powder 
using a SQUID (Figure 3.3). The NPs had a quasi-superparamagnetic behaviour at room 
temperature with a saturation magnetisation of 103 emu/g (measured 16 days after the 
synthesis) and a coercive field of 100 Oe. 
 
 
Figure 3. 3 Magnetisation curves of the Fe@Fe3O4 NPs at 300K. The inset shows a zoom 
into the low magnetic field region. 
 
The difference between the saturation magnetization of bulk iron (i.e. 218 emu/g)266 and 
the saturation magnetization obtained for the Fe@Fe3O4 NPs was mainly due to the 
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presence of an iron oxide shell in the NPs, which has a lower saturation magnetization (i.e. 
92 emu/g)267 than pure iron. Moreover, according to the XRD pattern, this iron oxide shell 
was amorphous and as a consequence would result in an even lower saturation 
magnetisation. 
 
3.3.3 Synthesis of Bi nanoparticles 
Bi NPs were also synthesized using the same synthetic conditions for comparison. Figure 
3.4 shows the TEM images of the obtained Bi NPs. The NPs were hexagonal in shape and 
very polydisperse in term of size. The average NP size (measured along one diagonal of 
the hexagon) was found to be equal to 57 ± 17 nm (n = 110). 
 
 
Figure 3. 4 TEM micrographs Bi nanoparticles A) at low magnification and B) higher 
magnification. 
  
The obtained XRD pattern shows a highly crystalline structure with peaks matching with 
reference JCPDF of rhombohedral Bi crystalline phase (Figure 3.5). No peak 
corresponding to the oxide phase could be observed. The crystallite size of the Bi NPs 
calculated from the XRD pattern was 38.7 ± 2.1 nm, which is smaller than the size obtained 
from TEM images, suggesting that the NPs were polycrystalline. 
 
No characterization of the magnetic properties of the Bi NPs was performed as bismuth is 
a diamagnetic material. 
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Figure 3. 5 XRD pattern of the Bi NPs. Peaks are indexed according to the reference 
patterns for bismuth (pdf ref. 00-005-0519) and bismuth oxide (pdf ref. 00-041-1449). 
 
 
3.3.4 Synthesis of core@shell Fe@Bi nanoparticles 
3.3.4.1 Preliminary experiment  
The first experiment was performed by adding the Bi-DT complex in one go. In the rest of 
the document, the NPs obtained via this synthetic process will be referred as sample 
FeBi_A (see Table 3.2 in section 3.2.3 for the details of experimental conditions used to 
synthesize FeBi_A NPs). 
 
 
Figure 3. 6 XRD pattern of the FeBi_A NPs. Peaks were indexed according to the reference 
patterns for bismuth (pdf ref. 00-005-0519), iron (pdf ref. 00-006-0696) and magnetite (pdf ref. 
00-019-0629). 
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XRD pattern of FeBi_A NPs shows the presence of both cubic α-Fe and rhomboedral Bi 
crystalline phases (Figure 3.6). The crystallite sizes calculated from the XRD pattern were 
DFe = 11.0 nm and DBi = 16.2 nm. The low intensity of the main bismuth peak may suggest 
that Bi ions had not been reduced entirely into Bi metal. However, there is a big decrease 
in the Bi crystallite size extracted from the XRD pattern of FeBi_A NPs as compared to the 
syntheses performed following the first synthetic scheme (part performed at UCL) and is 
more coherent with the size of the nanoparticles. 
 
Figure 3.7 shows TEM images of the FeBi_A NPs. The NPs had a spherical core@shell 
morphology with an average size of 16.3 ± 2.8 nm and an average core size of 9.4 ± 1.9 
nm (n = 116), which matches well with the sizes obtained from analysis of the XRD pattern. 
Moreover, from TEM images it did not seem possible to distinguish between two different 
types of nanoparticles. 
 
 
Figure 3. 7 A) and B) TEM micrographs of FeBi_A NPs. 
 
The obtained NPs were not stable in hexane, and were therefore aggregated. However, it 
was possible in a certain extent, to stabilize them by adding an excess of OAm and 
sonicating the suspension for 30 min. This step was repeated several times to obtain as 
many stable particles as possible. Then, the stable nanoparticles were separated from the 
ones still sinking in the bottom of the suspension, and after rewashing the nanoparticles 
by centrifugation, a grid with well separated particles could be obtained (Figure. 3.8). 
Again, on those images, only one type of NPs can be observed which leaned towards the 
hypothesis of obtaining core@shell Fe@Bi NPs. From the TEM images only, it was not 
possible to say whether the desired Fe@Bi core@shell nanoparticles were obtained for 
sure, because other core@shell structures could be obtained such as Fe@Fe3O4 for 
example. Indeed, Fe@Fe3O4 nanoparticles are very likely to be obtained if the bismuth 
does not grow on the iron seeds during the reaction and these nanoparticles looked similar 
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to the ones obtained in the synthesis of Fe@Fe3O4. The lighter shell and darker core of 
the nanoparticles would be more consistent with an iron oxide shell and an iron core in 
term of electron density. Indeed, Bi has a higher electron density than Fe and should 
therefore appear darker than Fe on TEM images. However, exceptions with TEM contrast 
have already been observed, i.e. in the case of iron and gold with core@shell Fe@Au NPs, 
it has often been reported that the gold shell appears lighter than the iron core268-271 This 
is attributed to the dominance of the mass-thickness contrast over the diffraction contrast, 
rendering the shell lighter despite Au having a higher electron density than Fe.272 
 
 
Figure 3. 8 TEM micrographs of FeBi_A NPs after stabilisation with OAm A) at low 
magnification and B) higher magnification. 
 
A void between the core and the shell of the NPs was observed. If the core@shell NPs 
are made of Fe@Bi NPs, the void could be due to the galvanic replacement 
phenomenon273,274 as the reduction potential of Bi is higher than the reduction potential of 
iron (EFe2+/Fe = -0.44, EFe3+/Fe = -0.037 and EBi3+/Bi = 0.317). Indeed, galvanic replacement 
reactions rely on the different reduction potential of two metals, which combine to give a 
more favourable reaction. It involves the oxidation of one metal (i.e. the one having the 
lowest reduction potential, which in our case is iron) by the ions of another metals having 
a higher reduction potential (here bismuth). As a result, atoms of the iron core are oxidized 
and dissolved into the solution, while the bismuth ions are simultaneously reduced and 
plated on the outer surface of the nanoparticles, leading to the formation of a void between 
the iron core and the bismuth shell. 
 
If the core@shell NPs are made of Fe@Fe3O4 NPs, the void could originate from the 
unbalanced interfacial diffusion of oxygen and iron during the oxidation process (when the 
NPs are exposed to air). This phenomenon is known as the Kirkendall effect: Fe metal 
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atoms diffuse faster outward than O diffuse inward leading to a net material flux across the 
spherical interface and consequent formation of a void.273 
 
In order to get a better idea of the composition of the obtained core@shell NPs, EDS 
analysis and elemental mapping were performed on this sample. Because the composition 
of the sample did not seem to be homogeneous, the atomic percentage of Bi and Fe were 
not averaged, and will be presented area per area. 
 
The iron and bismuth precursor were introduced with a molar ratio Fe/Bi = 10, which is 
equivalent to an atomic percentage of 91%Fe and 9%Bi. EDS analyses show that Bi is not 
homogeneously distributed in the sample, however, it is hard to distinguish the bismuth-
rich area (Figure 3.9). 
 
 
Figure 3. 9 TEM micrographs of areas of FeBi_A sample where EDS analyses were 
performed, with the corresponding atomic percentage of Fe and Bi. 
 
Figure 3.10 presents the Fe and Bi elemental mapping data for an ensemble of three 
particles, and two single particles. The images provided clear evidence of an iron core, 
and demonstrated that iron is also present in the shell but in a lesser extent, which is 
consistent with a Fe@Fe3O4 core@shell structure. From the images of the two single 
particles, it seems that some bismuth is also homogeneously distributed in the shell of the 
nanoparticles. However, the quantity of bismuth in the shell does not seem enough to 
match the initial feeding ratio in the synthesis, maybe indicating that bismuth ions were not 
entirely reduced during the synthesis, or some bismuth nanoparticles nucleate separately 
from the iron seeds. This hypothesis would explain the non-homogeneous distribution of 
Bi throughout the sample observed with EDS analyses, even though no separate Bi NPs 
could be observed on the TEM images. Moreover, on the image showing an ensemble of 
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three particles, it can clearly be observed that some bismuth atoms are also located where 
there is not any particle. 
 
 
Figure 3. 10 Local elemental mapping of FeBi_A NPs. Left: Bright field image; middle: Bi 
mapping; right: Fe mapping. 
 
Analysis of high resolution TEM images gave further information on the nature and 
structure of the nanodomains. Investigations of the outer shell of the particles evidence a 
polycrystalline shell (Figure 3.11). Lattice planes were observed in both the core and the 
shell of the particles. Spacing of the core lattice planes was found to be 2.0255 Å, which 
corresponds to the bcc crystalline structure of iron (Table 3.3). Spacing of the shell lattice 
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planes in two different crystalline domains were found to be 4.939 Å and 2.661 Å, which is 
close to the values of the cubic crystalline structure of magnetite (Table 3.3). 
 
 
Figure 3. 11 High resolution TEM images of FeBi_A NPs. Left: entire isolated particle; middle 
and right: shell. 
 
Table 3. 3 Lattice fringe parameters of different materials containing Fe and/or Bi (obtained 
from their respective PdF card). 
Material Plane Lattice fringe (Å) 
Fe 110 2.0268 
Fe3O4 
111 4.852 
222 2.426 
Fe2O3 111 4.822 
BiFeO3 110 2.7905 
Bi 012 3.28 
Bi2O3 120 3.255 
 
By combining all those results together, the most likely hypothesis is that some bismuth 
atoms deposit on the surface of the iron seeds. However, at the end of the synthesis, the 
bismuth layer is not thick enough to protect iron against oxidation and therefore, a layer of 
iron oxide is formed when the nanoparticles are exposed to air. The rest of the bismuth 
may be nucleating in separated particles, however their observation on TEM images was 
not possible. Another explanation is that all the Bi ions are not entirely reduced into bismuth 
metal during the synthesis, and the inhomegeneous dispersion of Bi in the sample could 
be due to some remaining Bi-DT complex despite the washing steps. 
 
Therefore, for the next experiments, the different  synthetic conditions will be changed in 
order to study the influence of the reaction time after addition of the Bi-DT complex, of the 
decanethiol content and of the rate of addition of the Bi-DT complex. 
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3.3.4.2 Influence of the reaction time after addition of the Bi-DT 
complex 
To study the influence of the reaction time after addition of the Bi-DT complex, the time 
was increased to 60 min as compared to 30 min used in the synthesis of FeBi_A (see 
Table 3.2 in section 3.2.3 for the experimental conditions used to synthesize FeBi_A and 
FeBi_B NPs).  
 
XRD patterns of FeBi_B NPs and FeBi_A NPs are quite similar and show the presence of 
both cubic α-Fe and rhomboedral Bi crystalline phases (Figure 3.12). 
 
 
Figure 3. 12 XRD pattern of the FeBi_A and FeBi_B NPs. Peaks were indexed according to 
the reference patterns for bismuth (pdf ref. 00-005-0519), iron (pdf ref. 00-006-0696), and 
magnetite (pdf ref. 00-019-0629). 
 
The crystallite size for FeBi_B NPs calculated from the XRD pattern were DFe = 12.4 nm 
and DBi = 16.5 nm. An increase in the crystallite size of iron as compared to FeBi_A sample 
was observed but the crystallite size of bismuth remained similar. Such as for FeBi_A NPs, 
the intensity of the main bismuth peak was very low. In fact, the XRD patterns of the two 
samples were very similar: no significant difference in the peak intensities or peak positions 
could be observed. As such, an increase in the reaction time did not seem to have any 
influence on the second step of the reaction (i.e. the reduction of bismuth ions into bismuth 
metal to form a bismuth shell on the already formed iron nanoparticles). Therefore, the 
hypothesis of the bismuth ions not being entirely reduced after 30 min of reaction could be 
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discarded, as no change is observed by increasing the reaction time. Moreover, given the 
high reduction potential of bismuth, it seems unlikely that the Bi ions would not be entirely 
reduced after 1 h of reaction at a temperature of 180 °C. 
 
Figure 3.13 shows TEM images of the FeBi_B NPs. The NPs have a spherical morphology 
and a core@shell structure. 
 
 
Figure 3. 13 TEM micrographs of FeBi_B NPs A) at low magnification and B) higher 
magnification. 
 
Figure 3.14 represents the quantitative atomic percentage of iron and bismuth obtained 
from EDS analysis, as well as the TEM images of the areas where EDS was performed. 
Again, because the composition of the sample did not seem to be homogeneous, the 
atomic percentages of Bi and Fe were not averaged, and will be presented area per area. 
The distribution of bismuth in the sample was not homogeneous and considering the initial 
feeding ratio, was lower than the expected atomic percentage of 9%. All the results 
obtained for FeBi_B sample were similar to those obtained for FeBi_A sample. 
 
Figure 3. 14 TEM micrographs of areas of FeBi_B sample where EDS analyses were 
performed, with the corresponding atomic percentage of Fe and Bi. 
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We can conclude that increasing the second step time does not seem to have much 
influence on the synthesized nanoparticles. At this point, it is most likely that Bi nucleates 
into separated particles. Indeed, due to the quick reduction process of bismuth, the Bi ions 
do not necessarily have the time to reach the Fe nanoparticle surfaces, and therefore 
nucleate into separate particles. Though no particles different from the core@shell 
nanoparticles could be observed on the TEM images, one should keep in mind that 
bismuth was introduced in a lesser amount than iron, therefore meaning that the number 
of bismuth nanoparticles would be much lower than the iron ones, and from the crystallite 
size obtained by XRD, the bismuth nanoparticles would be only a few nanometers bigger 
than the iron nanoparticles. Therefore, as the aggregation of the core@shell nanoparticles 
is quite important in those samples, the bismuth particles could easily be hidden in the 
high aggregation area, making their observation challenging. 
 
To conclude this section, increasing the reaction time of the second step did not change 
significantly the properties of the resulting particles. Therefore, the reaction time of the 
second step will be kept to 30 min in the next experiments. 
 
3.3.4.3 Influence of the decanethiol concentration 
As already mentioned previously, the synthesised nanoparticles were not stable in hexane 
suspension, which makes their observation challenging with TEM samples. In an attempt 
to tackle this issue, the amount of decanethiol in the formation of the Bi-DT complex was 
increased (molar ratio 1:12) as compared to the amount used in the synthesis of FeBi_A 
(molar ratio 1:4), and the effect of the decanethiol concentration on the resulting 
nanoparticles was studied (see Table 3.2 in section 3.2.3 for the experimental conditions 
used to synthesize FeBi_A and FeBi_C NPs). 
XRD patterns of FeBi_A and FeBi_C NPs presented in Figure 3.15 show the presence of 
both cubic α-Fe and rhomboedral Bi crystalline phases. 
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Figure 3. 15 XRD pattern of the FeBi_A and FeBi_C NPs. Peaks were indexed according 
to the reference patterns for bismuth (pdf ref. 00-005-0519), iron (pdf ref. 00-006-0696), and 
magnetite (pdf ref. 00-019-0629). 
 
The crystallite size calculated from the XRD pattern for FeBi_C NPs were DFe = 10.8 nm 
and DBi = 23.9 nm. A significant increase in the bismuth crystallite size could be observed 
as well as an increase in the bismuth peak intensities. Increasing the decanethiol 
concentration may facilitate the reduction of bismuth ion into crystalline bismuth metal. 
However, such a big crystallite size cannot be representative of the shell of the NPs, 
therefore pointing in the directions of the formation of separated bismuth particles. 
 
TEM images of the FeBi_C sample show the presence of dark sheets and spherical 
core@shell NPs (Figure 3.16). 
 
In order to identify what the dark sheets are made of, EDS analyses were performed on 
the sample (Figure 3.17). 
 
From the resulting atomic percentages, the dark sheets were identified as an iron sulfide 
phase with an amorphous structure as it does not appear on the XRD pattern. Indeed, 
decanethiol is a source of sulfur, and those sheets were not observed when using a smaller 
amount of decanethiol. Again the obtained atomic percentages for the different elements 
show an inhomogeneous distribution of bismuth throughout the sample, with high 
concentration areas and low concentration areas. However, it is hard to distinguish where 
the bismuth is located in the sample, due to particle agglomeration and the presence of 
the dark sheets. 
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Figure 3. 16 TEM micrographs of FeBi_C sample. Both dark sheets and nanoparticles can be 
observed.  
 
 
Figure 3. 17 TEM micrographs of areas of FeBi_C where EDS analyses were performed, with 
the corresponding atomic percentage of Fe, Bi and S. 
 
Using a high amount of decanethiol in the Bi-DT complex leads to the formation of 
amorphous iron sulfide sheets and does not help in the stabilisation of the particles. As the 
formation of this iron sulfide phase is not desired, we can conclude that using a molar ratio 
of 1:12 for the formation of the Bi-DT complex is not an appropriate condition for the 
synthesis. In the next experiments, the amount of decanethiol used for the preparation of 
the Bi-DT complex will be kept as initially chosen (molar ratio of 1:4). 
 
3.3.4.4 Influence of the rate of addition of the Bi-DT complex 
In this section, we controlled the rate of addition of the Bi-DT complex in an attempt to 
suppress the separated growth of the bismuth nanoparticles, and promote the growth of a 
bismuth shell on the already formed Fe NPs. To that aim, the Bi-DT complex was added 
dropwise at different rate, using a syringe pump, to manipulate the reaction kinetic. Table 
3.4 summarizes the different conditions used for the syntheses. 
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Table 3. 4 Reminder of the experimental conditions used to synthesize FeBi_D, FeBi_E, 
FeBi_F and FeBi_G nanoparticles. 
Sample BiCl3:DT (molar 
ratio) 
Rate of inj Bi-DT complex 
(mL/hr) 
T (°C) t (min) 
FeBi_D 1:4 30 180 30 
FeBi_E 1:4 15 180 30 
FeBi_F 1:4 10 180 30 
FeBi_G 1:4 10 160 30 
 
 
For each synthesis, XRD patterns show the presence of both cubic α-Fe and rhomboedral 
Bi crystalline phases (Figure. 3.18).  
 
 
Figure 3. 18 XRD pattern of the FeBi_D, FeBi_E, FeBi_F and FeBi_G NPs. Peaks were 
indexed according to the reference patterns for bismuth (pdf ref. 00-005-0519), iron (pdf ref. 
00-006-0696), and magnetite (pdf ref. 00-019-0629). 
 
The crystallite size calculated from the XRD pattern for a rate of addition of the Bi-DT 
complex of 30 mL/hr, are DFe = 15.2 nm and DBi = 28.4 nm. By decreasing the addition 
rate to 15 mL/hr, the bismuth crystallite size decreased to DBi = 22.5 nm while the iron 
crystallite size increased to DFe = 16.8 nm. This result is encouraging, as a decrease in the 
bismuth crystallite size could indicate that a larger proportion of bismuth grows on the iron 
nanoparticles instead of nucleating separately. However, this trend is not followed in the 
two next syntheses, as decreasing further the addition rate to 10 mL/hr does not influence 
the resulting grain sizes (DFe = 15.6 nm and DBi = 22.2 nm). By decreasing the temperature 
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at which the Bi-DT complex is added to slow down the kinetic of reduction of bismuth, a 
decrease in the Bi and Fe peaks intensities is observed, and the Bi crystallite size seems 
to increase again while the one of iron decreases (DFe = 13.7 nm and DBi = 27.2 nm). Thus, 
no logical trend can be concluded from those results. 
 
Figure 3.19 represents the TEM images of the different samples. The NPs look similar for 
all samples, they are spherical and possess a core@shell structure. The high 
agglomeration state of the nanoparticles makes the observation of the samples difficult. 
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Figure 3. 19 TEM micrographs of A), B) FeBi_D NPs, C), D) FeBi_E NPs, E), F) FeBi_F NPs 
and G), H) FeBi_G NPs. 
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The quantitative atomic percentage of iron and bismuth were measured with EDS analysis 
for the samples FeBi_D, FeBi_E, FeBi,F and FeBi_G. Again, because the composition of 
the samples did not seem to be homogeneous, the atomic percentage of Bi and Fe were 
not averaged, and will be presented area per area. 
 
EDS analysis reveals a completely inhomogeneous repartition of Bi in the sample FeBi_D 
(Figure 3.20). However, nothing particular or different from the rest of the sample could be 
observed in the image with the high Bi concentration area (left image). 
 
Figure 3. 20 TEM images of areas of FeBi_D where EDS analyses were performed and their 
corresponding atomic percentage of Bi and Fe. 
 
In the sample FeBi_E, areas containing bismuth such as in the middle image which is only 
composed of a few nanoparticles could be observed, but no distinct bismuth particles can 
be identified, which could lead to think that bismuth is equally present on each core@shell 
nanoparticle. On the other hand, a big agglomerate such as in the right TEM image, barely 
contains any bismuth, which therefore is more coherent with the opposite explanation: 
bismuth forms separated particles (Figure 3.21). 
 
Figure 3. 21 TEM images of the areas of FeBi_E where EDS analyses were performed, and 
their corresponding atomic percentage of Bi and Fe. 
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Again, in sample FeBi_F, areas with high and low concentration of bismuth could be 
observed (Figure 3.22). In the middle image where a high atomic percentage of bismuth 
was obtained, a particle of hexagonal shape - similar to the shape of the nanoparticles 
obtained with the Bi NPs synthesis (see section 3.3.2) - can be observed (circled in red). 
 
Figure 3. 22 TEM images of areas of FeBi_F where EDS analyses were performed and their 
corresponding atomic percentage of Bi and Fe. 
 
The presence of areas with high and low concentration of bismuth were also observed in 
sample FeBi_G (Figure 3.23). Attempt to perform EDS analysis on a single particle was 
made (right image), which showed a low bismuth content. 
 
 
Figure 3. 23 TEM images of the areas of FeBi_G where EDS analyses were performed and 
their corresponding atomic percentage of Bi and Fe. 
 
 
3.4 Conclusion 
In summary, iron nanoparticles were found to be highly magnetic. This resulted in highly 
aggregated nanoparticles that made their observation by TEM challenging. Despite 
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numerous trials, the synthetic route chosen in this part of the work did not appear to be 
successful for the synthesis of Fe@Bi core@shell NPs. Adding the Bi precursor slowly 
dropwise did not help in suppressing the separated growth of Bi particles. Table 3.5 
summarizes the crystallite sizes for Fe and Bi obtained with the different synthesis. In fact, 
the best results, (i.e. the smallest Bi grain sizes and most homogeneous distribution of Bi 
in the sample observed with EDS) were obtained for samples FeBi_A and FeBi_B where 
the Bi-DT complex was added in one go. 
 
Table 3. 5 Summary of Fe and Bi crystallite grain size obtained by varying the synthetic 
parameters. 
Sample T (oC) Rate inj 
(mL/hr) 
Time (min) DXRD Bi (nm) DXRD Fe (nm) 
FeBi_A 180 / 30 16.2 11.0 
FeBi_B 180 / 60 16.5 11.8 
FeBi_D 180 30 30 28.4 15.2 
FeBi_E 180 15 30 22.5 16.8 
FeBi_F 180 10 30 22.22 15.6 
FeBi_G 160 10 30 27.2 13.7 
 
While interpreting the results was not easy, the most likely hypothesis even in the case of 
samples FeBi_A and FeBi_B is that two types of particles having roughly the same sizes 
are obtained: Bi NPs and Fe@Fe3O4 core@shell NPs containing small amount of bismuth 
in the outer shell. 
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CHAPTER 4 
SYNTHESIS AND FUNCTIONALISATION OF IRON 
OXIDE NANOPARTICLES FOR THERMO-
CHEMOTHERAPY 
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4.1 Introduction 
 
In the previous chapter, despite the different attempts made, the synthesis of NPs with a 
high magnetic moment composed of an iron core and a bismuth shell was found to be 
unsuccessful. In order to be able to make progress towards the main goal of the study, 
that is to develop a magnetic nanocarrier for hyperthermia therapy and drug delivery, it 
has been decided that iron oxide nanoparticles will be used to develop the desired 
nanocarrier. Iron oxide nanoparticles may not have as much heating potential as iron 
nanoparticles do for hyperthermia therapy, but yet they have many advantages for their 
use in biomedical applications, such as chemical stability, biocompatibility and their ease 
of synthesis. 
 
In this chapter, the synthesis of iron oxide nanoparticles by a microwave-assisted co-
precipitation method previously developed in our lab was adapted for the purpose of this 
work. The thermo-responsive polymer composed of four main blocks p(DEGMA-co-
PEGMA-b-[TMSPMA-co-VBA]), was synthesized by RAFT polymerisation and then 
grafted onto the iron oxide nanoparticle surface via a silanisation reaction using a modified 
Stöber method. The functionalisation protocol was optimized by varying the MNPs to 
polymer ratio and the pH of the solution. The nanoparticles were characterized by XRD, 
TEM, DLS, FTIR and TGA and their potential as agents for magnetic hyperthermia was 
evaluated. Finally, doxorubicin was loaded into the nanosystem via formation of pH-
cleavable imine bonds between the amine group of doxorubicin and the aldehyde group 
of the polymer. The drug release kinetics were carefully studied as a function of the pH 
and the temperature. 
 
 
4.2 Materials and methods 
4.2.1 Reagents 
Iron(II) chloride tetrahydrate (FeCl2·4H2O, purity 99%), iron(III) chloride hexahydrate 
(FeCl3·6H2O, >99%), sodium carbonate (Na2CO3, 99%), hydrochloric acid (HCl, 37 vol%), 
poly(ethylene glycol) methyl ether methacrylate (PEGMA, H2C=C(CH3)CO2(CH2CH2O)nCH3,  
Mn = 300 g/mol), di(ethylene glycol) methyl ether methacrylate (DEGMA, 
H2C=C(CH3)CO2(CH2CH2O)2CH3, 95%), 3-(trimethoxysilyl)propyl methacrylate (TMSPMA, 
C10H20O5Si, 98%), 3-vinylbenzaldehyde (VBA, C9H8O, 97%), 4,4’-azobis(4-cyanovaleric acid) 
(ACVA, C12H16N4O4, ≥75%), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (CPPA, 
C13H13NO2S2, 97%), chloroform-d NMR solvent (CDCl3, 99.8 atom % D), triethylamine (TEA, 
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C6H15N, 98%), acetonitrile (C2H3N, 99.8%), toluene (C7H8, 99.8%), petroleum ether, sodium 
phosphate monobasic (NaH2PO4, 99%) and sodium phosphate dibasic (Na2HPO4, ≥99%) were 
purchased from Sigma Aldrich. Tetrahydrofuran (THF, C4H8O, stabilizer free, 99.8%) was 
provided from Wako Chemicals. Ethanol (EtOH, 99.5 % or 100%) was obtained from Nacalai 
Tesque Japan or from Hayman, UK. All the reagents were used as purchased without any 
further purification. The Spectra/Por Biotech grade dialysis membranes were obtained from 
SpectrumLabs and the Slyde-A-Lyzer (SAL) dialysis cassettes were obtained from Thermo 
Fischer Scientific. 
 
4.2.2 Experimental methods 
4.2.2.1 Synthesis of the copolymer P(DEGMA-co-PEGMA-b-[TMSPMA-
co-VBA]) 
The P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) polymer was synthesized by reversible 
addition fragmentation chain transfer (RAFT) polymerization according to a previous 
publication with some modifications.275 
 
4.2.2.1.1 Step 1: copolymerization of the two PEG chains 
The PEGMA and DEGMA monomers were mixed in different molar ratios (for the study of the 
LCST) with the CPPA as the RAFT chain transfer agent and ACVA as the initiator (molar ratio 
CPPA:ACVA 5:1). Under Ar atmosphere, anhydrous acetonitrile was added to the flask and 
the mixture was degassed by bubbling Ar for 30 min. After degassing, the mixture was heated 
to 70 °C and maintained at this temperature for 5 h. The resulting polymer was then washed 
several time using petroleum ether and dried under vacuum overnight. 
 
4.2.2.1.2 Step 2: chain extension 
A chain extension was then carried out by mixing the dry P(DEGMA-co-PEGMA) polymer used 
as macro-RAFT agent with ACVA initiator (ratio 5:1), TMSPMA and VBA in toluene. The two 
monomers were added in a molar ratio of 1:4. This mixture was then degassed under Ar and 
heated to 90 °C for 4 h. The resulting polymer was again purified by precipitation in petroleum 
ether, and dried under vacuum. 
 
4.2.2.1.3 Measurement of the LCST 
The LCST of the polymer in aqueous solution was determined by UV-Vis spectroscopy using 
a JASCO V-630 spectrophotometer equipped with an EYELA NCB-1200 temperature 
controller. The solution was heated from 25 °C to 47 °C whilst the transmittance was recorded 
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at 540 nm. The LCST value was interpreted as the temperature at which the solution 
transmittance reached 80%. 
 
4.2.2.2 Synthesis of bare iron oxide nanoparticles 
IONPs were synthesized following a modified procedure consisting of microwave-assisted co-
precipitation of Fe(II) and Fe(III) salts with Na2CO3 and the aid of a SP-Discovery Microwave 
(CEM, USA).276 In a typical synthesis, FeCl2·4H2O (0.4 mmol, 0.0795 g) and FeCl3·6H2O (0.8 
mmol, 0.2162 g) were dissolved in 20 mL of Milli-Q water (Millipore, 18.2 MΩ/cm), transferred 
into a 35 mL microwave vial and sealed with a pressure cap. The solution was heated to 60 °C 
(300 W, power max on), and Na2CO3 aqueous solution (4 mL, 1 M, 0.4240 g) was added drop 
wise at a rate of 2 mL/min using a syringe pump. The solution was kept at this temperature for 
20 min before allowing to cool down to room temperature. The NPs were then washed three 
times with ultrapure water by magnetic separation (Figure 4.1) and redispersed in ultrapure 
water for further use. 
 
Figure 4. 1 Photo of the washing step of the iron oxide nanoparticles by magnetic 
separation. 
 
4.2.2.3 Grafting of the copolymer onto the iron oxide 
nanoparticle surface 
Functionalisation of the MNPs with the polymer P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) 
was carried out via a silanisation reaction between the trimethoxysilane groups of the polymer 
and the hydroxyl groups naturally present on the surface of the bare IONPs, forming a covalent 
Si-O-Fe bond. The functionalisation parameters were optimized to find the best conditions. 
Typically, freshly synthesized naked IONPs were sonicated for 20 – 30 min in order to break 
all the aggregates that could have been formed. The IONPs were then mixed straightaway with 
the P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) copolymer dissolved in 20 mL of ethanol 
with different ratio w/w (Table 4.1). The mixture was acidified to a certain pH (Table 4.1) by 
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adding HCl 37%. The NPs suspension was then sonicated for 10 min and vigorously stirred at 
room temperature for 24 h. The copolymer-functionalized IONPs, hereafter referred to as 
magnetic nanocomposites (MNCs) were washed by magnetic separation twice with ethanol 
and once with ultrapure water before being redispersed in ultrapure water at a concentration 
of 10 mg/mL for further use. 
 
Table 4. 1 Experimental conditions used for the functionalisation of the iron oxide 
nanoparticles. 
Sample pH NPs:polymer ratio (w/w) 
P-IO4,1:1 4 1:1 
P-IO2,1:1 2 1:1 
P-IO2,1:3 2 1:3 
P-IO2,1:5 2 1:5 
P-IO2,1:7 2 1:7 
 
4.2.2.4 In vitro hyperthermia of the magnetic nanocomposites 
Magnetic heating measurements were performed to assess the heating performances of 
the different nanocomposites using a magnetic alternating current hyperthermia (MACH) 
system (Resonant Circuit Ltd, UK). Preliminary experiments to assess which 
nanomaterials had the best heating potential were performed at an operating frequency f 
= 970 kHz and field amplitude H = 6.8 kA/m. Samples made of 0.5 mL of MNCs dispersed 
in water with a concentration of 3 mg/mL were placed in the middle of the coil. The increase 
in temperature was continuously logged using fibres optic probes centred in the 
suspension. Two probes were used in order to limit possible errors coming from a non-
homogeneous spatial heating of the suspension. The measurement was started when the 
temperature of the suspension was stabilised to room temperature, and the measurement 
time was limited to 10 min. Both the SAR and ILP parameters were calculated. 
 
Once the nanomaterials with the best heating performances was identified, the SAR of the 
MNCs was also measured in biological media. In order to have conditions closer than what 
will be used for magnetic hyperthermia on cells, samples made of 0.5 mL of MNCs 
dispersed in biological media, i.e. Dubelcco’s modified Eagles medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), at a concentration of 1 mg/mL were 
placed in the middle of the coil maintained at 37 °C, and subjected to an AMF of frequency 
f = 950 kHz and field amplitude H = 10.5 kA/m. These field conditions were used so that a 
higher temperature could be reached in a shorter amount of time. In order to verify that the 
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change of conditions do not influence the ILP, the same experiment was performed with 
the original frequency and field amplitude conditions of f = 970 kHz and H = 6.8 kA/m. 
 
4.2.2.5 Preparation of the phosphate buffer solutions 
Phosphate buffer solutions 0.01 M (PBS) at pH = 7.4 and pH = 5.7 were used in many 
experiments. A pH of 7.4 was used to mimic physiological condition while the pH of 5.7 
was used to mimic acidic tumour environment. 
 
Firstly, stock solutions of Na2HPO4 (base) and NaH2PO4 (acid) at a concentration of 0.1 M 
were prepared. For a volume of 100 mL, the stock solution of Na2HPO4 requires 1.42 g of 
Na2HPO4 to be dissolved in 100 mL of ultrapure water, and the stock solution of NaH2PO4 
requires 1.20 g of NaH2PO4 to be dissolved in 100 mL of ultrapure water. 
 
Preparation of 100 mL of PBS at pH = 7.4 was carried out as follows: 7.70 mL of Na2HPO4 
(0.1 M) were mixed with 2.30 mL of NaH2PO4 (0.1 M) and diluted 10 times with ultrapure 
water. Similarly, 100 mL of PBS at pH = 5.7 was prepared as follows: 0.60 mL of Na2HPO4 
(0.1 M) were mixed with 9.40 mL of NaH2PO4 (0.1 M) and diluted 10 times with ultrapure 
water. 
 
The pH of both PBS solutions was then checked with a pH meter, and adjusted to the right 
pH values with diluted NaOH or HCl aqueous solutions if needed. 
 
4.2.2.6 Colloidal stability of the magnetic nanocomposites 
Colloidal stability of the MNCs in an aqueous dispersion over time was investigated by 
monitoring the hydrodynamic size of the MNCs using the dynamic light scattering technique 
throughout 14 days after being synthesised. Effect of pH on the stability of the MNCs was also 
assessed as well as the colloidal stability of the MNCs in phosphate buffer solutions and in 
biological media in the presence of serum. 
 
4.2.2.7 Working with DOX: risks and safety precautions 
DOX is an antineoplastic agent classified as anthracycline antibiotic that has been used to treat 
many cancers such as leukaemia, breast, ovarian, bladder, lung cancers and more. DOX can 
have severe side effects such as acute and chronic toxic effects (cardiotoxicity, dermatitis, 
anemia, skin and eye tissue vesication, and it is also embryotoxic, carcinogenic, teratogenic 
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and mutagenic. Therefore, protective equipment when handling DOX must be worn such as 
gloves, safety goggles, lab coat and complete coverage of skin 
 
4.2.2.8 Determination of DOX calibration curves for UV-vis and 
study of the photodegradation of DOX with time 
To be able to find the concentration of DOX in PBS at pH = 5.7 and PBS at pH = 7.4 by 
UV-vis, calibration curves of DOX in each media must be determined. The absorption of 
DOX solution of known concentration in each media (i.e. 1, 2, 8, 12, and 16 μg/mL) at a 
wavelength of 480 nm, which is the typical absorption for DOX, was measured. The 
absorption as a function of DOX concentration was recorded to generate the calibration 
curves. 
DOX is a light-sensitive chemical. In order to study the photodegradation of DOX with time, 
the absorption of the DOX solutions of known concentrations in PBS at pH = 7.4 were 
recorded again 3 days later. The absorption as a function of DOX concentration was 
recorded and compared to the calibration curve to study the time-dependency of the 
absorbance of DOX. 
 
4.2.2.9 Dialysis of free DOX 
Because dialysis is the method used for the determination of the drug release behaviour, 
dialysis of free DOX was performed as preliminary experiments. Dialysis rests on the 
principle of diffusion of solutes, which is that substances in solution tends to naturally move 
from an area of high concentration to an area of low concentration to make a 
homogeneous system. Dialysis also uses the principle of ultrafiltration, where the 
concentration gradients lead to a separation through a semipermeable membrane. In 
dialysis, the donor solution containing the solutes is placed in the dialysis membrane, 
which is soaked in the receiver phase (Figure 4.2). Due to the concentration gradients, the 
solutes in the donor phase will pass through the membrane. By choosing appropriately the 
molecular weight cut-off (MWCO) of the dialysis membrane used during the dialysis 
experiment, solutes of higher molecular weights than the MWCO are retained in the 
dialysis bag, while lower molecular weight ones can pass through the membrane. 
 
The main advantage of using dialysis to study the release behaviour of a drug from a 
nanosystem as compared to other conventional methods such as ultracentrifugation or 
magnetic separation, is that no additional step of separating nanoparticles from the free 
drug molecules at various time points is necessary. Indeed, by choosing the dialysis 
membrane judiciously, the nanoparticles are retained in the dialysis bag while only the 
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drug molecules can pass through. The concentration of the drug in the receiver phase can 
be analyzed at different time points to get the drug release profile.  
 
 
Figure 4. 2 Schematic representation of a dialysis set-up (image taken and modified from 
http://schoolworkhelper.net/selective-permeability-of-dialysis-tubing-lab-explained/). 
 
However, with dialysis, one has to keep in mind that the apparent release rate is the net 
results of drug transport across two barriers: diffusion from the nanoparticles followed by 
diffusion across the dialysis membrane.277,278 Therefore, the drug release profile obtained 
may not necessarily represent the rate of drug release from the nanoparticles, and it is 
important to assess in what extent the rate of drug transfer from the donor phase to the 
receiver phase is affected by the dialysis membrane. For that purpose, dialysis of free 
DOX was performed prior to the drug release experiments. Two parameters greatly 
influence the transport of the drug across the dialysis membrane: the solubility of the drug 
in the media and the MWCO of the membrane.279 Indeed, the dialysis set up must respect 
sink conditions, meaning that as the drug dissolves, it is essential that the presence of the 
already dissolved drug in solution should not affect the ability of more drug to be dissolved 
in any way. The MWCO of the dialysis membrane must be at least high enough to permit 
drug transport. The higher the MWCO of the membrane, the easier is drug transport across 
the membrane. 
 
According to Gupta et al., the apparent permeation constant KCV of the drug through the 
membrane can be determined by monitoring the DOX concentration in the receiver phase 
as a function of time, using the following equations:280 
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 𝑙𝑛  (𝑚0 − 𝐶1(𝑉1 − 𝑉2)) = 𝑙𝑛 (𝑚0) − 𝐾𝐶𝑉𝑡 (4.7) 
With: 
 
𝐾𝐶𝑉 =
𝑘𝐴(𝑉1 − 𝑉2)
𝑉1𝑉2𝜀
 (4.8) 
 
Where m0 is the total amount of drug in the system, C1 is the drug concentration in the 
receiving phase, V1 is the volume of the receiver phase, V2 is the volume of the donor 
phase, k is the drug permeability constant of dialysis membrane, A is the surface area of 
the membrane and ε is the thickness of the membrane.  
Thus, a plot of 𝑙𝑛  ( 𝑚0 − 𝐶1(𝑉1 + 𝑉2)) versus time would give a straight line with a slope 
equal to - 𝐾𝐶𝑉 and an intercept of 𝑙𝑛 (𝑚0). 
 
4.2.2.9.1 Dialysis of free DOX and determination of KCV using a dialysis bag 
This dialysis of DOX was performed using a dialysis membrane in regenerated cellulose 
with a 10 000 Da MWCO. A MWCO of 10 000 Da was found to be suitable for our system 
as the polymer used to functionalize the MNPs has a molecular weight higher than 10 000 
Da, while DOX has a molecular weight of 543 Da. It is therefore small enough to retain the 
MNCs while letting the DOX molecules through the membrane easily. 
 
Prior to the experiment, the dialysis membrane was immersed in the dialysis buffer for 48 
h, and was replaced three times with fresh buffer, to remove the sodium azide 
preservative. One extremity of the membrane was tight up with elastic bands to make sure 
no solution could be leaking. A 4 mL solution of DOX in PBS (pH 7.4) at 16 μg/mL was 
introduced in the membrane, and the other extremity of the membrane was sealed with 
rubber bands to prevent any leak. The dialysis bag was soaked and dialyzed against 40 
mL of PBS at pH = 7.4 under mild stirring in a polypropylene container. A receiver phase 
volume of 10 times that of the dialysis bag was chosen to ensure sink conditions for the 
DOX, while the absorbance of DOX in solution remains in the UV-vis detectable range. 
The dialysis setup was covered with foil to avoid any light degradation of the drug during 
the experiment. At predetermined time points (i.e. 0.25, 0.5, 0.75, 1, 2, 4, 8 and 10 h), 3 
mL of dialysate were taken out for UV-visible spectroscopy, and replaced with 3 mL of 
fresh PBS to keep the total volume constant and preserve sink conditions. The DOX 
content of the extracted solution was measured by UV-visible spectrophotometry and the 
diffusion profile of DOX through the dialysis membrane was determined. 
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4.2.2.9.2 Dialysis of free DOX and determination of KCV using a Slyde-A-Lyzer 
dialysis cassette 
The dialysis of DOX was performed using a SAL dialysis cassette composed of a low-
binding regenerated cellulose membrane with a 10 000 Da MWCO. The SAL cassette 
provides high surface-area to volume ratio that maximizes diffusion rate (Figure 4.3). 
 
Figure 4. 3 Photo of a Slyde-A-Lyzer dialysis cassette. 
 
In a typical procedure, the dialysis cassette was soaked in the dialysis buffer for 24 h prior 
to the experiment to hydrate the membrane. 6 mL of DOX solution (in PBS at pH = 7.4) at 
16 μg/mL were inserted in the cassette through the gasket via one of the corner ports, and 
the excess of air was withdrawn with a syringe to insure that the DOX solution was in 
contact with all the surface area of the membrane. The dialysis cassette was soaked and 
dialyzed against 60 mL of PBS at pH = 7.4 under mild stirring in a polypropylene container. 
A receiver phase volume of 10 times that of the dialysis cassette was chosen to ensure 
sink conditions for the DOX, while the absorbance of DOX in solution remains in the UV-
vis detectable range. The dialysis setup was covered with foil to avoid any light degradation 
of the drug during the experiment.  At predetermined time points (i.e. 0.25, 0.5, 0.75, 1, 2, 
4, 8 and 10 h), 3 mL of dialysate were taken out for UV-visible spectroscopy, and replaced 
with 3 mL of fresh PBS to keep the total volume constant and preserve sink conditions. 
The DOX content of the extracted solution was measured by UV-visible spectrophotometry 
and the diffusion profile of DOX through the SAL dialysis membrane was determined. 
 
4.2.2.10 Drug conjugation to the magnetic nanocomposites 
Conjugation of DOX with the MNCs was achieved through formation of imine bonds, also 
called Schiff base bonds, between the primary amine group of DOX and the aldehyde 
group of the P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) polymer. DOX and MNCs were 
mixed in PBS at pH = 7.4 with a ratio 1:10 w/w. The mixture was shaken gently in the dark 
for 24 h at room temperature, thereby leading to the conjugation of DOX via imine linkage. 
The DOX-loaded MNCs (DOX-MNCs) were retrieved by magnetic separation and washed 
thoroughly with PBS until no DOX was detected in the supernatant (at least 10 washing 
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cycles). The drug conjugation efficiency (%) is calculated by measuring the absorbance of 
the supernatant at 480 nm of the free DOX remaining in solution, and after each washing 
cycle, using the following equation:  
 
𝐷𝑟𝑢𝑔 𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =  
𝑀𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑒𝑑
𝑀𝑓𝑒𝑒𝑑
∗ 100
=  
𝑀𝑓𝑒𝑒𝑑 − 𝑀𝑒𝑥𝑐𝑒𝑠𝑠
𝑀𝑓𝑒𝑒𝑑
∗ 100 
(4.9) 
 
Here Mfeed is the initial mass of DOX used for the conjugation, Mconjugated is the mass of 
DOX actually conjugated to the MNCs, and Mexcess is the total mass of DOX found in the 
supernatants after the drug loading and each washing step. The DOX content in DOX-
MNCs (%) was also evaluated, and is defined as follow:  
 
𝐷𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 (%) =  
𝑀𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑒𝑑
𝑀𝑐𝑎𝑟𝑟𝑖𝑒𝑟
∗ 100 (4.10) 
 
where Mcarrier is the total mass of the nanosystem DOX-MNCs. 
 
4.2.2.11 In vitro drug release behaviour in the absence of an 
AMF 
In order to study the pH and temperature dependence of the drug release kinetics in the 
absence of an AMF, 6 sets of experiments were performed. The drug release was studied 
at 25 °C (room temperature), 37 °C (physiological temperature, <LCST) and 50 °C 
(hyperthermia temperature, >LCST). For each temperature, one sample was held at pH = 
7.4 (physiological pH) and another at pH = 5.7 to mimic acidic tumour pH. Typically, 3.3 
mg of DOX-MNCs dispersed in 6 mL of PBS with the appropriate pH (7.4 or 5.7) were 
inserted in a SAL dialysis cassette (MWCO 10 kDa) and dialyzed against 60 mL of PBS 
with the appropriate pH under mild stirring in a polypropylene container. A receiver phase 
volume of 10 times that of the dialysis cassette was chosen to insure sink conditions for 
the DOX. This volume was required for the dialysis cassette to be fully immersed in the 
medium, while the absorbance of DOX in solution remained in the detectable range of UV-
Vis. Dialysis setups were either maintained to room temperature, or placed into preheated 
water baths at 37 °C and 50 °C. They were also covered with foil to protect them against 
light and avoid photodegradation of DOX as much as possible during the all duration of 
the experiments. At predetermined time points (i.e. 0.25, 0.5, 0.75, 1, 2, 4, 8, 24 and 48 
h), 3 mL of dialysate were taken out for UV-Visible spectroscopy, and replaced with 3 mL 
of fresh PBS of the appropriate pH to keep the total volume constant and preserve sink 
conditions. The DOX content of the extracted solution was determined from the 
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absorbance measured by UV-Visible spectrophotometry at 480 nm and the DOX 
cumulative release was calculated. 
 
4.2.2.12 Drug release kinetics 
In order to determine the mechanism of drug release and the release rate, the data 
obtained from the drug release studies were fitted with the most relevant kinetic models 
for our system, such as first order, Higuchi and Korsmeyer-Peppas models.281 
 
The first order kinetic release is concentration dependant and can be expressed as: 
 
 𝑀𝑡 =  𝑀∞[1 − exp(𝐾1𝑡)] (4.11) 
 
where Mt is the amount of drug released at time t, M∞ is the amount of drug release at 
infinite time, and K1 is the first order rate constant.  
 
The Higuchi model describes drug release from solid matrices, and is described as: 
 
 𝑀𝑡 = 𝐾ℎ√𝑡 (4.12) 
where Kh is the dissolution constant.  
 
The Korsmeyer-Peppas model consists in a simple relationship, which describes drug 
release from a polymeric matrix, and is written as: 
 
 𝑀𝑡 = 𝑀∞𝐾𝑘𝑝𝑡
𝑛 (4.13) 
 
where Kkp is the rate constant which is characteristic of the drug delivery system and n is 
the exponent. The value of n changes depending on the release mechanism. In order to 
determine the drug release mechanism, first 60% of the drug release data was fitted with 
the Korsmeyer-Peppas model.  
 
By comparing the regression coefficient (R²) of the different model, the accuracy of each 
fitting could be verified. For each pH and temperature conditions, the model that gives the 
highest R² was considered as the best fit of release data. 
 
4.2.2.13 In vitro drug release behaviour in the presence of an 
AMF 
In order to study the drug release behaviour in the presence of an AMF, 4 sets of 
experiments were performed. Four identical samples containing 1 mg/mL of DOX-MNCs 
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were prepared. Two samples were held at pH = 7.4 (physiological pH) and the two others 
were held at pH = 5.7 to mimic acidic tumour pH. The drug release was studied at room 
temperature for one sample of each pH, while one sample of each pH was exposed to an 
AMF (H = 10.5 kA/m, f = 950 kHz). After either 15 min, 30 min or 1 h, the MNCs were 
separated from the supernatant by magnetic separation. The DOX content of the 
supernatant was determined from the absorbance measured by UV-Visible 
spectrophotometry at 480 nm and the DOX cumulative release was calculated. 
 
 
 
4.3 Results and discussion 
4.3.1 Polymer characterisation 
4.3.1.1 Polymer synthesis 
The P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) polymer is presented in Figure 4.4.  
 
 
Figure 4. 4 Chemical structure of P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) polymer. 
 
The polymer is composed of four mains groups: two PEG chains of different lengths, a 
benzaldehyde group and a trimethoxysilane group. PEG is FDA-approved and is widely 
used for biomedical applications, as it is non-toxic to cells and biocompatible with both 
blood and tissue. Therefore, PEG chains in the P(DEGMA-co-PEGMA-b-[TMSPMA-co-
VBA]) polymer provide biocompatibility and water dispersibility to the nanosystem. PEG 
also reduces protein adsorption and thus confers prolonged blood circulation time in the 
body.282 Finally, the two PEG chains of different length confer a temperature-responsivity 
to the polymer. The benzaldehyde group is the drug storage unit and by reacting the 
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aldehyde group with a primary amine a pH-labile imine bond can be formed. The 
trimethoxysilane group is the grafting group and will be used to attach the polymer onto 
iron oxide nanoparticle surfaces via the formation of covalent Si-O-Fe bond. 
 
The first step in the synthesis of the polymer involves the co-polymerisation of the two PEG 
chains via RAFT polymerisation. CPPA was chosen as RAFT agent because it is 
especially suited for the polymerisation of methyl methacrylate monomers. The ACVA 
initiator was chosen so that the radical I• derived from the initiator is the same as the 
reinitiating radical R• derived from the RAFT agent. 
 
In a first step, the polymerisation reaction advancement was followed by NMR 
spectroscopy. To that aim, the reaction was left on for 24 h. The reaction medium was 
sampled at predetermined time point and subsequently analysed by NMR to monitor the 
disappearance of the vinyl protons of the two PEGMA and DEGMA monomers. Because 
the initial ratio of PEGMA:DEGMA is known, the initial number of vinyl protons is also 
known, and the percentage of conversion can be calculated. The conversion was plotted 
as a function of time (Figure 4.5). 
 
 
Figure 4. 5 Follow up of the RAFT polymerisation reaction by NMR spectroscopy. 
 
The percentage of conversion increases linearly at the beginning of the reaction and 
reaches a plateau after 6 h. For that reason, the reaction time was limited to 5 h. 
The quantities of RAFT agent and monomers were calculated to obtained the desired final 
polymer molecular weight according to the following equation: 
 
 
𝑀𝑛
𝑡ℎ =  
[𝑚𝑜𝑛𝑜𝑚𝑒𝑟]0
[𝑅𝐴𝐹𝑇]0
∗ 𝑥 ∗ 𝑀𝑚𝑜𝑛𝑜𝑚𝑒𝑟 (4.13) 
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After this first step, Mn of the polymer is around 12000 g/mol (PDI = 1.10) as determined 
by SEC. Calculation of the theoretical molecular weight of the polymer by NMR was in 
close accordance with SEC results. Subsequently, a chain extension was carried out with 
the TMSPMA and VBA monomers (molar ratio TMSPMA:VBA = 1:4), using the 
synthesized P(DEGMA-co-PEGMA) polymer as macro-RAFT agent. The successful chain 
extension was confirmed by NMR, dominantly shown by the new signal at 10 ppm 
corresponding to the proton of the aldehyde group (Figure 4.6). An increase in the 
molecular weight of the polymer from 12 000 g/mol to 14 000 g/mol (PDI = 1.15) further 
confirms the polymer was chain extended. 
 
 
Figure 4. 6 1H-NMR spectra of A) P(DEGMA-co-PEGMA) and B) the chain extended 
polymer P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]). Inset shows the peak at 10 ppm 
corresponding to the aldehyde. 
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4.3.1.2 Tuning of the LCST of the polymer 
Copolymerizing two PEG chains of different length provides temperature-responsive 
behaviour to the polymer, with the possibility to tune the LCST by varying the molar ratio 
PEGMA:DEGMA (Figure 4.7). Indeed, by varying the ratio of hydrophilic/hydrophobic co-
monomer, the LCST of a given polymer can be tuned.149,154 Generally, increasing the 
content of hydrophobic co-monomer lowers the LCST, while increasing the content of 
hydrophilic co-monomer increases the LCST. PEGMA is more hydrophilic than DEGMA 
due to its higher number of ethylene glycol units, consequently, increasing its content 
during the synthesis also increases the LCST of the final copolymer. 
 
 
Figure 4. 7 LCST of P(DEGMA-co-PEGMA-b-[TMSPMA-co-VBA]) as measured by UV-
vis spectroscopy at 540 nm depending on the DEGMA:PEGMA molar ratio. 
 
A molar ratio of DEGMA:PEGMA of 1:2.2 (corresponding to 69:31 mol%) was selected for 
this work as it yields a polymer with a sharp LCST at 40 °C. This LCST is ideal because it 
is higher than the physiological temperature of 37 °C and can be easily reached via 
magnetic hyperthermia.  
 
4.3.2 Characterization of the naked iron oxide nanoparticles 
Figure 4.8 shows TEM images of the bare IONPs. The IONPs are spheroidal in shape with 
an average size of 13.3 ± 2.2 nm calculated from TEM images (n = 305). Some extent of 
aggregation can be observed on the TEM micrographs, which could be due to the absence 
of any stabilizing ligand on the surface of the nanoparticles and the drying effects that 
cause the accumulation and aggregation of particles on the TEM grid. 
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Figure 4. 8 A) TEM micrographs of the as-synthesized IONPs at low magnification, B) at 
higher magnification and C) their size distribution histogram. 
 
Sharp and clearly defined peaks can be observed in the XRD pattern of the IONPs (Figure 
4.9), which indicates a high degree of crystallinity of the particles. 
 
Figure 4. 9 XRD pattern of the as-synthesized IONPs. Peaks were indexed according to 
the reference pattern for magnetite (JCPDS PDF No. 00-019-0629). 
 
Diffraction peaks matching with a Fe3O4 magnetite phase seems to indicate that the IONPs 
are primarily constituted of magnetite. A mean crystallite size of 11.1 nm was calculated 
from the XRD pattern, which is slightly lower than the particle size measured from the TEM 
images.  
 
The magnetic properties of the IONPs were evaluated at 5 K and 300 K (Figure 4.10). 
Superparamagnetic behaviour was observed at 300 K with a saturation magnetisation 
around 78 ± 4 emu/g and a very low coercive field of 8 ± 3 Oe. At 5 K, a hysteresis cycle 
can be observed due to the transition to a low temperature blocked state, that comes with 
an increase of the saturation magnetisation to 92 ± 5 emu/g and of the coercive field to 
275 ± 30 Oe. 
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Figure 4. 10 Typical magnetisation curves of IONPs at 300 K (blue line) and 5 K (orange 
line). The inset shows a zoom into the low magnetic field region. 
 
The magnetic properties of the bare IONPs were measured again at 300 K three months 
after the first MH curves were recorded, which roughly is equivalent to three months after 
the synthesis (Figure 4.11). 
 
 
Figure 4. 11 Typical magnetisation curves of IONPs at 300 K three months after the 
synthesis. 
 
Again, a superparamagnetic behaviour was observed at 300 K with a saturation 
magnetisation around 70 ± 3 emu/g and a coercive field of 12 ± 3 Oe. The drop of the 
saturation magnetisation over time is due to the oxidation of the nanoparticles. However, 
this drop remains quite small over a three-months period, most likely due to the high 
crystallinity of the particles. The coercive field seems to slightly increase, and can be 
attributed to a slight agglomeration of the particles, as aggregates of superparamagnetic 
nanoparticles can behave as a ferromagnetic material. 
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Inductively coupled plasma atomic emission spectroscopy revealed an average iron 
percentage of 64.2 % in the bare iron oxide nanoparticles. 
 
4.3.3 Functionalisation of the IONPs with the polymer 
Coating the IONPs with a polymer can usually be done either during the polymerization 
process, referred as in-situ functionalization, or separately, once the IONP has already 
been synthesized prior to the functionalization. In our case, in-situ functionalization was 
not an option as the nanoparticle synthesis is performed in water and the two steps of the 
polymerization reaction are performed in organic solvents. Moreover, the presence of the 
polymer during the synthesis of the nanoparticles can impede with the nucleation and 
growth of the particles and often results in magnetic nanoparticles with smaller sizes and 
saturation magnetisation than the equivalent nanoparticles prepared in the absence of 
polymer.283 For those reasons, a post-synthetic functionalization protocol has been 
preferred. 
 
The grafting of the polymer onto the IONP surface was realized through a silanisation 
reaction between the hydroxyl groups naturally present on the surface of the naked IONPs 
and the trimethoxysilane groups of the polymer, to form covalent Si-O-Fe bonds. The pH 
of the medium as well as the NP to polymer ratio (w/w) were found to have a significant 
impact on the functionalization step, and as such, had to be optimized (see Table 4.1 in 
section 4.2.2.3 for the details of the experimental conditions tested).  
 
4.3.3.1 Influence of the pH during the functionalization step 
Surface functionalization of the IONPs was assessed by ATR-FTIR spectrum. The 
presence of the polymer on the nanoparticle surface was confirmed by the presence of 
characteristic absorption peaks at 1750 cm-1, 1450 cm-1, 1110 cm-1 and 1050 cm-1 which 
were assigned to carbonyl ester bonds C=O, a small aromatic peak C=C, Si-O bonds and 
ether bonds C-O-C in PEG chains (Figure 4.12).284,285 The absorption bands observed 
around 3100 – 3500 cm-1 may correspond to OH groups from the polymer, but is mainly 
associated to OH groups from the physisorbed water molecules on the nanoparticle 
surface.276 The stretching band at 1635 cm-1 present for each sample also shows the 
presence of residual physisorbed water molecules.285 
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Figure 4. 12 ATR-FTIR spectra of the functionalised IONPs with a NPs to polymer ratio of 
1:1 at pH 4 (P-IO4,1:1 sample) and pH 2 (P-IO2,1:1 sample). Spectra of the as-synthesised 
bare IONPs was included for reference. 
 
The organic content of each sample could be determined by TGA analysis in the 
temperature range from 25 °C to 500 °C. Figure 4.13 shows the weight loss of bare IONPs, 
P-IO4,1:1 and P-IO2,1:1 samples as a function of temperature. Polymer thermal 
decomposition occurs between 240 °C and 420 °C with a weight loss of 3.7 wt% and 4.5 
wt% for sample P-IO4,1:1 and P-IO2,1:1 respectively, therefore corresponding to the 
polymer content in each sample.  
 
Figure 4. 13 Weight loss curves as a function of temperature of the as-synthesized bare 
IONPs, P-IO4,1:1 and P-IO2,1:1 samples. 
 
It is well known that silanisation reactions are catalysed by an acidic pH, thus two acidic 
pH (i.e. pH 2 and pH 4) were studied. Indeed, the silanisation reaction is comprised of two 
steps: first, hydrolysis of the trimethoxysilane group and then condensation with the 
hydroxyl groups present on the surface of the IONPs as follows: 
 
1) Hydrolysis : -Si(OMe)3 + H2O  -Si(OMe)2(OH) + MeOH 
2) Condensation : -Si(OMe)2(OH) + Fe-OH  -Si(OMe)2-O-Fe + H2O 
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An acidic pH has been shown to catalyze both the hydrolysis and the condensation 
reaction.286 For the functionalisation of the iron oxide nanoparticles, an acidic pH of 2 
resulted in a better grafting density than a pH of 4. Therefore, the grafting of the polymer 
on the nanoparticle surface will be performed at pH 2 for all the next experiments. 
 
TEM images of samples P-IO4,1:1 and P-IO2,1:1 are presented in Figure 4.14. The IONPs 
are clearly more dispersed in the case of P-IO2,1:1 as compared to P-IO4,1:1 which is 
consistent with a higher grafting density, therefore preventing particles agglomeration in a 
greater extent. The grafting density is an important criterion to ensure the colloidal stability 
of the iron oxide nanoparticles. Low polymer grafting densities may not form a coating 
structure compact enough to prevent the formation of aggregates. For both samples, the 
particle stability was compromised with the appearance of particle flocculation within a few 
days. 
 
 
Figure 4. 14 TEM micrographs of A) P-IO4,1:1 and B) P-IO2,1:1 samples. 
 
4.3.3.2 Influence of the NP:polymer ratio w/w 
Likewise, surface functionalization of the IONPs was assessed by ATR-FTIR spectrum. 
The presence of the polymer on the nanoparticle surface was confirmed by the presence 
of the same characteristic absorption peaks at 1750 cm-1, 1450 cm-1, 1110 cm-1 and 1050 
cm-1, assigned to carbonyl ester bonds C=O, a small aromatic peak C=C, Si-O bonds and 
ether bonds C-O-C in PEG chains (Figure 4.15).284,285 
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Figure 4. 15 ATR-FTIR spectra of the functionalised IONPs at pH 2 with a NPs to polymer 
ratio of 1:3 (P-IO2,1:3 sample), 1:5 (P-IO2,1:5 sample) and 1:7 (P-IO2,1:7 sample). Spectra 
of the as-synthesised bare IONPs was included for reference. 
 
The absorption bands observed around 3100 – 3500 cm-1 may correspond to OH groups 
from the polymer, but is mainly associated to OH groups from the physisorbed water 
molecules on the nanoparticle surface.276 The stretching band at 1635 cm-1 present for 
each sample also shows the presence of residual physisorbed water molecules.285 
 
The organic content of each sample could be determined by TGA analysis in the 
temperature range from 25 °C to 500 °C. Figure 4.16 shows the weight loss of bare IONPs, 
P-IO2,1:1, P-IO2,1:3, P-IO2,1:5 and P-IO2,1:7 samples as a function of temperature. 
  
 
Figure 4. 16 Weight loss curves as a function of temperature of the as-synthesized bare 
IONPs, P-IO2,1:1, P-IO2,1:3, P-IO2,1:5 and P-IO2,1:7 samples. 
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Polymer thermal decomposition occurs between 240 °C and 420 °C with a weight loss 
increasing with an increasing ratio of NP to polymer, i.e 4.5 wt% at ratio 1:1, 6.9 wt% at 
ratio 1:3, and 8.1 wt% at ratio 1:5 and 1:7, respectively, therefore corresponding to the 
polymer content in each sample. No increase in the polymer content constituting the 
nanoparticles is observed between the ratio 1:5 and 1:7, which is most likely because no 
more polymer chain can reach the surface of the nanoparticles. 
 
The grafting density used in the synthesis of P-IO2,1:3 to P-IO2,1:7 is enough to confer 
the nanoparticles a good colloidal stability as no flocculation was observed even after a 
few months. Assuming the nanoparticles are spherical, and using the magnetite density, 
the nanoparticle size and the molecular weight of the polymer, a number of 25 polymer 
chains/nanoparticle can be calculated. This corresponds to a low grafting density of 0.05 
polymer chain/nm². The strategy adopted for the grafting of the polymer chains onto the 
nanoparticle surface is a major factor influencing the grafting density. There are two 
commons approaches for the functionalisation of nanoparticles with a polymer, the 
“grafting from” and “grafting to” approach.287 Here, a “grafting to” approach was used, that 
involves chemical binding of already formed polymer chains to the surface of the 
nanoparticles. This method usually results in low grafting densities as the diffusion of 
polymer chains to the surface is obstructed once a certain number of chains has already 
attached. On the other hand, with the “grafting from” method polymer chains are grown 
from initiators already bound to the nanoparticle surfaces. While this technique usually 
results in higher grafting density, it could not be envisaged to apply it to our system 
considering polymerisation conditions were not compatible with this technique. De Gennes 
described two polymer conformations depending on whether the grafting density is low or 
high,288 that are called mushroom and brush conformation. At high grafting density, the 
polymer chains adopt a brush structure, with the chain extending from the NP surface, 
while at low grafting density, the polymer chains acquire a mushroom structure.289,290 Here, 
the mushroom conformation is most likely the conformation obtained considering the low 
grafting density calculated after functionalisation of the particles. If polymer segments 
attractively interact with the nanoparticle surface, a pancake-like structure can also be 
obtained at low grafting density.291 
 
TEM images of samples P-IO2,1:3, P-IO2,1:5 and P-IO2,1:7 show that the nanoparticles 
are well dispersed, even in area of high concentration (Figure 4.17).  
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Figure 4. 17 TEM micrographs of A) P-IO2,1:3 NPs at low magnification and B) higher 
magnification, C) P-IO2,1:5 NPs at low magnification and D) higher magnification and E) P-
IO2,1:7 NPs at low magnification and F) higher magnification. 
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4.3.4 Magnetic heating measurements - MACH 
In vitro heating behaviour of the different nanoparticle suspensions were evaluated with a 
MACH system. Heat dissipation power measurements were performed on aqueous 
suspensions of concentration of 3 mg/mL subjected to an AMF of frequency f = 970 kHz 
and field amplitude H = 6.88 kA/m. The generated heat was characterized in terms of the 
ILP parameter, defined by Q. Pankhurst et al.,4 as an alternative to the more widely used 
SAR parameters. The SAR is commonly employed to quantify the heat dissipation rate of 
a given ferrofluid, even though it is not an intrinsic property of the system as it is strongly 
dependent upon the frequency and field amplitude used during the measurement. On the 
contrary, the ILP can be considered as an intrinsic property of the NPs because it is 
obtained by normalizing the SAR by f and H (equation 4.14). Hence one can directly 
compare the heating efficiency between different nanosystems measured under different 
experimental conditions using ILPs. The heating power of each nanoparticle suspension 
will therefore be characterized with the ILP value, but the SAR will be given as indication. 
 
 
𝐼𝐿𝑃 =  
𝑆𝐴𝑅
𝐻²𝑓
 (4.14) 
 
The calculated ILP and SAR values from the respective experimental heating curves of 
the studied suspensions are shown in Table 4.4. 
 
Table 4. 2 SAR and ILP values of the P-IO sample series measured at a frequency of 
970 kHz and a field amplitude of 6.88 kA/m. 
Sample SAR (W/g) ILP (nHm2/K) 
P-IO4,1:1 31.6 ± 2.5 0.7 ± 0.05 
P-IO2,1:1 67.8 ± 3.6 1.5 ± 0.09 
P-IO2,1:3 94.1 ± 5.3 2.1 ± 0.10 
P-IO2,1:5 91.9 ± 7.0  2.0 ± 0.15 
P-IO2,1:7 85.5 ± 6.8 1.9 ± 0.18 
 
The heating efficiencies vary significantly between the samples, ranging from 0.7 nHm²/K 
to 2.1 nHm²/K for sample P-IO4,1:1 and P-IO2,1:3 respectively. 
 
After analysis of the results, it seems that the ILP values reflect the colloidal stability of the 
suspensions. Indeed, a good colloidal stability is necessary to ensure a constant 
homogeneous magnetic heating. P-IO2,1:7, P-IO2,1:5, and P-IO2,1:3 are equally stable 
and, as can be seen from their respective TEM images, are well dispersed (Figure 4.17). 
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The slight decrease in the ILP from 2.1 nHm²/K to 1.9 nHm²/K for P-IO2,1:3 and P-IO2,1:7 
respectively, can be attributed to the increase organic content for the fabrication of the 
nanoparticle polymeric shell. However, the colloidal stability of P-IO2,1:3 > P-IO2,1:1 > P-
IO4,1:1 and so is their ILP values. This is mainly due to the change in dipolar interactions. 
Indeed, it is well-known that Néel relaxation is strongly dependent upon dipole-dipole 
interactions.292,293 The role of interparticle dipole-dipole interactions still remains an open 
question. Some investigations showed that dipolar interactions can lead to an increase of 
the SAR while others showed a decrease. G.T. Landi reports that dipole-dipole interactions 
can be used to increase the SAR of nanoparticles made of soft magnetic materials as it 
increases the anisotropy energy barrier. On the other hand, he also reports a decrease of 
the SAR for nanoparticles made of hard magnetic materials caused by a larger freezing of 
the magnetic spins that hampered the particles.294 However, once needs to be careful and 
distinguish the effect of nanoclustering and single particle in suspension. Indeed, 
nanoclustering acts to reduce the SAR while a peak against concentration is obtained for 
well-dispersed suspensions.295 It is therefore clear the dipolar interaction can both 
decrease or increase the SAR. For a given nanoparticle, interparticle dipole-dipole 
interactions vary with the nanoparticle concentration. The SAR increases for increasing 
concentration, reaches a maximum, and then decreases for higher concentration.295,296 An 
aggregated state means particles form clusters and are very close from each other, 
increasing their dipolar magnetic moment interaction inside the cluster in presence of an 
AMF. The higher the dipole-dipole interaction, the longer Néel relaxation time, and the 
lower the SAR. C. Blanco-Andujar et al., demonstrated that a better magnetic heating is 
associated with less core-to-core magnetic interactions.276 In the same way, D. Cabrera et 
al. showed that the aggregate compactness plays a major role in the decrease of the ILP. 
An increase aggregate compactness leads to a drastic decrease of the ILP as magnetic 
dipolar interactions between NPs in the aggregates are maximized.297 P-IO4,1:1 is the 
sample where the highest nanoparticle agglomeration is found as could be seen in the 
TEM images presented in Figure 4.14 in section 4.3.3.1, which explains its lower ILP value. 
 
According to the magnetic heating measurements, the ideal conditions for the 
functionalisation of the iron oxide nanoparticles were found to be at pH 2 with a 
NPs:polymer ratio w/w of 1:5 to obtain the highest ILP and grafting density. From now one, 
the experiments will be conducted with NPs prepared according to this protocol and the 
magnetic nanocomposites will be referred to as MNCs in the rest of the thesis. 
 
The MNCs exhibited a temperature rise of 16 °C in only 10 min, sufficient to reach 
hyperthermia temperatures, and yielding an ILP of 2.1 nHm²/K, that translated into a SAR 
of 94.1 W/g (Figure 4.18). Considering the percentage of polymer and iron that compose 
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the MNCs, a SAR of 159.5 W/gFe and an ILP of 3.5 nHm²/K can be calculated. This ILP 
value compares favourably to other ILP values obtained for iron oxide magnetic materials 
specially synthesized for hyperthermia applications,298 and commercially available 
ferrofluids with ILP values ranging from 0.15 nHm²/K to 3.1 nHm²/K.4  
 
 
Figure 4. 18 Typical heating curve of the MNCs dispersed in water with a concentration of 
3 mg/mL and subjected to an AMF (f = 970 kHz and H = 6.88 kA/m) using the MACH 
instrument. 
 
The concentration of MNCs of 3 mg/mL used to determine their heating abilities, is lower 
than that used by most other research groups, and the average concentration of 112 
mgFe/mL used by Jordan et al. for clinical trials.37,38,299,300  
 
Heat dissipation power measurements were also performed on suspensions in biological 
media (DMEM) supplemented with fetal bovine serum with a concentration of 1 mg/mL, 
maintained at physiological temperature (37 °C) and subjected to an AMF of frequency f = 
970 kHz and field amplitude H = 6.88 kA/m. A lower concentration of MNCs in solution 
was used in order to be closer from the conditions that will be used later for magnetic 
hyperthermia on cells. Under these conditions, the MNCs exhibited an ILP of 2.4 nHm²/K, 
which translated into a SAR of 108.5 W/g. The field conditions were changed to f = 950 
kHz and H = 10.5 kA/m to obtain a quicker rise of the temperature (Figure 4.19).  
 
Under these field conditions, a quick temperature rise is indeed obtained, from 34 °C to 
50 °C in 12 min. The ILP was still found to be 2.4 nHm²/K, which is coherent as the ILP 
parameter is independent of the AMF conditions, but translated into a SAR of 247.2 W/g 
It can be noted that a slight increase of the ILP is obtained in biological media (2.4 nHm²/K) 
as compared as in water (2.1 nHm²/K). 
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Figure 4. 19 Typical heating curve of the MNCs dispersed in DMEM supplemented with 
10% FBS with a concentration of 1 mg/mL and subjected to an AMF (f = 950 kHz and H = 
10.5 kA/m) using the MACH instrument. 
 
4.3.5 Colloidal stability of the magnetic nanocomposites 
The colloidal stability of nanoparticles over time and in different media is of significant 
importance for biomedical application purposes. The stability in aqueous suspension of 
the MNCs over time was estimated by measuring the change in hydrodynamic diameter 
DH of the MNCs. No significant changes in hydrodynamic radius was determined by DLS 
over two weeks, indicating that the MNCs remain well dispersed in water (Figure 4.20A). 
Moreover, after a month, the MNCs are still well dispersed in aqueous suspension as can 
be seen from the picture (Figure 4.20B). The obtained DH of 120 nm indicates that the 
MNCs possess a multicore structure.  
 
 
Figure 4. 20 A) Hydrodynamic diameter of MNCs as a function of time and B) photo of the 
MNCs aqueous suspension after one month. 
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As the pH in the human body can vary considerably, the DH of the MNCs was measured 
in aqueous suspension with a pH varying from 2 to 12. The DH of the MNCs remained 
constant at each different pH condition, suggesting that the pH does not have any impact 
on the colloidal stability of the MNCs (Figure 4.21). Finally, the DH of the MNCs was 
measured in biological media (DMEM supplemented with 10% FBS) yielding a DH of 147 
nm, representing a 27 nm increase as compared to MNCs in water. The increase in DH is 
most likely due to the formation of a protein corona around the MNCs that is formed 
instantaneously.87 The MNCs remain stable in DMEM + 10% FBS for several weeks before 
any aggregation of the MNCs could be observed. 
 
 
Figure 4. 21 Hydrodynamic diameter of MNCs as a function of pH in aqueous suspension. 
 
4.3.6 Evolution of the magnetic behaviour from the bare 
iron oxide nanoparticles to the MNCs 
The evolution of the magnetic behaviour from the bare IONPs to the MNCs was evaluated 
by recording the MH curves of both the IONPs and the MNCs under the same conditions 
(Figure 4.22). After functionalisation of the bare IONPs with the polymer, only a small drop 
of 5 emu/g is observed in the saturation magnetisation both at 300 K and 5 K. In general, 
silane-coated IONPs still maintains the physical properties of bare IONPs with high 
saturation magnetisation, the decrease value of saturation magnetisation being often less 
than 5 or 10 emu/g.301,302 The coercive field slightly decreases from 8 Oe to 5 Oe at 300 
K, and from 275 Oe to 200 Oe at 5 K, respectively. After stabilization of the IONPs with a 
polymer layer, the aggregates have been broken down to smaller aggregates, therefore 
resulting in a lower coercive field. 
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Figure 4. 22 Typical magnetisation curves of A) bare IONPs at 300 K (blue line) and 5 K 
(orange line) and B) MNCs at 300 K (green line) and 5 K (red line). The insets show a zoom 
into the low magnetic field region. 
 
Zero Field Cooled/Field Cooled (ZFC/FC) magnetisation curves for both the bare IONPs 
and IONPs after functionalisation were obtained by cooling the sample without any applied 
magnetic field (ZFC curve), and in a second step by heating the sample under a low 
magnetic field of 100 Oe (Figure 4.23). The ZFC curves do not indicate any sharp transition 
for both samples. Increasing the nanoparticles size polydispersity widens the blocking 
temperature range due to an increase on width of the anisotropy energy barrier.303 This 
phenomenon is clearly observed for the bare IONPs. Due to the absence of any stabilizing 
ligands, many aggregates of different sizes are present in the sample. Though after 
functionalisation of the IONPs with the polymer the blocking temperature range remains 
wide, a clear improvement in the nanoparticle polydispersity is observed, with a sharper 
transition. It is crucial to consider that the nanoparticles were stabilized by the formation of 
multicore structures, as revealed by the previous DLS measurements. The fast decrease 
of the magnetisation in the ZFC curves at low temperature is due to the presence of surface 
spin.304 Interparticle interactions due to particle agglomeration will cause surface spins, 
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which rearrange much slower than interior spins. As expected, this effect is more apparent 
for bare IONPs. 
 
 
Figure 4. 23 ZFC/FC magnetisation curves of the bare IONPs (blue line) and the MNCs 
(red line) recorded between 5 K and 400 K. 
 
4.3.7 DOX calibration curve and DOX photodegradation 
The calibration curves of DOX in PBS at pH = 7.4 and in PBS at pH = 5.7 could be plotted 
by recording the absorbance of DOX solution of known concentration at a wavelength of 
480 nm, which is the typical absorption for DOX, by UV-vis. The calibration curves are 
shown in Figure 4.24. 
 
 
Figure 4. 24 Calibration curves of DOX in PBS at pH 7.4 (black curve) and at pH 5.7 (red 
curve) obtained by UV-vis spectroscopy. 
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Because DOX is light-sensitive and was to be used in very small concentrations, the 
photodegradation of DOX as a function of time was studied over a 3-day period. The 
samples prepared for the calibration curve of DOX in PBS at pH = 7.4 were kept in the 
dark for three days and their absorbance measured again 3 days later. The results can be 
observed in Figure 4.25. 
 
Figure 4. 25 Absorbance of DOX solutions in PBS at pH = 7.4 (red curve) and measured 
again 3 days later (purple curve). 
 
Depending on the DOX concentration, a decrease of 7% to 10% of the original absorbance 
value can be observed for the absorbance of the DOX solutions measured 3 days later, 
which is most likely due to light degradation of DOX. Wood et al. reported that the 
photodegradation of DOX follow a first-order kinetic and is dependent on both the 
concentration and the pH of the solution.305 Low concentrated solutions (in the range of 
the low microgram and nanogram quantities in solution) may be degraded by light rapidly 
and acidic pH tends to slow down the photodegradation process. The authors also 
mentioned that another possible cause for the decrease of the absorbance, especially on 
low concentration solutions, is the loss of drug due to the adsorption of DOX onto the walls 
of the container. It is said that adsorption of DOX can be best minimized by using 
polypropylene containers, which is in good accordance with other reports.306-308 
 
According to those conclusions, all the experiments involving DOX, such as the dialysis of 
DOX and the drug release experiments, were carried out in polypropylene containers and 
protected from light as much as possible by using foil to cover the setups. 
 
 
 
 
 151 
 
4.3.8 Dialysis of free DOX 
Dialysis experiments of a solution of free DOX of known concentration were performed 
prior to the drug release experiments in order to determine the influence of the dialysis 
membrane on the diffusion of free DOX from the donor phase to the receiver phase. 
 
4.3.8.1 Dialysis of free DOX and determination of KCV using a 
dialysis bag 
The first experiment was performed with a common dialysis membrane of MWCO 10 kDa. 
Plot of the concentration of DOX retrieved in the receiver phase as a function of dialysis 
time is presented in Figure 4.26. 
 
 
Figure 4. 26 Cumulative DOX release in the receiver phase as a function of dialysis time 
using a dialysis membrane of MWCO 10 kDa. 
 
The plot indicates that the equilibrium between the donor phase and the receiver phase is 
reached after 2 - 4 h. However, the experimental equilibrium concentration (taken at the 
concentration of DOX in the receiver phase after 10 h of dialysis time) is equal to 1.28 
μg/mL. Knowing that the total volume is 44 mL (i.e. 4 mL of donor phase and 40 mL of 
receiver phase), and the initial amount of DOX dissolved in the donor phase was 64 μg, 
the equilibrium concentration should be 1.45 μg/mL. The reason behind the disappearance 
of DOX could be explained by the adsorption of DOX onto the dialysis membrane. 
 
The apparent permeation constant KCV of DOX for that membrane was determined by 
plotting 𝑙𝑛  ( 𝑚0 − 𝐶1(𝑉1 + 𝑉2)) versus dialysis time as previously explained in section 
4.2.2.8 (the equilibrium section was not considered). 
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Figure 4. 27 Plot of 𝒍𝒏  ( 𝒎𝟎 − 𝑪𝟏(𝑽𝟏 + 𝑽𝟐)) versus different dialysis time for the dialysis of 
free DOX using a dialysis membrane of MWCO 10 kDa. 
 
As can be observed in Figure 4.27, the initial amount of DOX dissolved in the donor phase 
m0 obtained from the plot was found to be 55.6 μg, while the actual initial amount of DOX 
was 64 μg. This result suggests that a non-negligible 13.1% of DOX is lost during the 
dialysis process, which might be caused by its adsorption on the membrane. The value of 
the permeation constant KCV was found to be 0.720 h-1mL-1. 
 
To conclude, DOX seems to adsorb onto this dialysis membrane, and therefore cannot be 
used for the drug release experiments. Indeed, the adsorption of DOX onto the membrane 
is non-negligible when using small concentration in the range of the μg and for experiments 
with duration of 48 h. 
 
In order to solve that issue, the experiment was repeated with another dialysis membrane 
that seemed more suitable for our system, the SAL dialysis cassette. 
 
4.3.8.2 Dialysis of free DOX and determination of KCV using a 
dialysis cassette 
As the first membrane used was proven to be unsuitable for the study of the drug release 
behaviour due to non-negligible adsorption of DOX onto the membrane, the dialysis of 
DOX was repeated with a SAL dialysis cassette. This dialysis cassette was chosen 
because it is composed of a low binding regenerated cellulose membrane of MWCO 10 
kDa and its design provides high surface-area to volume ratio that maximizes diffusion 
rate and ensure the maximum contact between the donor phase and the membrane.  
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Plot of the concentration of DOX retrieved in the receiver phase as a function of dialysis 
time is presented in Figure 4.28. 
 
Figure 4. 28 Cumulative DOX release in the receiver phase as a function of dialysis time 
using a dialysis cassette composed of a low binding membrane of MWCO 10 kDa. 
  
The plot indicates that the equilibrium between the donor phase and the receiver phase is 
reached after 2 – 4 h of dialysis. The experimental equilibrium concentration (took at the 
concentration of DOX in the receiver phase after 10 h of dialysis time) is equal to 1.42 
μg/mL. Knowing that the total volume is 66 mL (i.e. 6 mL of donor phase and 60 mL of 
receiver phase), and the initial amount of DOX dissolved in the donor phase was 96 μg, 
the theoretical equilibrium concentration should be 1.45 μg/mL, which is really close from 
the determined experimental equilibrium concentration. The apparent permeation constant 
KCV of DOX for that membrane was determined by plotting 𝑙𝑛  ( 𝑚0 − 𝐶1(𝑉1 + 𝑉2)) versus 
dialysis time as previously explained in section 4.2.2.8 (the equilibrium section was not 
considered). 
 
Figure 4. 29 Plot of 𝒍𝒏  ( 𝒎𝟎 − 𝑪𝟏(𝑽𝟏 + 𝑽𝟐))  for the dialysis of free DOX using a SAL 
dialysis cassette composed of a low binding membrane of MWCO 10 kDa. 
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The value of m0 (initial amount of DOX dissolved in the donor phase obtained from the 
plot) was found to be 100.0 μg (Figure 4.29), which is in close accordance with the actual 
initial amount of DOX of 96 μg. This result suggests that DOX does not absorb on the 
membrane of the SAL dialysis cassette. The value of the permeation constant KCV was 
found to be 1.065 h-1mL-1, which is higher than the value of KCV obtained with the previous 
tested membrane. 
 
The SAL dialysis cassette were therefore suitable for the drug release experiments, as 
negligible adsorption of DOX onto the membrane was found by using the SAL dialysis 
cassette. 
 
4.3.9 Drug loading – Dox conjugation efficiency 
In this work, DOX was chosen as anti-cancer drug because of its primary amine group, 
which can react with an aldehyde to form a Schiff base bond, releasing one molecule of 
water. Under acidic conditions, DOX can then be released by hydrolysis of the Schiff base 
bond without any damage to its chemical structure (Figure 4.30). 
 
 
Figure 4. 30 Schematic representation of the drug loading and drug release mechanisms. 
 
DOX is one of the most widely used chemotherapeutic drugs because of its efficacy 
against an extensive range of cancers.309 Its major mode of action is as a toiposomerase 
II inhibitor: it intercalates into DNA and inhibits the enzyme topoisomerase II, which is 
necessary for cell division and growth, therefore resulting in DNA damage and cell 
death.135,310 DOX can also generate free radicals (reactive oxygen species) that damage 
the cellular membrane, DNA, and proteins and lead to apoptotic cell death 135 and form 
adducts with DNA which enhances the cytotoxic response.311 
 
However, its use as anti-cancer agent is still limited by its detrimental side effects, and 
especially its cardiotoxicity.135,309 DOX encapsulation and targeting to the desired site, is 
therefore a very attractive solution to alter the pharmacokinetics and biodistribution of DOX 
toward its specific accumulation in tumour tissue, therefore reducing side effects and the 
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therapeutic dose needed for an efficient therapy. Ideally, the drug would be harmless to 
healthy tissue while circulating in the body because it is stored and protected in the MNCs 
until it enters the tumour, where it would be released in high concentrations. Two methods 
can be used to encapsulate a drug in an inorganic core/organic shell NPs: physical loading 
and chemical conjugation via labile bonds. The second method being more reliable, as 
chemical binding of the drug limits the leakage in a great extent through the polymer shell. 
In this study, DOX was efficiently encapsulated in the MNCs via heat- and acid-cleavable 
amine linkage with a conjugation efficiency of 82%, demonstrating a high efficacy of the 
drug loading process. The DOX content of the nanocarrier was calculated to be 7.6 wt%. 
A weight ratio of DOX to MNC of 1:10 was used, as a higher amount of DOX did not lead 
to significant increase in the conjugation efficiency. 
 
4.3.10 In vitro drug release profiles  
4.3.10.1 Drug release profiles as a function of pH and 
temperature 
Plots for cumulative DOX release as a function of time without application of an AMF but 
at different temperatures, i.e. 25 °C, 37 °C and 50 °C, in PBS at pH = 7.4 or 5.7 are 
represented in Figure 4.31. While 50 °C may seem slightly high temperature to simulate 
hyperthermia, it was chosen because the existence of local heating effects in the vicinity 
of magnetic NPs has been demonstrated, leading to high temperatures at the magnetic 
NP surface without necessarily observing a significant increase in the surrounding 
medium.182-184 For example, T. T. T. N’Guyen and co-workers demonstrated that by 
subjecting magnetic NPs to an AMF, they could initiate a retro-Diels-Alder reaction in the 
polymer layer functionalizing the magnetic NPs, which generally requires temperatures up 
to 90 – 110 °C.181 Kim et al. showed that the amount of drug released from a thermo-
sensitive micelle a 43 °C was found at least three times higher when the micelles were 
subjected to an AMF than when heated with a water bath, due to the direct thermal energy 
transfer from the SPIONs to the lipid layer.312 Therefore, as the temperature was 
maintained via a water bath, we chose to use 50 °C to simulate magnetic hyperthermia 
conditions instead of the more widely used temperature of 45 °C.  
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Figure 4. 31 In vitro cumulative drug release profiles of DOX-MNCs dispersed in PBS at 
pH = 7.4 or pH = 5.7 at 25 °C, 37 °C and 50 °C. 
 
The drug release profiles of DOX-MNCs under each condition show two stages: a rapid 
release of DOX is obtained within 8 h followed by a slower rate of release. This behaviour 
is more pronounced at pH = 5.7 and 50 °C with 57.8 % of DOX released after 8 h and 
85.2 % after 48 h, while at pH = 7.4 and 25 °C, 13.6 % of DOX is released after 8 h and 
19.7 % after 48 h. However, with dialysis, one has to keep in mind that the apparent release 
rate is the neat results of drug transport across two barriers: diffusion from the 
nanoparticles followed by diffusion across the dialysis membrane.277,278 As such, the 
release of the DOX is actually faster than what is shown with the results obtained from 
dialysis. This was proven by performing the dialysis of free DOX in section 4.3.8. 
 
The pH and the temperature greatly influence the release behaviour of DOX. The minimal 
release of DOX is obtained at pH = 7.4 and 25 °C (followed by pH = 7.4 and 37 °C), 
because at room temperature and physiological pH the imine bond is quite stable and its 
hydrolysis kinetic is really slow. The initial small burst release of DOX at pH = 7.4 and 
25 °C is probably due to physically adsorbed DOX on the outer shell of the polymer layer, 
despite the numerous washing of the DOX-MNCs. By using a pH stimulus, the amount of 
DOX released at 25 °C is doubled, with 26.5 % of DOX released after 8 h and 39.4 % after 
48 h. This is because acidic pH facilitates the release of the drug by promoting the 
hydrolysis of the Schiff base bond (pKa of imine bond is usually around 4). When only the 
temperature stimulus was used (pH = 7.4 and 50 °C), 38.1 % of DOX was released after 
8 h and 72.3 % after 48 h. The maximal release of DOX was found at pH = 5.7 and 50 °C, 
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when the DOX-MNCs were exposed to both pH and temperature stimuli. The temperature 
has two different effects: first, it accelerates the rate of the hydrolysis reaction. Second, 
the polymer being thermo-responsive, upon reaching the LCST, the polymer becomes 
hydrophobic and shrinks, expelling its aqueous content and pushing the DOX molecules 
out at the same time. It should also be noted that at acidic pH, the primary amine group of 
free DOX is protonated (pKa = 8.3), therefore increasing its solubility in aqueous medium 
and facilitating its expulsion out of the polymer layer. Thus, by combining both the effect 
of the pH and the temperature, a controlled release of the DOX can be obtained. A 
summary of the percentage of DOX released after 8 h and after 48 h for each temperature 
and pH conditions can be found in Table 4.5. 
 
Table 4. 3 Cumulative DOX released after 8 h and 48 h at the different temperature and pH 
conditions. 
Temperature 
(°C) 
pH 
Cumulative DOX 
released after 8 h (%) 
Cumulative DOX released 
after 48 h (%) 
25 7.4 13.6 19.7 
25 5.7 26.5 39.4 
37 7.4 23.1 33.0 
37 5.7 32.3 45.6 
50 7.4 38.1 72.3 
50 5.7 57.8 85.2 
 
 
4.3.10.2 Drug release kinetic and mechanism of release 
In this system, the DOX molecules are chemically bound to the polymer shell of the MNCs. 
The drug release is therefore mainly dependant on two mechanisms; firstly, the cleavage 
of the imine bond to release the DOX molecules of the bond, and secondly diffusion of 
DOX molecules from the polymer matrix to the surrounding dialysis medium. 
 
The use of mathematical models is necessary to predict the drug release kinetics of a 
particular system. In this study, different kinetic models i.e. first order kinetic, Higuchi and 
Korsmeyer-Peppas were used to fit the release data obtained for each pH and temperature 
condition applied. The release kinetic and mechanism of DOX from the DOX-MNCs 
nanosystem were therefore determined according to those mathematical models. The 
release parameters for each model (K1, Kh, Kkp and n) are shown in Table 4.6 as well as 
the correlations values (R²).  
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Table 4. 4 Correlation coefficients and drug release parameters based on drug release data 
for each temperature and pH conditions. 
Temperature 
(°C) 
pH 1st order Higuchi Korsmeyer-Peppas 
K1 R² Kh R² Kkp n R² 
25 7.4 0.794 0.8188 2.352 0.8523 8.181 0.277 0.9918 
25 5.7 0.288 0.8861 5.510 0.9204 12.530 0.361 0.9893 
37 7.4 0.293 0.8821 4.589 0.9179 10.548 0.363 0.9911 
37 5.7 0.353 0.9039 6.232 0.9040 14.841 0.378 0.9981 
50 7.4 0.127 0.9385 10.585 0.9844 14.520 0.451 0.9913 
50 5.7 0.259 0.9536 12.282 0.9177 22.175 0.475 0.9875 
 
The first order kinetic model does not fit well with experimental data as manifested by low 
R² values, though an increasing of R² can be observed with increasing temperature and 
decreasing pH, suggesting a more concentration-dependant release kinetic. The Higuchi 
model also does not fit well with experimental data, even though it has better R² values 
than the first order model. The highest R² value is obtained with the Korsmeyer-Peppas 
model. Values for the release exponent n were found to be lower than 0.5 indicating a 
Fickian diffusion mechanism. However, an increase in the n values with the increasing 
temperature and decreasing pH can be observed, such as at pH = 5.7 and 50°C, the n 
value reached 0.475, which becomes close to the limit with anomalous diffusion. This can 
be attributed to the involvement of the imine bond cleavage, which becomes more and 
more important as the pH becomes more acidic and the temperature increases. 
 
4.3.10.3 Drug release profiles in the presence of an AMF 
The study of the drug release as a function of pH in the presence of an AMF was performed 
differently as the study of the drug release profiles as a function of pH and temperature. 
Indeed, it was not possible to introduce a dialysis setup in the MACH system, therefore 
the magnetic separation method was chosen. For each pH, one sample was held at 25 °C, 
and the other was exposed to an AMF of f = 950 kHz and H = 10.5 kA/m for either 15 min, 
30 min or 1 h. Samples that were exposed to acidic pH and AMF were found to release 
DOX more rapidly than samples exposed to only one stimulus (Figure 4.32) 
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Figure 4. 32 In vitro cumulative DOX release of DOX-MNCs dispersed in PBS at pH = 7.4 
or pH = 5.7 with or without application of an AMF. 
 
After 1 h of hyperthermia at pH 5.7, 89% of DOX has been released, which is even more 
than the DOX released when the DOX-MNCs were heated with a water bath at 50 °C 
(85.2% after 48 h of dialysis). This might be due to the fact that the thermal energy is 
directly transferred from the SPIONs to the polymer layer. 
 
 
4.4 Conclusions 
 
In summary, a thermo-responsive polymer with a LCST around 40 °C has been 
synthesised via RAFT polymerisation. Highly crystalline iron oxide nanoparticles of 13 nm 
were obtained through a microwave-assisted co-precipitation method. These 
nanoparticles were superparamagnetic at room temperature with a high average 
saturation magnetisation of 78 emu/g. The magnetic properties of the nanoparticles were 
retained for long periods of time, with almost no loss of the saturation magnetisation three 
months after the synthesis. The as-synthesized IONPs were functionalized with the 
thermo-responsive polymer via a silanisation reaction. The functionalisation governing 
factors, i.e. the pH and the NPs:polymer ratio, were optimized to yield highly stable 
aqueous colloidal suspensions over time, under different pH conditions and in biological 
media. Considering the polymer content of the MNCs, it is likely that the polymer chains 
adopt a mushroom conformation.  
 
Magnetic heating measurements performed with the MACH revealed that the MNCs 
exhibit an ILP of 2.1 nHm²/K. In vitro heating behaviour of the different samples showed 
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that the SAR is negatively affected by the presence of compact aggregates of 
nanoparticles in solution due to the increase of magnetic dipolar interactions within the 
aggregates.  
 
High conjugation of the anticancer drug DOX to the MNCs was achieved through formation 
of heat- and acid-labile imine bonds using a weight ratio of DOX to MNC of 1:10. The DOX 
release behaviour was studied using the dynamic dialysis method. After careful choice of 
the dialysis membrane, plots for cumulative DOX release were obtained by studying the 
release of DOX as a function of time at different temperatures and pH conditions, i.e. 25 °C 
(room temperature), 37 °C (physiological temperature) and 50 °C (hyperthermia 
temperature), in PBS at pH = 7.4 (physiological pH) or 5.7 (tumour 
microenvironment/cellular organelles acidic pH). As expected, a minimum of DOX was 
released at physiological pH and room temperature, with less than 20% of DOX being 
released. The imine bond is stable under these conditions and therefore this was attributed 
to physisorbed DOX molecules on the outer shell of the polymer. A maximum of DOX was 
released under acidic pH and hyperthermia conditions, with more than 85% of DOX being 
released due to the dual stimuli-responsive features of the DOX-MNCs. An acidic pH 
facilitates the release of the drug by promoting the hydrolysis of the imine bond. Moreover, 
the primary amine group of free DOX molecules becomes protonated under acidic 
conditions, increasing its solubility in aqueous medium and facilitating its expulsion out of 
the polymer layer. Upon reaching the LCST, the polymer becomes hydrophobic and 
shrinks, expelling its aqueous content and pushing the DOX molecules out of the polymer 
due to squeezing effects. The temperature also accelerates the hydrolysis reaction rate. 
Study of the DOX release kinetic revealed that it follows the Korsmeyer-Peppas model and 
displays Fickian diffusion mechanism. Finally, samples that were exposed to acidic pH and 
an AMF were found to release even more DOX with 89% of DOX released after 1 h of 
hyperthermia. 
 
The dual temperature-and pH-responsive behaviour of the nanocarrier is an important 
feature of the nanosystem to control where and when the drug is released. A burst release 
of the drug can be achieved under hyperthermia and tumour acidic pH conditions, as high 
temperature and acidic pH were shown to act as triggers for the release of the drug. At 
physiological pH and temperature, the amount of released drug is low; that is the drug is 
correctly retained in the nanocarrier, which is desirable in clinical applications to limit 
distribution of the drug to healthy tissues and unwanted side effects. The nanosystem 
developed here is therefore promising for thermo-chemotherapy applications. 
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CHAPTER 5  
CELLULAR STUDIES ON CHEMOTHERAPY, 
MAGNETIC HYPERTHERMIA AND COMBINED 
THERMO-CHEMOTHERAPY FOR THERAPEUTIC 
APPLICATIONS 
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5.1 Introduction 
In the previous chapter, a magnetic delivery system was developed for magnetic 
hyperthermia and drug delivery applications. Its good heating performances, high drug 
loading capability and on demand release properties as a result of pH and temperature 
stimuli make this nanocarrier an ideal candidate for thermo-chemotherapy applications. 
 
The next step towards therapeutic applications of the DOX-MNCs for thermo-
chemotherapy of cancer requires their testing in cellular systems. As discussed in the 
introductory chapter, hyperthermia has the potential to target cancer cells because healthy 
tissues are able to withstand elevated temperatures at which malignant cells undergo 
apoptosis.21,22 Hyperthermia has also the potential to make cancer cells more sensitive to 
the effects of certain anti-cancer drugs,42,46 and chemotherapy applied with concurrent 
hyperthermia can result in a synergistic effect. 
 
This chapter focuses on the suitability of the DOX-MNCs for the killing of human glioma 
and breast cancer using U-87 and MCF-7 cell line models by thermo-chemotherapy. 
Firstly, the MNCs were tested for their biocompatibility. The IC50 values of free DOX and 
DOX-MNCs were evaluated on both cell lines for different incubation time. The cellular 
uptake of the nanoparticle as well as the fate of DOX in cells were investigated. Finally, 
the effect of magnetic hyperthermia, chemotherapy and the combinatorial treatment was 
assessed for both cell lines using two different treatment methods so that the effect of 
nanoparticle internalisation and hyperthermia temperature in the synergistic effect of the 
combined therapy could be studied. 
 
 
5.2 Materials and methods 
5.2.1 Reagents 
Trypan blue solution (0.4%, sterile-filtered), accutase solution (sterile-filtered, for molecular 
biology), dimethyl sulfoxide (DMSO, for molecular biology, ≥ 99.9%), hydrochloric acid 
(HCl, 36.5%-38%, for molecular biology), potassium hexacyanoferrate trihydrate 
(K4Fe(CN)6.3H2O) and nuclear fast red solution (0.1% w/v) were obtained from Sigma-
Aldrich, UK. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (Thiazolyl 
Blue tetrazolium bromide, MTT, 98%) was obtained from Alfa Aesar, UK. Dulbecco’s 
phosphate buffered saline (DPBS, no calcium, no magnesium, sterile) and trypsin (0.5%, 
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with ethylenediaminetetraacetic acid, no phenol red, sterile) were obtained from Gibco by 
Thermo Fisher Scientific. Ethanol (EtOH, 100%) was obtained from Hayman, UK.  
 
Cell culture reagents: Minimum Essential Medium Eagle (MEM, with Earl’s salt, non-
essential amino-acids and sodium bicarbonate, no L-glutamine, sterile), was obtained from 
Sigma, UK. Dulbecco’s modified Eagle’s medium (DMEM, with 4.5 g/L D-glucose, 0.11 g/L 
sodium pyruvate, no L-glutamine, sterile) and Fetal Bovine Serum (FBS, sterile-filtered), 
L-glutaMAX (sterile) and antibiotics Penicillin/Streptomycin (P/S, sterile) were obtained 
from Gibco by Thermo Fisher Scientific, UK. 
 
Unless stated, all reagents were used as purchased, without any further modifications. 
 
5.2.2 Cell culture media 
DMEM was supplemented with 1% penicillin/streptomycin used to prevent bacterial 
contamination of cell culture, 10% FBS and 1% L-glutaMAX. In the rest of the document, 
this will be referred to as complete DMEM. In this work, L-glutaMAX was used instead of 
L-glutamine. This is because L-glutaMAX is an improved cell culture supplement that can 
be used as a substitute of L-glutamine. Indeed, L-glutamine is a vital nutrient for cells to 
generate energy as well as for the synthesis of proteins and nucleic acids. However, L-
glutamine spontaneously degrades in cell culture media, producing ammonia and 
pyrrolidone carboxylic acid as by-products. L-glutaMAX is more stable and is suitable for 
both adherent and suspension mammalian cell cultures. Cells cleave the dipeptide bond 
to release L-glutamine as needed. This system prevents waste build-up and maintains a 
fresh supply of L-glutamine during long-term culture. 
 
MEM was supplemented with 1% P/S, 10% FBS and 1% L-glutaMAX. In the rest of the 
document, this will be referred to as complete MEM. 
 
5.2.3 Buffers and stains 
Prussian blue stained was always prepared fresh before use, by using a ratio 1:1 v/v of 
4% HCl solution in Milli-Q water and 4% K4Fe(CN)6.3H2O solution in Milli-Q water. 
 
Paraformaldehyde fixation buffer was prepared with the following percentage: 4% 
paraformaldehyde in DPBS. 
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FITC Annexin V apoptosis detection kit I (contains Annexin V-FITC, propidium iodide 
staining solution and Annexin V binding buffer) was obtained from BD Pharmingen, BD 
Biosciences, UK. 
 
 
5.2.4 Experimental methods 
5.2.4.1 Cell culture 
5.2.4.1.1 U-87 human glioblastoma cell line and L929 mouse fibroblast cell line 
Human glioblastoma cell line U-87 was cultured in 10 mL of complete DMEM medium in a 
T-75 culture flask and incubated at 37 °C under 5% CO2 in a humidified atmosphere. When 
the cells reached 80% – 90% confluence, adherent cells were detached by trypsinization 
(see section 5.2.4.2) and seeded on a new tissue culture plate for subculture (cells 
passaging) or frozen and stored (see section 5.2.4.3), or used directly for experiments. 
 
Mouse fibroblast cell line L929 was cultured in the same way as the U-87 cells (but in 
JAIST - Japan). 
 
5.2.4.1.2 MCF-7 human breast cancer cell line 
Human breast cancer cell line MCF-7 was cultured in 10 mL of complete MEM medium in 
a T-75 culture flask and incubated at 37 °C under 5% CO2 in a humidified atmosphere. 
When the cells reached 80% – 90% confluence, adherent cells were detached by 
trypsinization (see section 5.2.4.2) and seeded on a new tissue culture plate for subculture 
(cells passaging) or frozen and stored (see section 5.2.4.3), or used directly for 
experiments. 
 
5.2.4.2 Trypsinization of adherent cells 
The cell culture medium was discarded and the cell layer washed with DPBS. 2 mL of pre-
warmed trypsin at 37 °C was added to the cell layer. Trypsin is an enzyme that breaks 
down protein, to detach adherent cells from the flask they are being cultured. The culture 
flask was then returned to the incubator (37 °C, 5% CO2) for 3 min. 8 mL of complete 
medium was added for a T-75 culture flask to inactivate the trypsin. The cells, now 
suspended in the medium, were centrifuged at 1200 rpm for 3 min to obtain a cell pellet. 
The supernatant was discarded and the cells were redispersed in 4 mL of fresh medium. 
The average number of viable cells in suspension was determined with the aid of a 
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hemocytometer and the trypan blue exclusion method. Trypan blue is a dye used to colour 
dead cells. The cell viability should be at least 90% for a healthy log-phase culture. After 
determining the number of cells/mL, the cells were either passaged and returned to culture 
in a new culture flask with approximately 1.106 cells in 10 mL of complete medium for a T-
75 flask, or frozen for cryoconservation (see section 5.2.4.3), or used directly for 
experiments. 
 
5.2.4.3 Cryoconservation of viable cells 
5.2.4.3.1 U-87 human glioblastoma cell line 
After trypsinization and counting of the U-87 cells as explained in section 5.2.4.2, the cell 
pellet obtained after centrifugation was re-suspended in the freezing media, composed of 
95% complete DMEM and 5% DMSO. In the freezing media, DMSO is a cryoprotective 
agent. It is used to reduce the freezing point of the medium and to allow a slower cooling 
rate, therefore greatly reducing the risk of formation of ice crystals, which can damage 
cells and cause cell death. 1 mL aliquots containing a minimum of 1.106 cells/mL in 
cryovials were firstly placed in a freezing chamber partially filled with isopropanol to 
gradually freeze the cells to -80 °C at a rate of -1 °C/min. The next day, cryovials containing 
the cells were stored in liquid nitrogen for long conservation. 
 
5.2.4.3.2 MCF-7 human breast cancer cell line 
After trypsinization and counting of the MCF-7 cells as explained in section 5.2.4.2, the 
cell pellet obtained after centrifugation was re-suspended in the freezing media, composed 
of 90% complete MEM and 10% DMSO. 1 mL aliquots containing a minimum of 1.106 
cells/mL in cryovials were firstly placed in a freezing chamber partially filled with 
isopropanol to gradually freeze the cells to -80 °C at a rate of -1 °C/min. The next day, 
cryovials containing the cells were stored in liquid nitrogen for long conservation. 
 
5.2.4.4 Cells thawing from frozen storage 
Cells stored in liquid nitrogen for cryoconservation were returned to culture by thawing the 
cryovial in a water bath maintained at 37 °C. The thawed cells were transferred to a 
centrifuge tube and pre-warmed complete medium at 37 °C (DMEM for U-87 cells and 
MEM for MCF-7 cells) was added dropwise into the cell suspension for a 10-fold dilution, 
while gently mixing the cells. In order to remove the cryoprotective agent DMSO that is 
harmful to cells in a non-frozen medium, the cell suspension was centrifuged at 1200 rpm 
for 3 min to obtain a cell pellet. The supernatant was discarded and the cells were 
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redispersed in 2 mL of fresh medium. The average number of viable cells in suspension 
was determined with the aid of a hemocytometer and the trypan blue exclusion method. 
The cell viability should be at least 90% to start a new culture from a frozen sample. After 
determining the number of cells/mL, the cells were cultured in 10 mL of complete medium 
in a T-75 culture flask is the number of viable cells was greater than 6.105 and in 5 mL of 
complete medium in a T-25 culture flask if the number of viable cells was lower than 6.105. 
The cells were then culture as explained in section 5.2.4.1, and were allowed to grow for 
one or two weeks (at least two passages) before being used for experiments. 
 
5.2.4.5 Biocompatibility study of the MNCs on L929 cells by MTT 
assay 
This experiment was performed in Japan and was the only in vitro experiment which was 
performed in JAIST. All the other studies were performed at UCL. 
 
L929 cells were cultured as explained in section 5.2.4.1. After trypsinization, counting of 
the cells and confirmation that the cell viability was superior to 90% by trypan blue 
exclusion (section 5.2.4.2), cells suspended in a 0.1 mL complete DMEM medium at a 
concentration of 1.0 x 103 cells/well were plated in 96 well, flat-bottomed culture plates. 
After 72 h of incubation at 37 °C, 0.1 mL of medium containing different concentrations of 
sterile MNCs was added to the cells, followed by 48 h incubation at 37 °C. To evaluate the 
cell viability, 0.1 mL of MTT solution at a concentration of 300 μg/mL in complete DMEM 
medium was added to the cultured cells. After 4 h of incubation at 37 °C, the medium was 
removed, and 0.1 mL DMSO was added to each well to dissolve the purple formazan 
precipitate. The resulting color intensity, which is proportional to the number of viable cells, 
was measured using a microplate reader (VersaMax, Molecular Devices, USA) at 540 nm. 
The percentage of viable cells for each concentration of MNCs was determined based on 
the absorbance readings, and expressed as a percentage of the vehicle control as follows: 
 
 
𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑡𝑒𝑠𝑡 − 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑏𝑙𝑎𝑛𝑘
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑏𝑙𝑎𝑛𝑘
 (5.1) 
 
Where absorbancetest is the absorbance reading for a given concentration of MNPs, 
absorbancecontrol is the absorbance reading of the control wells (containing only cells, not 
exposed to MNCs) and absorbanceblank is the absorbance reading of the blank wells 
(containing only culture medium, no cells and no MNCs). MTT assay for the 
biocompatibility study of the MNCs on healthy cells was performed in duplicate.  
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5.2.4.6 Determination of the IC50 of free doxorubicin in MCF-7 
and U-87 by MTT assay 
MCF-7 and U-87 cells were cultured as explained in section 5.2.4.1. After trypsinization, 
counting of the cells and confirmation that the cell viability was superior to 90% by trypan 
blue exclusion (section 5.2.4.2), cells suspended in 0.2 mL complete culture medium 
(DMEM for U-87 cells and MEM for MCF-7 cells) at a concentration of 5.0 x 103 cells/well 
were plated in 96 well, flat-bottomed culture plates. Cells were allowed to adhere and grow 
by incubation at 37 °C for 24 h before exposure to drug treatment. Briefly the medium was 
removed from each well, and the cells were exposed to 0.2 mL of complete medium 
containing various fixed concentration of DOX for 24 h, 48 h or 72 h at 37 °C in the 5 % 
CO2 incubator. DOX solution at 2.5 mg/mL was firstly prepared in DMSO and then diluted 
into the culture medium to obtain the desired concentration, as DOX solubility is low in cell 
culture medium. However, DMSO is toxic to cells and therefore the final percentage of 
DMSO in the well should not exceed 0.5 % of the total volume. Dilution from the most 
concentrated solution of DOX were made, meaning that the wells containing the highest 
concentration of DOX were also the ones containing the highest volume of DMSO (kept 
below 0.2% for each cell line). Control wells were therefore prepared to contain the highest 
percentage of DMSO used in the medium, in order to verify that DMSO had no toxic effect 
to cells at that percentage. At the end of incubation, culture medium was removed from 
each well. To evaluate the cell viability, MTT solution was added to the cells at a final 
concentration of 200 μg/mL in complete medium. After 4 h of incubation at 37 °C, culture 
medium was removed from each well, and 0.15 mL of DMSO was added to each well to 
dissolve the purple formazan precipitate. The resulting color intensity, which is proportional 
to the number of viable cells, was measured using a microplate reader (SpectraMax M2, 
Molecular Devices, USA) at 570 nm. The percentage of viable cells for each concentration 
of DOX was determined based on the absorbance readings, and expressed as a 
percentage of the vehicle control following Equation 5.1. All assays were performed in 
triplicate. Data obtained from the MTT assay were subject to median effect analysis using 
the CompuSyn® software to determine the half maximal inhibitory concentration (IC50) of 
DOX on both MCF-7 and U-87 cell lines for each incubation period. 
 
 
5.2.4.7 Determination of the IC50 of DOX-MNCs in MCF-7 and U-
87 by MTT assay 
MCF-7 and U-87 cells were cultured as explained in section 5.2.4.1. After trypsinization, 
counting of the cells and confirmation that the cell viability was superior to 90 % by trypan 
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blue exclusion (section 5.2.4.2), cells suspended in 0.2 mL complete culture medium 
(DMEM for U-87 cells and MEM for MCF-7 cells) at a concentration of 5.0 x 103 cells/well 
were plated in 96 well, flat-bottomed culture plates. Cells were allowed to adhere and grow 
by incubation at 37 °C for 24h before exposure to drug treatment. Briefly the medium was 
removed from each well, and the cells were exposed to 0.2 mL of complete medium 
containing various fixed concentration of DOX-MNCs for 24 h, 48 h or 72 h at 37 °C in the 
5 % CO2 incubator. At the end of incubation, culture medium was removed from each well. 
To evaluate the cell viability, MTT solution was added to the cells at a final concentration 
of 200 μg/mL in complete medium. After 4 h of incubation at 37 °C, culture medium was 
removed from each well, and 0.15 mL of DMSO was added to each well to dissolve the 
purple formazan precipitate. The resulting color intensity, which is proportional to the 
number of viable cells, was measured with the help of a microplate reader (SpectraMax 
M2, Molecular Devices, USA) at 570 nm. The percentage of viable cells for each 
concentration of DOX-MNCs was determined based on the absorbance readings, and 
expressed as a percentage of the vehicle control following Equation 5.1. All assays were 
performed in triplicate. Data obtained from the MTT assay were subject to median effect 
analysis using the CompuSyn® software to determine the IC50 of DOX on both MCF-7 and 
U-87 cell lines for each incubation period. 
 
5.2.4.8 Histology and visualization of MNCs internalization in 
cells 
MCF-7 and U-87 cells were cultured, trypsinized and counted as explained in section 
5.2.4.1 and 5.2.4.2. For histology study and visualization of nanoparticles internalization in 
both MCF-7 and U-87 cancer cells, cells suspended in 1 mL of complete medium were 
seeded in 24 well, flat-bottomed culture plates containing glass coverslips, at a density of 
50,000 cells/well. Cells were incubated at 37 °C for 72 h to be allowed to reach confluence. 
After growing the cells to confluence, the medium was removed from each well and 1 mL 
of complete medium containing different concentration of sterile MNCs (i.e. 1 mg/mL, 0.5 
mg/mL, 0.1 mg/mL, 0.05 mg/mL, 0.01 mg/mL and 0.00 mg/mL) was added to the wells. 
The cells were then incubated for either 4 h or 24 h at 37 °C. The culture medium was then 
removed from each well, and the cells were washed three times with pre-warmed complete 
medium (37 °C) and twice with pre-warmed DPBS (37 °C) to remove the nanoparticles not 
internalized or attached to the cells. Cells were then fixed with paraformaldehyde buffer 
(400 μL, 30 min, room temperature), and rinsed twice with DPBS. Cells were stained for 
iron content by Prussian blue staining (310 μL, 2 min), rinsed twice with Milli-Q water, and 
counterstained with nuclear fast red (400 μL, 2 min). Stained cells were then rinsed twice 
with Milli-Q water, and dehydrated with ascending alcohol, 70% EtOH (2 min) and 100% 
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EtOH (5 min) and mounted onto microscope slides. Stained cells were observed by light 
microscopy using an inverted microscope (DMI6000B, Leica, UK). 
 
5.2.4.9 Quantification of the cellular uptake of MNCs using a 
SQUID magnetometer 
Cells were cultured, trypsinised and counted as explained in section 5.2.4.1 and 5.2.4.2. 
For the quantification of nanoparticles internalization in both MCF-7 and U-87 cancer cells, 
cells suspended in 2 mL of complete medium were seeded in 12 well, flat-bottomed culture 
plates at a density of 100,000 cells/well. Cells were incubated at 37 °C for 72 h to be 
allowed to reach confluence. After growing the cells to confluence, the medium was 
removed from each well and 1 mL of complete medium containing different concentration 
of sterile MNCs (i.e. 1 mg/mL, 0.5 mg/mL, 0.1 mg/mL, 0.05 mg/mL, 0.01 mg/mL and 0.00 
mg/mL) was added to the wells. The cells were then incubated for either 4 h or 24 h at 
37 °C. The culture medium was then removed from each well, and the cells were washed 
three times with pre-warmed complete medium (37 °C) and twice with pre-warmed DPBS 
(37 °C) to remove the nanoparticles not internalized or attached to the cells. Cells were 
then detached by trypsinization (0.4 mL, 3 min, 37 °C), re-suspended in 2 mL of complete 
media and centrifuged (1200 rpm, 3 min, 4 °C). The supernatant was discarded and the 
cell pellet was re-dispersed in 0.5 mL of complete media. The cell density was counted 
with the aid of a hemocytometer and the cells were pelletized again by centrifugation (1200 
rpm, 3 min, 4 °C). The cell pellet was transferred into powder polycarbonate sample holder 
for SQUID-VSM as a suspension, and dried in a low temperature oven at 37 °C overnight 
before carrying out the magnetic measurements. 
 
5.2.4.10 Fluorescence imaging of free DOX and DOX-MNCs in 
cells 
MCF-7 and U-87 cells were cultured, trypsinized and counted as explained in section 
5.2.4.1 and 5.2.4.2. For fluorescence study and visualization of DOX internalization in both 
MCF-7 and U-87 cancer cells, cells suspended in 1 mL of complete medium were seeded 
in 24 well, flat-bottomed culture plates containing glass coverslips, at a density of 50,000 
cells/well. Cells were incubated at 37 °C for 72 h to be allowed to reach confluence. After 
growing the cells to confluence, the medium was removed from each well and 1 mL of 
complete medium containing different concentration of free DOX or DOX-MNCs (i.e. 4 μg 
and 2 μg) was added to the wells. The cells were then incubated for either 3 h or 24 h at 
37 °C. The culture medium was then removed from each well, and the cells were washed 
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four times with pre-warmed complete medium (37 °C) to remove the free DOX or the 
nanoparticles not internalized in the cells. Cells were then washed twice with DPBS and 
fixed with paraformaldehyde buffer (400 μL, 30 min, room temperature), and rinsed twice 
again with DPBS. Cell nuclei were stained with DRAQ5 in the dark (5 μM, 15 min, room 
temperature). Stained cells were then rinsed once with Milli-Q water, and mounted onto 
microscope slides with either FluorSave or FluorPreserve mounting medium. Stained cells 
were observed by fluorescence microscopy using an inverted microscope (DMI6000B, 
Leica, UK) with an excitation wavelength of 488 nm for both DOX and DRAQ5. 
Fluorescence emissions of DOX and DRAQ5 were observed using a rhodamine (N3 ET, 
600/40 bandpass filter, Leica) and a far-red (Y5 ET, 700/75 bandpass filter, Leica) filter 
sets, respectively. Images were captured using LAS X software. 
 
5.2.4.11 In vitro anticancer studies by trypan blue dye exclusion 
assay 
For in vitro anticancer studies, two methods were employed: hyperthermia treatment after 
internalization of the nanoparticles in the cells and direct hyperthermia treatment. 
 
5.2.4.11.1 Treatment after internalization 
The treatment after internalization consists in using only the nanoparticles internalized in 
the cells for the hyperthermia treatment. To that aim, cells and MNCs are incubated 
together for 24 h. The cells are then washed before being subjected to the hyperthermia 
treatment. 
 
MCF-7 and U-87 cells were cultured, trypsinized and counted as explained in section 
5.2.4.1 and 5.2.4.2. Cells suspended in 1 mL of complete medium were seeded in 12 well, 
flat-bottomed culture plates, at a density of 150,000 cells/well. Cells were incubated at 
37 °C for 24 h before replacing the medium from each well with 1 mL of fresh complete 
medium only or containing MNCs or DOX-MNCs. The cells were then incubated for an 
additional 24 h at 37 °C. Six groups were formed: control- (media only, no AMF), control+ 
(media only, AMF), MNCs- (media containing MNCs, no AMF), MNCs+ (media containing 
MNCs, AMF), DOX-MNCs- (media containing DOX-MNCs, no AMF) and DOX-MNCs+ 
(media containing DOX-MNCs, AMF). Therefore, the group MNCs+ corresponds to 
hyperthermia treatment, DOX-MNCs- corresponds to chemotherapy treatment, and DOX-
MNCs+ corresponds to thermo-chemotherapy treatment. A concentration of MNCs of 1 
mg/mL was used for each group. After the 24 h incubation period, the three AMF positive 
groups (control+, MNCs+ and DOX-MNCs+ groups) were exposed to an AMF (H = 10.5 
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kA/m and f = 950 kHz) for 1 h using the MACH instrument. To that aim, the supernatant in 
each well was discarded to keep only the nanoparticles internalized or adsorbed on the 
cell surface. The cells were trypsinized with 0.4 mL trypsin (3 min, 37 °C) and 2 mL of fresh 
complete media was added. The cells were centrifuged (1200 rpm, 5 min, 4 °C), and the 
obtained pellet was redispersed in 0.5 mL complete media, and transfer into a vial for 
hyperthermia treatment. The cells in the three AMF negative groups (control-, MNCs- and 
DOX-MNCs- groups) were subjected to the same protocol, without being subjected to an 
AMF, in order to remove any environmental effect on cell death. After hyperthermia 
treatment, the cell suspension was properly mixed and separated in two, so that it could 
be seeded in two different 12 well, flat-bottomed culture plates. The volume of the cell 
suspension was adjusted to 1 mL for each well and the cells were incubated at 37 °C. One 
plate was analyzed 24 h later while the other one was analyzed after 48 h. Cell viability 
was determined using trypan blue dye exclusion method. Cells were trypsinized with 0.4 
mL trypsin (3 min, 37 °C) and 1 mL of fresh media was added. 50 μL of cell suspension 
was mixed with 50 μL of sterile-filtered trypan blue. Cells were counted with the aid of a 
hemocytometer. Values of viability of treated cells were expressed as a percentage of that 
from corresponding control cells. All experiments were repeated at least three times. 
The combined effect of the thermo-chemotherapy treatment was evaluated by the 
Valeriote’s method. With (A), (B) and (A + B) representing the percentage of cell viability 
for treatments A (hyperthermia) and B (chemotherapy) and A + B (thermo-chemotherapy 
treatment). Combined effects were defined as follows:313,314 
➢ synergistic: (A + B) < (A) × (B)/100  
➢ additive: (A + B) = (A) × (B)/100 
➢ sub-additive: (A) × (B)/100 < (A + B) < (A) if (A) < (B) 
➢ interference: (A) < (A + B) < (B), if (A) < (B)  
➢ antagonistic: (B) < (A + B), if (A) < (B).  
 
5.2.4.11.2 Direct hyperthermia treatment 
The direct hyperthermia treatment consists in using only nanoparticles that are not 
internalized in the cells, but are in the surrounding medium for the hyperthermia treatment. 
To that aim, the hyperthermia treatment is applied directly after mixing the cells with the 
MNCs. The same protocol as for the treatment after internalisation method was used, 
excepted that the nanoparticles were added only right before the exposure of the cells to 
an AMF for hyperthermia treatment. 
 
MCF-7 and U-87 cells were cultured, trypsinized and counted as explained in section 
5.2.4.1 and 5.2.4.2. Cells suspended in 1 mL of complete medium were seeded in 12 well, 
 172 
 
flat-bottomed culture plates, at a density of 150,000 cells/well. Cells were incubated at 
37 °C for 24 h before replacing the medium from each well with 1 mL of fresh complete 
medium and the cells were then incubated for an additional 24 h at 37 °C. The cells were 
trypsinized with 0.4 mL trypsin (3 min, 37 °C) and 2 mL of fresh complete medium was 
added. The cells were centrifuged (1200 rpm, 5 min, 4 °C), and the obtained pellet was 
redispersed in a volume of 0.5 mL of fresh complete media only, or containing the desired 
amount of MNCs or DOX-MNCs, and transferred into a vial for hyperthermia treatment. 
Again, six groups were formed as previously described in section 5.2.4.11.1. The 
concentration of MNCs in solution was adapted to obtain the desired temperature. A 
concentration of 75 µg/mL was used for the hyperthermia treatment at 40 °C, that was also 
calculated as the concentration of nanoparticle being internalized after exposure of U-87 
cells for 24 h with a solution of 1 mg/mL of MNCs. A concentration of 200 µg/mL and 300 
µg/mL were used for the hyperthermia treatment at 42 °C and 44 °C, respectively. The 
three AMF positive groups (control+, MNCs+ and DOX-MNCs+ groups) were exposed to 
an AMF (H = 10.5 kA/m and f = 950 kHz) for 1 h using the MACH instrument. The cells in 
the three AMF negative groups (control-, MNCs- and DOX-MNCs- groups) were subjected 
to the same protocol, without being subjected to an AMF, in order to remove any 
environmental effect on cell death. After hyperthermia treatment, the cell suspension was 
properly mixed and separated in two, so that it could be seeded in two different 12 well, 
flat-bottomed culture plates. The volume of the cell suspension was adjusted to 1 mL for 
each well and the cells were incubated at 37 °C. One plate was analyzed 24 h later while 
the other one was analyzed after 48 h. Cell viability was determined using trypan blue dye 
exclusion method as previously explained in section 5.2.4.11.1. All experiments were 
repeated at least three times. 
The combined effect of the thermo-chemotherapy treatment was evaluated by the 
Valeriote’s method as described in section 5.2.4.11.1.  
 
5.2.4.12 Statistical analysis 
Statistical analysis was performed using the Student’s t-test for unpaired data and the 
results are presented as mean ± standard deviations. Statistical significance was accepted 
at a level of p < 0.05. 
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5.3 Results and discussion 
5.3.1 Biocompatibility of the MNCs 
The first experiment to be performed in vitro, is to verify that the nanoparticles are 
biocompatible. Indeed, a good biocompatibility is fundamental for in vivo use and further 
clinical use. A good biocompatibility is achieved when a material interacts with the body 
and its biological environment without inducing intolerable degree of toxic, carcinogenic, 
immunogenic and thrombogenic responses. It is well-known that the biocompatibility of a 
material is affected by their physical and chemical properties, such as composition, shape, 
size, surface chemistry and charge, and stability.290,315 Therefore, surface engineering of 
nanoparticles to find an appropriate surface coating is required. The coating plays an 
important role in the biocompatibility as it determines the physicochemical properties of 
the surface, hydrophilicity/hydrophobicity degree, the surface charge and influence the 
colloidal stability.316  The surface coating of the MNCs is made of a hydrophilic polymer 
mainly composed of PEG chains. PEG is one of the most promising coating materials for 
biomedical applications due to its good biocompatibility, and its ability to provide a steric 
barrier to protein adsorption, resulting in reduced uptake by macrophages of the reticulo-
endothelial system, and therefore increases the blood circulation lifetime of the 
nanoparticle.317 PEG was also demonstrated to diminish cell adhesion, and materials 
coated with PEG do not show antigenic activity. PEG also suppresses platelet adhesion, 
reducing risk of thrombus formation and tissue damage.318  
 
As such, biocompatibility studies on a L929 mouse fibroblast cell line was performed by 
MTT assay to assess the biocompatibility of the MNCs with healthy cells after 48 h of 
exposure with various concentration of MNCs (Figure 5.1).  
 
 
Figure 5. 1 Biocompatibility study on L929 cells in the presence of MNCs for concentration 
ranging from 0.0 mg/mL to 1.0 mg/mL. 
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No apparent cytotoxicity of the MNCs towards healthy cells was observed for concentration 
up to 1.0 mg/mL, indicating a good biocompatibility of the nanosystem. 
 
5.3.2 Nanoparticle cellular uptake 
The cell plasma membrane is the interface regulating any exchange between the 
intracellular and extracellular environment. For example, cellular internalization of vital 
small molecules such as sugars, water or amino-acids occurs via membrane diffusion or 
through membrane channels.319 The internalization of larger entities such as nanoparticles 
occurs via endocytosis. During the endocytic process, membrane-bound vesicles called 
endosomes are formed. They engulf the nanoparticles and carry them into the cells. The 
main intracellular endocytic mechanisms are briefly described here, and more detailed 
information can be found elsewhere.319-321 Endocytosis takes place by multiple pathways 
and can be divided into two broad categories, phagocytosis (the uptake of large particles) 
and pinocytosis (the uptake of fluids and solutes).  
 
Phagocytosis is primarily used by specialized cells, such as macrophages and monocytes, 
whose role is to clear dead cells, cell debris and pathogens. Phagosomes formation starts 
with cup-shaped membrane protrusions, which gradually surround and enclose the 
particles (Figure 5.2). Different modes of phagocytosis can be observed dependent on the 
receptor that recognizes the particles to be ingested and the particle itself. The size of a 
phagosome depends on the size of the particle, and can range from hundreds of 
nanometers to dozens of micrometers.320 
 
Pinocytosis, unlike phagocytosis, exists in all type of cells. Pinocytosis can further be 
classified into at least four basic mechanisms: macropinocytosis, clathrin-mediated 
endocytosis, caveolae-mediated endocytosis, and clathrin- and caveolae-independent 
endocytosis. 
Macropinocytosis involves the formation of membrane ruffles that protrude to engulf a 
large amount of extracellular fluid and particles. The membrane ruffles then close by fusing 
with the plasma membrane, generating vacuoles called macropinosomes (Figure 5.2). The 
macropinosomes are the larger vesicles that can be formed during a pinocytosis process, 
with size ranging from 0.5 to 10 μm. 
Clathrin-mediated endocytosis (CME) is the common pathway of cellular entry in all 
mammalian cells. It carries out the constant supply in nutrients to the cells. CME is 
triggered by transmembrane receptor-ligand binding, which are then engulfed through the 
formation of coated pits, formed by the assembly of clathrin cytosolic proteins (Figure 5.2). 
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The pits self-assemble into polygonal cages, to form clathrin-coated vesicles of size 
around 120 nm. 
Caveolae-mediated endocytosis can particularly be found in endothelial cells. It is triggered 
by the binding of the cargo to caveolin membrane proteins. The cargo is engulfed in flask-
shaped caveolae of size ranging from 50 to 80 nm (Figure 5.2). 
Clathrin- and caveolae-independent endocytosis occurs in cells lacking clathrin and 
caveolin proteins. There are multiple entry pathways, which are likely to depend on many 
parameters, including the nature of the cargo molecule. However, mechanisms behind 
clathrin- and caveolae-independent endocytosis are still poorly understood. 
 
 
Figure 5. 2 Schematic representation of the different endocytic pathways.322 
 
The nature of a nanomaterial, including its structure and physicochemical properties 
(composition, size, morphology, surface charge and chemistry and degree of 
hydrophobicity/hydrophilicity), greatly influence the endocytic process by which it will be 
internalized in the cells.320,321,323-325 Usually, each type of particles exhibits a preferential 
uptake pathway. For example, in nonphagocytic cells, the internalization of charged iron 
oxide nanoparticles is favoured as compared to their uncharged counterparts, and the 
positively charged ones seem to be preferred over the negatively charged particles.323 
Positively charged particles appears to be mainly internalized through CME or 
macropinocytosis, while negatively charged particles were shown to be more likely 
internalized via caveolae-mediated endocytosis and clathrin- and caveolae-independent 
endocytosis.320,325 But exceptions exist, and some charged/uncharged particles can also 
be taken up through multiple endocytosis pathways. In term of size, it is commonly 
believed that particles need to have a diameter between 10 to 100 nm to enter cells. 
However, these small particles may be internalized faster but studies revealed that 
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particles up to 5 μm in size can enter cells through macropinocytosis.320 Nanoparticle 
suspensions often have a size distribution and not a specific size, mainly depending on 
the aggregation and polydispersity of the nanoparticles. Thus, a given type of nanoparticle 
can enter cells using different pathways depending on its size. In the case of non-specific 
adhesion to cells, small nanoparticles of diameters less than 10 nm are not internalized 
via endocytosis, but can enter cells through other routes such as diffusion through the 
membrane.321 In the case of specific interactions, small nanoparticles coat the plasma 
membrane before being taken up by cells, while bigger particles are internalized 
immediately.324 This may be due to the insufficient interaction with receptors of the cell 
membrane to trigger an endocytic response. The concentration of nanoparticles at which 
cells are exposed can also influence the uptake pathway. A study showed that at a low 
concentration, nanoparticles may have cross the membrane individually through diffusion 
process, while at higher concentrations, nanoparticles were taken up as clusters, enclosed 
inside vesicles, which is sign of an endocytic pathway.326 As a consequence, the uptake 
of nanoparticles may not be proportional to the concentration. In term of morphology, the 
highest uptake seems to be obtained for spherical-shaped nanoparticles as compared to 
nanoparticles of other shape. This behaviour has been observed for gold nanoparticles, 
where spherical nanoparticles enter cells more easily than rods.325 Molecular simulations 
predict that the fastest internalization rate is obtained for spherical nanoparticles, followed 
by cubic, rod and then disk nanoparticles.327 For rod-like particles, the aspect ratio plays 
an important role: a high aspect ratio leads to the particles being internalized with their 
long edge parallel to the membrane therefore requiring longer membrane wrapping time 
due to high wrapping fraction, while rods with low aspect ratio enter cells tip first.328 
 
Finally, the uptake of nanoparticle is also highly dependent on the cell or tissue type. 
Different internalization pathways for a same particle have already been observed between 
healthy and cancer cells. This may help to selectively target cancer cells. For example, a 
polymeric micelle was shown to selectively be cytotoxic to cancer cells. The micelles were 
not entering healthy endothelial cells even after 24 h, while they were reaching lysosomes 
in 30 min in cancer cells.329 As a consequence, it is critical to evaluate the suitability of a 
given nanomaterial on different cell types. 
 
5.3.2.1 Histology and visualization of MNCs internalization in 
cells 
The ability of a cell or tissue to uptake nanoparticles can vary between different cells or 
tissue types. Therefore, it was important to investigate the cellular uptake of the MNCs 
was on both MCF-7 and U-87 cell lines. Different concentration of MNCs ranging from 0.0 
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mg/mL to 1.0 mg/mL and different incubation time of the cells in contact with the MNCs 
(i.e. 4 h and 24 h) were studied. Iron oxide nanoparticles were stained with Prussian blue, 
and the cells counterstained with nuclear fast red before observing by light microscopy. 
No significant morphological changes were observed after incubation of the MNCs with 
both cancer cell lines, even with the highest concentration of MNCs and 24 h of incubation. 
The cellular uptake of the MNCs is clearly dependent on both the nanoparticle 
concentration and the exposure time for both cell lines (Figure 5.3 and Figure 5.4). The 
presence of Prussian blue staining inside the cells is due to the presence of iron oxide 
nanoparticles, therefore confirming the cellular internalization of the MNCs. A higher MNCs 
concentration as well as a longer incubation times lead to an increase in the cellular uptake 
as exhibited from the increase Prussian blue staining for the iron. However, because cell 
images obtained by light microscopy are only 2D images, nanoparticles internalized in the 
cells and nanoparticles only adsorbed on the cell membrane cannot be distinguished. U-
87 cells seem to take up more MNCs as compared to the MCF-7 cells as can be seen from 
the higher amount of Prussian blue staining for a same nanoparticle concentration and 
incubation time (Figure 5.3 and Figure 5.4). Only images acquired after incubation with 
media only (negative control), or with a solution containing 0.1 mg/mL, 0.5 mg/mL and 1.0 
mg/mL of MNCs are shown in Figure 5.3 and Figure 5.4. Smaller tested concentrations of 
0.01 mg/mL and 0.05 mg/mL are not presented as almost no particles can be observed in 
the cells. 
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Figure 5. 3 Microscope images of human glioblastoma U-87 cells and human breast 
adenocarcinoma MCF-7 cells loaded with MNCs after 4 h of incubation with a solution 
containing different concentration of MNCs, i.e. no particles, 0.1 mg/mL, 0.5 mg/mL and 1.0 
mg/mL. Cells were stained with Prussian blue and counterstained with nuclear fast red. Scale 
bar: 20 µm. 
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Figure 5. 4 Microscope images of human glioblastoma U-87 cells and human breast 
adenocarcinoma MCF-7 cells loaded with MNCs after 24 h of incubation with a solution 
containing different concentration of MNCs, i.e. no particles, 0.1 mg/mL, 0.5 mg/mL and 1.0 
mg/mL. Cells were stained with Prussian blue and counterstained with nuclear fast red. Scale 
bar: 20 µm. 
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5.3.2.2 Quantification of MNCs cellular uptake 
Cellular internalisation of the MNCs could be observed by flow cytometry in both U-87 and 
MCF-7 cell lines (Figure 5.5). An increase of the SSC when cells have been incubated with 
MNCs can be observed as compared to cells culture in media only. As the side scattered 
light increases with the degree of loading due to a change in cell granularity upon 
internalisation of nanoparticles, it can be concluded that both cell line internalized the 
MNCs in some extent. The increase in side scattered light compared to non-loaded cells 
seems to be greater in the case of U-87 cells, indicating that U-87 cells internalize more 
MNCs than MCF-7 cells. 
 
Figure 5. 5 Side scatter as a function of forward scatter flow cytometry dot plots of A) 
human glioma U-87 cells loaded with no particles, B) loaded with MNCs and of C) human 
breast cancer MCF-7 cells loaded with no particles and D) loaded with MNCs. Cell debris have 
been removed for simplification. 
 
Cell uptake was quantitatively determined by magnetic measurements using the SQUID 
magnetometer on cell samples loaded with MNCs. Table 5.1 summarizes the different 
results obtained for each tested conditions. The results confirm what was observed by cell 
staining and flow cytometry, cell uptake increased with the concentration of MNCs in 
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solutions and a clear variation of cell uptake with cell type is observed. U-87 cells uptake 
the MNCs in larger quantity with a maximum non-targeted cell uptake of 125 pg(Fe3O4)/cell 
as compared to only 13 pg(Fe3O4)/cell for MCF-7 cells in the same conditions. 
 
Table 5. 1  MNCs uptake expressed in pg(Fe3O4)/cell from magnetic measurements on 
MCF-7 and U-87 cells for incubation time of 4 h and 24 h with the MNCs and concentrations 
ranging from 0.01 mg/mL to 1.00 mg/mL in solution.  
Cell line Time (h) MNC concentration (mg/mL) 
  0.01 0.05 0.10 0.50 1.00 
MCF-7 
4 / / 1 3 6 
24 / / 2 5 13 
U-87 
4 / 2 7 15 32 
24 2 6 12 55 125 
 
 
5.3.3 Determination of the IC50 of free DOX and DOX-MNCs 
in MCF-7 and U-87 
The MTT metabolic activity assay was performed to examine and compare the cytotoxicity 
of free DOX and DOX-MNCs and determine the IC50 values of the drug on both cell lines. 
The concentration effect of DOX in both formulations as well as the exposure time on the 
cell viability were investigated. Incubation time points of 24 h, 48 h, and 72 h were chosen. 
For each condition, the IC50 values were calculated. IC50, the half maximal inhibitory 
concentration, is the concentration of drug at which only 50% of the cells remains viable. 
It is therefore in this case, an assessment of the effectiveness of the drug for those 
particular two cell lines. The IC50 values for each condition were determined by 
constructing a dose-response curve according to the results obtained from the MTT 
viability assays. The IC50 values are summarized in Table 5.2. For both the breast cancer 
cells and glioma cells, the cytotoxicity of free DOX was dependent on concentration and 
exposure time (Figure 5.6A and 5.6B). The IC50 values decrease as the exposure time 
increases. The IC50 values for U-87 cells exposed to free DOX are 0.13 µg/mL, 0.06 µg/mL 
and 0.04 µg/mL for an incubation period of 24 h, 48 h and 72 h, respectively. The IC50 
values for MCF-7 cells exposed to free DOX are 0.95 µg/mL, 0.29 µg/mL and 0.16 µg/mL 
for an incubation period of 24 h, 48 h, and 72 h, respectively. By comparing the IC50 values 
for U-87 cells and MCF-7 cells for a same incubation time, it is clear free DOX is more 
cytotoxic towards the glioma cell line than the breast cancer cell line.  
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Figure 5. 6  Dose response curves. Cell viability of U-87 cells incubated with DOX 
concentrations of either A) free DOX or C) DOX-MNCs and cell viability of MCF-7 cells 
incubated with DOX concentrations of either B) free DOX and D) DOX-MNCs for 
incubation period of 24 h, 48 h and 72 h. 
 
The IC50 values for U-87 cells exposed to DOX-MNCs are 0.90 µg/mL, 0.12 µg/mL and 
0.50 µg/mL for an incubation period of 24 h, 48 h and 72 h, respectively. The IC50 values 
for MCF-7 cells exposed to DOX-MNCs are >10 µg/mL, 7.91 µg/mL and >10 µg/mL for an 
incubation period of 24 h, 48 h, and 72 h, respectively. The IC50 values of DOX-MNCs are 
higher than those of free DOX for both cell lines, meaning that the DOX-MNCs are less 
cytotoxic towards cells than free DOX. This effect is particularly present in the MCF-7 cells, 
which can be explained by the fact that they internalised less MNCs than the U-87 cells 
(as demonstrated in section 5.3.2.1 and 5.3.2.2), and are therefore less exposed to the 
drug. The lower cytotoxicity of DOX-MNCs as compared to free DOX, mainly due to the 
drug being partially retained in the MNCs, is desired in order to reduce side effects on 
healthy cells. Another interesting point is that for both cell line, the IC50 of DOX-MNCs is 
higher after 72 h of incubation than after 48 h (Figure 5.6C and 5.6D). This might be as a 
result of the release regimes of the drug from the MNCs. Whether the MNCs are 
internalized in the cells or still in the media, it was shown in section 4.3.11 that the drug 
release reaches a plateau after 24 h. If no more drug is released from the DOX-MNCs, 
cells might be able to recover and grow faster, resulting in an increase in cell viability.  
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Table 5. 2  IC50 values of free DOX and DOX-MNCs for U-87 and MCF-7 cell lines after 
exposure time of 24 h, 48 h and 72 h. 
  IC50 (µg/mL) 
  24 h 48 h 72 h 
U-87 
Free DOX 0.13 0.06 0.04 
DOX-MNCs 0.90 0.12 0.50 
MCF-7 
Free DOX 0.95 0.29 0.16 
DOX-MNCs >10 7.91 >10 
 
 
5.3.4 The fate of DOX in cells 
The intracellular internalization of DOX plays an important role in its anticancer activity. As 
explained in section 4.3.10, DOX acts by binding to DNA and inhibiting the topoisomerase 
II enzyme,135,310 and therefore localizes into the cell nucleus. However, in nanoparticle-
based drug delivery systems, endocytosis is often the main cell penetration pathway, 
which is particularly interesting to overcome drug resistance in drug resistant cancer. 
Indeed, when a cancer developed drug resistance, efflux of the drug from the cancer cell 
cytoplasm is observed.330 Nanoparticle-based drug delivery systems can avoid the 
activation of the efflux pump in the cells due to internalization pathways and the triggering 
of processes which are different from those of free DOX,331 therefore circumventing the 
mechanisms of drug resistance. 
 
Free DOX and DOX-MNCs internalization in U-87 and MCF-7 cells was studied by 
fluorescence microscopy based on the intrinsic red fluorescence of DOX. The drug 
localization in the cells was efficiently monitored by incubating the cells either with free 
DOX or with the DOX-MNCs for different period of time. DRAQ5, a far-red fluorescing DNA 
dye, was employed as a nuclear stain for labelling of the cell nucleus. LysoTracker Green, 
a green fluorescent dye, was introduced to stain acidic compartments in cells (i.e. 
lysosomes). Unfortunately, the fluorescence of this dye was greatly hindered after fixing 
the cells with paraformaldehyde buffer, and substantial spillover of DOX fluorescence in 
the green filter made the use of LysoTracker Green not appropriate. Free DOX solution 
and DOX-MNCs were added to the cells with an equivalent amount of DOX (4 μg and 2 
μg), and fluorescence images were acquired 3 h or 24 h later. As expected DOX 
fluorescence was more visible when using 4 μg than 2 μg, but the obtained results were 
the same. Consequently, only images acquired using a DOX amount of 4 μg under the 
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form of free DOX or DOX-MNCs are presented in Figure 5.7, Figure 5.8, Figure 5.9 and 
Figure 5.10. 
 
 
Figure 5. 7 Fluorescence images of MCF-7 cells after 3 h of incubation with either free 
DOX (left) or DOX-MNCs (right). Cells were counterstained with DRAQ5. Scale bar: 20 µm. 
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Figure 5. 8 Fluorescence images of MCF-7 cells after 24 h of incubation with either free 
DOX (left) or DOX-MNCs (right). Cells were counterstained with DRAQ5. Scale bar: 20 µm. 
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Figure 5. 9 Fluorescence images of U-87 cells after 3 h of incubation with either free DOX 
(left) or DOX-MNCs (right). Cells were counterstained with DRAQ5. Scale bar: 20 µm. 
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Figure 5. 10 Fluorescence images of U-87 cells after 24 h of incubation with either free 
DOX (left) or DOX-MNCs (right). Cells were counterstained with DRAQ5. Scale bar: 20 µm. 
 
In both MCF-7 and U-87 cells, the fluorescence signal of DOX for both free DOX and DOX-
MNCs is more visible 24 h than 3 h later, that is because more DOX has penetrated into 
the cells after 24 h of incubation. The fluorescence signal of DOX for DOX-MNCs is 
stronger in U-87 cells than in MCF-7 cells, which confirm again that U-87 cells internalize 
the MNCs in a larger quantity as compared to MCF-7 cells. The fluorescence signal of 
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DOX for free DOX was also found stronger in U-87 cells than in MCF-7 cells, which might 
explain why the IC50 values of free DOX against U-87 cells is much lower than for MCF-7 
cells.  
 
Unlike with confocal microscopy, it cannot be concluded for certain whether DOX is 
localised inside the cells or only on their surfaces because the images obtained by 
fluorescence microscopy are 2D images. Therefore, the following hypotheses are only true 
if DOX is indeed localised inside the cells. 
 
Drug intracellular distribution of DOX-MNCs is quite different from that of free DOX. After 
3 h of incubation with free DOX solution, the strong co-localisation of DOX and DRAQ5 
fluorescence indicates that free DOX only localised in the cell nuclei in both MCF-7 (Figure 
5.6) and U-87 cells (Figure 5.9), suggesting that free DOX permeates cellular and nuclear 
membrane by passive diffusion and rapidly accumulate in the cell nuclei and intercalate to 
the chromosomal DNA. This phenomenon is well-known and has been previously reported 
many times.177,190,332,333 In contrast, DOX-MNCs were expected to be taken up by 
malignant cells through endocytosis, followed by some extent of drug release in the 
cytoplasm due to acidic pH of endosomes/lysosomes organelles and subsequent DOX 
diffusion to the nucleus. The endocytic pathway and mechanism of drug release result in 
a much slower process than passive drug diffusion and consequent slower delivery of DOX 
to the cell nuclei and was reported elsewhere many times.177,190,334 This hypothesis seem 
to be confirmed by the fluorescence images revealing that DOX-MNCs were initially 
trapped in endosomal compartments after cellular uptake. Indeed, DOX molecules 
delivered by the MNCs are predominantly distributed in the cytoplasm after 3 h of 
incubation for both MCF-7 (Figure 5.6) and U-87 cells (Figure 5.9). After 24 h of incubation, 
in the case of MCF-7 cells, fluorescence attributed to DOX is still dominantly seen in the 
cytoplasm (Figure 5.8), while for U-87 cells, DOX molecules are located in the cytoplasm 
but have also diffused in the nuclei (Figure 5.10). These data not only demonstrated that 
the internalisation pathway of DOX-MNCs differs from that of free DOX, but also that MNCs 
are efficient vectors to carry the DOX molecules into the cytoplasm and later in the nuclei. 
These data also explain why the conjugation of DOX molecules to the MNCs results in 
lower in vitro anticancer activity than that of free DOX. Indeed, it was shown in section 
5.3.3 that the IC50 values of DOX-MNCs were much higher than the IC50 values of free 
DOX for both U-87 and MCF-7 cells. In culture conditions, DOX conjugation to the MNCs 
is less cytotoxic than free DOX due to longer time required for drug nuclear transportation. 
The slow release of DOX from the MNCs can be realised in a controlled manner from 
inside endosomes and lysosomes, to potentially increase the cytotoxicity of drugs with 
long-term effect, which is more desirable for chemotherapy than the use of drug with acute 
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cytotoxicity. Such a delivery system also reduces the amount of available free drug 
molecules present in the extracellular environment therefore reducing unwanted side 
effects, which is one of the major drawbacks of chemotherapies nowadays. Finally, the 
MNCs have also the potential to bypass multidrug resistance mechanisms because they 
enter the cells through endocytosis and avoid p-glycoprotein pumps responsible for fast 
drug efflux.335-337  
 
5.3.5 In vitro anticancer studies by trypan blue dye 
exclusion assay 
5.3.5.1 Preliminary experiments 
In this chapter, cell viability has been investigated by trypan blue dye exclusion assay. Two 
methods of treatment were employed: the direct treatment and treatment after 
internalization methods as explained in section 5.2.4.11. Preliminary experiments of 
hyperthermia, chemotherapy and the combined thermo-chemotherapy after internalization 
were realized on U-87 cells and MCF-7 cells with a concentration of MNCs or DOX-MNCs 
of 1 mg/mL. This MNCs concentration, previously shown to be not cytotoxic to cells, was 
chosen so that enough nanoparticles could be internalized in the U-87 and MCF-7 cells 
after an incubation period of 24 h to have a cytotoxic effect under application of an AMF. 
 
The typical heating curves obtained by recording the temperature during the in vitro 
hyperthermia treatment of U-87 and MCF-7 cells after nanoparticle internalisation are 
shown in Figure 5.11. 
 
 
Figure 5. 11 Local environment temperature of A) U-87 cells and B) MCF-7 cells 
suspensions dispersed in DMEM supplemented with 10% FBS after internalisation of MNCs 
or DOX-MNCs and subjected to an AMF (f = 950 kHz and H = 10.5 kA/m). Control cells were 
not treated with nanoparticles. 
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The oscillations of the temperature observed in every curve is due to the water running 
through the inductor coil used to maintain the temperature to 37 °C. The chiller temperature 
was set to 37 °C so that the coil was maintained at physiological temperature and so was 
the cell sample. 
 
The control experiments for both MCF-7 and U-87 cells show that under application of an 
AMF of f = 950 kHz and H = 10.5 kA/m, the local temperature of the suspensions do not 
exceed 37.6 °C. The local temperature of U-87 cell suspensions for cell samples that have 
been treated with either MNCs or DOX-MNCs stabilizes around 39.2 °C with a maximum 
at 39.5 °C. In the case of MCF-7 cells, only a slight increase of the temperature as 
compared to the control can be observed. The temperature stabilizes around 37.7 °C with 
a maximum of 38 °C. These types of heating curves were expected as it was shown 
previously in section 5.3.2 that, unlike U-87 cells, MCF-7 cells do not internalise the MNCs 
in a high amount. 
 
The resulting cell viabilities 24 h and 48 h after treatment for both MCF-7 and U-87 cells 
are presented in Figure 5.12. 
 
  
Figure 5. 12 Treatment after internalisation method, cell viabilities of A) U-87 cells 24 h, B) 
U-87 cells 48 h, C) MCF-7 cells 24 h and D) MCF-7 cells 48 h following treatment with or 
without a 1 h exposure to an AMF (f = 950 kHz and H = 10.5 kA/m) after nanoparticle 
internalisation with media alone (control cells), MNCs or DOX-MNCs. The asterisks refer to 
significant levels compared to the corresponding control experiment or the combined therapy; 
p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). 
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For both cell lines, the effect of the MNCs only and the magnetic field alone have no 
detrimental effect on the cell viability. Control experiments of free DOX in presence of an 
AMF to assess the effect of the magnetic field on free DOX cytotoxicity were not carried 
out. It has been shown in many studies that free DOX treatment with or without application 
of a magnetic field does not result in significant changes in viability.168,178,190,338,339 Another 
study showed that pre-exposure of cells to a static magnetic field does not sensitize the 
cells to free doxorubicin treatment either.340  
 
For both cell lines, the combinatorial treatment (DOX-MNCs, AMF) is the most effective 
treatment. In the case of MCF-7 cells, the relative cell viabilities 24 h after treatment were 
83% for hyperthermia, 48% for chemotherapy and 35 % for thermo-chemotherapy; 48 h 
after treatment, cell death increases, with the relative cell viabilities being 76% for 
hyperthermia, 30 % for chemotherapy, and 11 % for thermo-chemotherapy.  
 
In the case of U-87 cells, the relative cell viabilities 24 h after treatment were 74 % for 
hyperthermia, 21 % for chemotherapy and 12 % for thermo-chemotherapy. 48 h after 
treatment, the relative cell viabilities are 80 % for hyperthermia, 12 % for chemotherapy 
and 4 % for thermo-chemotherapy. U-87 cells seem to start recovering from the 
hyperthermia treatment as an increase of the cell viability is observed after 48 h. 
 
Interestingly, even though it was demonstrated that U-87 cells internalize a higher quantity 
of MNCs as compared to MCF-7 cells, hyperthermia treatment results in about the same 
percentage of cell death for both cell lines, indicating that MCF-7 cells are more sensitive 
to the effect of heat released from internalised nanoparticles than U-87 cells. 
 
For both cell lines, the cytotoxic effect of the combinatorial treatment achieved with the 
developed delivery system after cellular uptake of the nanoparticles is superior to each of 
the two treatments applied separately, and an evaluation using Valeriote’s formula showed 
that the combined effects were synergistic in nature (Table 5.3). 
 
Table 5. 3 Evaluation of the combined effect of the thermo-chemotherapy treatment after 
nanoparticles internalisation for both MCF-7 and U-87 cell lines according to Valeriote’s 
formula. 
  (A)*(B)/100 (%) (A+B) (%) Effect 
MCF-7 
24 h 40 35 synergistic 
48 h 23 11 synergistic 
U-87 
24 h 16 12 synergistic 
48 h 10 4 synergistic 
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5.3.5.2 Combined effect of DOX and magnetic hyperthermia on 
U-87 cells 
5.3.5.2.1 Initial considerations 
Numerous studies have already demonstrated that the combination of hyperthermia with 
a number of conventional anticancer agents results in additive or synergistic effects.298 
Therefore, the aim of this work was not to kill the tumour cells with high concentrations of 
chemotherapeutic drug or high temperature, but rather to show an efficacy of the combined 
thermo-chemotherapy achieved at lower therapeutic doses of chemotherapeutic drug and 
MNCs. For that purpose, experiments with a lower DOX concentration were performed by 
mixing the MNCs with DOX-MNCs to obtain the desired nanoparticle concentration and 
the desired DOX concentration. Indeed, in the preliminary experiments presented in the 
above section and especially in the case of the U-87 cells, while the nanoparticle 
concentration is appropriate, the DOX concentration is too high and the chemotherapy 
treatment alone results in almost complete cell death. Using the IC50 values of DOX-MNCs 
for U-87 cells obtained from the dose-response curves determined by MTT assay in 
section 5.3.3, a DOX concentration of 0.15 µg/mL was chosen for the current study.  
 
Another aim of this study was to compare the direct treatment method with the treatment 
after internalisation method for the cell lines used in this work, as both methods are widely 
found in the literature.341,342 Comparing both methods allows to answer whether a heat 
treatment is more effective in the case of heat being released from the inside of the tumour 
cells, or in the case of the surrounding medium being heated, and in which case the 
combinatorial treatment is the most effective. To be able to compare both treatment 
methods, the concentration of nanoparticles used during the hyperthermia treatment must 
be the same. In order to determine what is the amount of nanoparticle being internalised 
by the cells after 24 h, the number of cells at the time of the hyperthermia treatment, i.e. 
48 h after seeding the cells, must be known. Under optimal conditions, a cell population in 
a culture will increase exponentially. Exponential growth of a cell population N at the 
growth rate r, as time t goes on in discrete intervals can be expressed by equation 5.2: 
 
 𝑁(𝑡) = 𝑁0(1 + 𝑟)
𝑡 (5.2) 
 
Where N0 is the number of cells at time 0. The growth rate could be easily determined from 
counting cells from one cell passaging to the next one. Therefore, the cell number at the 
time of the hyperthermia treatment could be calculated and was found to be equal to 
600,000 cells. Previously cellular uptake of the MNCs using a SQUID magnetometer was 
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quantified in section 5.3.2.2. Under the same conditions, it was shown that an average of 
125 pg(Fe3O4)/cell was internalised. Thus, it can be concluded that a total of 75 µg of 
MNCs is internalised in the cells. 
 
In order to be able to compare the direct treatment method with the treatment after 
internalisation method, a total of 75 µg of MNCs was chosen for the direct treatment. Other 
experiments with 200 µg and 300 µg of MNCs were also realized to assess the effect of 
the temperature on the effectiveness of the thermo-chemotherapy treatment. 
 
5.3.5.2.2 Treatment after internalisation U-87 cells 
Experiments of hyperthermia, chemotherapy and the combined thermo-chemotherapy 
after internalization were repeated on U-87 cells with a concentration of nanoparticles of 1 
mg/mL. However, this time the concentration in DOX was kept low, i.e. 0.15 µg/mL, by 
mixing MNCs and DOX-MNCs (ratio 454:1 w/w) to obtained the desired final concentration 
in DOX and in nanoparticles. The obtained cell viabilities 24 h and 48 h after treatment are 
presented in Figure 5.13.  
 
 
Figure 5. 13 Treatment after internalisation method, cell viabilities of U-87 cells after A) 24 
h and B) 48 h incubation following treatment with or without a 1 h exposure to an AMF (f = 950 
kHz and H = 10.5 kA/m) after nanoparticle internalisation with media alone (control cells), 
MNCs or DOX-MNCs containing 0.15 µg of DOX. The asterisks refer to significant levels 
compared to the corresponding control experiment or the combined therapy; p < 0.05 (*), p < 
0.01 (**) and p < 0.001 (***). 
 
The relative cell viabilities 24 h after treatment were 72% (p < 0.05) for hyperthermia, 52% 
(p < 0.01) for chemotherapy and 17% (p < 0.001) for thermo-chemotherapy; 48 h after 
treatment, the relative cell viabilities were 79% (p < 0.05) for hyperthermia, 34% (p < 0.001) 
for chemotherapy and 2% (p < 0.001) for thermo-chemotherapy. As already observed in 
the preliminary experiments, U-87 cells start recovering from magnetic hyperthermia 24 h 
after the treatment as an increase of the cell viability is observed after 48 h. 
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Again, the cytotoxic effect of the combinatorial treatment achieved with the developed 
delivery system after cellular uptake of the nanoparticles was found superior to either 
hyperthermia (p < 0.001 after 24 h and 48 h) or chemotherapy (p < 0.01 after 24 h, and p 
< 0.001 after 48 h) applied separately. An evaluation using Valeriote’s formula showed that 
the combined effects were synergistic in nature (Table 5.4). 
 
Table 5. 4 Evaluation of the combined effects of the thermo-chemotherapy treatment after 
nanoparticle internalisation with 0.15 µg of DOX for U-87 cells according to Valeriote’s formula. 
  (A)*(B)/100 (%) (A+B) (%) Effect 
U-87 
24 h 37 17 Synergistic 
48 h 27 2 Synergistic 
 
 
Several factors play a role in the synergism of the combined therapy. Here, the delivery 
system employed is both pH- and thermo-sensitive. We have shown previously that the 
DOX-MNCs are internalized through endocytosis. The main components of the endocytic 
pathway are lysosomes, early and late endosomes. Many research groups have reported 
that these intracellular organelles have an acidic pH, ranging from pH 4 to pH 6.343,344 This 
acidic pH combined with the local heat generation promoted the release of DOX. 
Moreover, mild hyperthermia was shown to inhibit the DNA repair of lethal and sublethal 
damages induced by the anticancer agent and to accelerate the cytotoxic reaction rate of 
the drug resulting in an increased anti-tumour activity of the chemotherapy.133 
 
5.3.5.2.3 Direct treatment U-87 cells 
Experiments of hyperthermia, chemotherapy and the combined thermo-chemotherapy 
using the direct treatment method were realized on U-87 cells at different hyperthermia 
temperature obtained by varying the total nanoparticle concentration in solution. However, 
the concentration of DOX was kept constant for each experiment, i.e. 0.15 µg/mL, by 
mixing MNCs and DOX-MNCs (ratio 33:1 w/w, 90:1 w/w and 135:1 w/w for a total amount 
of nanoparticles of 75 µg, 200 µg and 300 µg, respectively) to obtain the desired final 
concentration of DOX and of nanoparticle.  
 
The typical heating curves obtained by recording the temperature during the in vitro direct 
hyperthermia treatment of U-87 cells are shown in Figure 5.14. 
 
The obtained cell viabilities 24 h and 48 h after treatment are presented in Figure 5.15. 
Control experiment of the effect of application of the AMF on the viability of U-87 cells were 
not repeated as it was already shown it had no harmful effect. 
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Figure 5. 14 Local environment temperature of U-87 cells suspensions dispersed in DMEM 
supplemented with 10% FBS containing 75 µg, 200 µg or 300 µg of MNCs and subjected to 
an AMF (f = 950 kHz and H = 10.5 kA/m). 
 
 
Figure 5. 15 Direct treatment method, cell viabilities of U-87 cells A) 24 h and B) 48 h 
following direct treatment with or without a 1 h exposure to an AMF (f = 950 kHz and H = 10.5 
kA/m) with media alone (control cells), MNCs or DOX-MNCs containing 0.15 µg of DOX. The 
asterisks refer to significant levels compared to the corresponding control experiment or the 
combined therapy; p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). 
 
The relative cell viabilities 24 h after treatment were 70% (p < 0.05) for chemotherapy, 
84 % for hyperthermia and 42% (p < 0.001) for thermo-chemotherapy at 40 °C; 60% (p < 
0.01) for hyperthermia and 40% (p < 0.001) for thermo-chemotherapy at 42 °C; 38% for 
hyperthermia (p < 0.001) and 30% (p < 0.001) for thermo-chemotherapy at 44 °C. 48 h 
after treatment, the relative cell viabilities were 45% (p < 0.01) for chemotherapy, 78% (p 
< 0.05) for hyperthermia and 25% (p < 0.001) for thermo-chemotherapy at 40 °C; 50% (p 
< 0.01) for hyperthermia and 21% (p < 0.001) for thermo-chemotherapy at 42 °C; 26% for 
hyperthermia (p < 0.001) and 15% (p < 0.001) for thermo-chemotherapy at 44 °C. 
 
For each hyperthermia temperature, the cytotoxic effect of the combinatorial treatment 
achieved with the developed delivery system with the direct treatment method was also 
found to be superior to each of the two treatments applied separately. For each 
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hyperthermia temperature, the difference in cell death between hyperthermia and thermo-
chemotherapy is higher 48 h after the treatment than 24 h after and translates into a 
decrease of p, while the difference in cell death between chemotherapy and thermo-
chemotherapy is smaller 48 h after the treatment than 24 h after and translates into an 
increase of p. It is at mild hyperthermia temperature (40 °C) that the thermo-
chemosensitisation effect is the biggest. The difference in cell death between hyperthermia 
alone and the thermo-chemotherapy treatment decreases with increasing magnetic 
hyperthermia temperature. An evaluation of the combined effects using Valeriote’s formula 
reflects this trend, as with increasing hyperthermia temperature (A)*(B)/100 decreases and 
becomes inferior to (A+B) at 44 °C (Table 5.5). As a consequence, the combined effects 
were found to be synergistic in nature at 40 °C and 42 °C, and sub-additive at 44 °C. 
 
 
Table 5. 5 Evaluation of the combined effects of the direct thermo-chemotherapy 
treatment with 0.15 µg of DOX at different hyperthermia temperatures for U-87 cell line 
according to Valeriote’s formula. 
   
(A)*(B)/100 
(%) 
(A+B) (%) Effect 
U-87 
40 °C 
24 h 59 42 synergistic 
48 h 35 25 synergistic 
42 °C 
24 h 42 40 synergistic 
48 h 23 21 synergistic 
44 °C 
24 h 27 32 sub-additive 
48 h 12 15 sub-addtive 
 
 
The delivery nanosystem used in this experiment is both pH- and thermo-sensitive. The 
direct treatment method does not allow any time for the nanoparticles to be taken up by 
the cells, as such the nanocarrier is not in contact with an acidic environment and therefore 
only the temperature promotes the release of the DOX. However, mild hyperthermia has 
been shown to increase cell membrane permeability, thus promoting nanoparticles and 
drugs accumulation into tumour cells.129 Remarkably, Peller et al. showed that after 
intravenous application of DOX-loaded thermo-sensitive liposome, heating of the tumour 
above 40 °C for 1 h using laser light resulted in highly selective DOX uptake.345 The DOX-
concentration in the heated tumour tissue compared to the non-heated tumour showed an 
almost 10-fold increase. 
 
Mild hyperthermia also inhibits DNA repair of lethal and sublethal damages induced by the 
anticancer agent and accelerates the cytotoxic reaction rate of the drug resulting in an 
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increased anti-tumour activity of the chemotherapy.133 This direct treatment experiment 
proves that an appropriate thermal dose is critical for the synergy of the combined therapy.  
 
5.3.5.2.4 Comparison of the direct treatment and treatment after internalisation 
methods 
In the case of a cell line that internalised the desired nanoparticles in a high amount, such 
as the U-87 cells with the MNCs, the treatment after internalisation results in higher cell 
death than the direct treatment method. Indeed, the cell viabilities for the combined therapy 
after nanoparticle internalisation were 17% and 2%, 24 h and 48 h after the treatment, 
respectively. It was calculated that the total amount of nanoparticle internalised in the cells 
was equal to 75 µg. This amount of MNCs was used for the direct treatment in order to be 
able to compare the two treatments. The cell viabilities for the direct combined therapy at 
40 °C are 40% and 25%, 24 h and 48 h after the treatment, respectively. 
The mechanisms responsible for the synergy of the combined therapy are not yet fully 
understood, but generally involve: 
• Improve intracellular uptake of nanoparticles or drug molecules due to increase cell 
membrane permeability 
• Inhibition of DNA repair of the chemically induced lethal or sub-lethal damages 
• Acceleration of the cytotoxic chemical reaction 
Both methods show a synergistic effect of the combined therapy, which suggest that the 
best method could actually be a mix of the two methods tested in this chapter, i.e. some 
nanoparticles internalised in the cells and some in the surrounding environment. Indeed, 
the different mechanisms behind the synergistic effects of the combined therapy may be 
more or less triggered and thus play a more or less important role depending on the 
treatment method used. 
 
Finally, because the MNCs are pH- and thermo-sensitive, a maximized drug release will 
be obtained with both stimuli at the same time, and therefore a better synergism of the 
combined therapy. To that aim, the MNCs need to be internalised in cell acidic 
compartments. However, from an in vivo point of view, tumour extracellular environment 
is often more acidic than normal tissue, with a pH ranging from 5.7 to 7.8,344 that would 
facilitate the release of the drug from MNCs that have not been yet internalised, and 
subsequent quick accumulation in the cell nuclei of released DOX molecules through 
cellular membrane diffusion. 
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5.3.5.3 Combined effect of DOX and magnetic hyperthermia on 
MCF-7 cells 
5.3.5.3.1 Initial considerations 
The same initial considerations as for U-87 cells were made for MCF-7 cells. Experiments 
with a lower DOX concentration were performed by mixing the MNCs with DOX-MNCs to 
obtain the desired nanoparticle concentration and the desired DOX concentration. Using 
the IC50 values of DOX-MNCs for MCF-7 cells obtained from the dose-response curves 
determined by MTT assay in section 5.3.3, a DOX concentration of 5.25 µg/mL was chosen 
for the current study.  
 
Because one of the aims of this study was to compare the direct treatment method with 
the treatment after internalisation method for the two cell lines used in this work, both 
experiments should have been performed on the MCF-7 cells. However, MCF-7 cells were 
shown to not internalise the MNCs to a great extent. Instead, we chose to realise the direct 
treatment with the same concentration of nanoparticles used for U-87 cells so that the 
effects of hyperthermia on both cell lines using the direct treatment method could be 
compared. 
 
The treatment after internalisation was planned to be repeated with the lower concentration 
of DOX, unfortunately contamination of cells happened two weeks before the end date of 
my PhD. Because I had to go to Bordeaux for a short term scientific mission funded by EU 
COST TD1402 Action it was impossible to perform this experiment. However, the 
preliminary experiments performed on both U-87 and MCF-7 cell lines showed that the 
treatment after internalisation method is more efficient for U-87 cells (section 5.3.5.2.1). 
This was expected due to the low internalisation of MNCs by MCF-7 cells. This preliminary 
experiment also indicates that MCF-7 cells are more sensitive to the effect of heat released 
from internalised nanoparticles than U-87 cells, as cell death occurs in the same extent for 
both cell lines. 
 
Consequently, only the results issued from the direct treatment experiments on MCF-7 
cells are presented in this section. The same hyperthermia temperatures were tested using 
75 µg, 200 µg and 300 µg of MNCs to assess the effect of the temperature on the 
effectiveness of the thermo-chemotherapy treatment for the MCF-7 cell line. The 
concentration of DOX was kept constant for each experiment, i.e. 5.25 µg/mL, by mixing 
MNCs and DOX-MNCs (ratio 0:1 w/w, 1.7:1 w/w and 3:1 w/w for a total amount of 
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nanoparticles of 75 µg, 200 µg and 300 µg, respectively) to obtain the desired final 
concentration of DOX and of nanoparticle.  
 
5.3.5.3.2 Direct treatment MCF-7 cells 
The obtained cell viabilities 24 h and 48 h after treatment are presented in Figure 5.16. 
 
  
Figure 5. 16 Direct treatment method, cell viabilities of MCF-7 cells A) 24 h and B) 48 h 
following direct treatment with or without a 1 h exposure to an AMF (f = 950 kHz and H = 10.5 
kA/m) with media alone (control cells), MNCs or DOX-MNCs containing 5.25 µg of DOX. The 
asterisks refer to significant levels compared to the corresponding control experiment or the 
combined therapy; p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). 
 
Control experiments of the effect of application of the AMF on the viability of MCF-7 cells 
were not repeated as it was already shown it had no detrimental effect. 
 
The relative cell viabilities 24 h after treatment were 70% (p < 0.05) for chemotherapy, 
78% (p < 0.05) for hyperthermia and 53% (p < 0.01) for thermo-chemotherapy at 40 °C; 
65% (p < 0.01) for hyperthermia and 47% (p < 0.01) for thermo-chemotherapy at 42 °C; 
38% for hyperthermia (p < 0.001) and 14% (p < 0.001) for thermo-chemotherapy at 44 °C. 
48 h after treatment, the relative cell viabilities were 45% (p < 0.01) for chemotherapy, 72% 
(p < 0.05) for hyperthermia and 28% (p < 0.001) for thermo-chemotherapy at 40 °C; 56% 
(p < 0.01) for hyperthermia and 30% (p < 0.001) for thermo-chemotherapy at 42 °C; 24% 
for hyperthermia (p < 0.001) and 6% (p < 0.001) for thermo-chemotherapy at 44 °C. 
 
For each hyperthermia temperature, the cytotoxic effect of the combinatorial treatment 
achieved with the developed delivery system with the direct treatment method was found 
superior to each of the two treatments applied separately. For each hyperthermia 
temperature, the difference in cell death between hyperthermia and thermo-chemotherapy 
is higher 48 h after the treatment than 24 h after and translates into a decrease of p, while 
the difference in cell death between chemotherapy and thermo-chemotherapy is smaller 
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48 h after the treatment than 24 h after and translates into an increase of p. It is at mild 
hyperthermia temperature (40 °C) that the thermo-chemosensitisation effect is the biggest, 
followed by hyperthermia temperature at 44 °C. An evaluation of the combined effects 
using Valeriote’s formula reflects this trend, as with increasing hyperthermia temperature 
(A)*(B)/100 decreases and becomes inferior to (A+B) at 42 °C and then becomes superior 
to (A+B) again at 44 °C (Table 5.6). As a consequence, the combined effects were found 
to be synergistic in nature at 40 °C and 44 °C, and sub-additive at 42 °C. 
 
Table 5. 6 Evaluation of the combined effects of the direct thermo-chemotherapy treatment 
with 5.25 µg of DOX at different hyperthermia temperatures for MCF-7 cells according to 
Valeriote’s formula. 
   
(A)*(B)/100 
(%) 
(A+B) (%) Effect 
MCF-7 
40 °C 
24 h 55 53 synergistic 
48 h 32 28 synergistic 
42 °C 
24 h 46 47 sub-additive 
48 h 25 30 sub-additive 
44 °C 
24 h 27 14 synergistic 
48 h 11 6 synergistic 
 
 
The direct treatment method is quite effective on MCF-7 cells. The MCF-7 cells were 
shown to internalize the MNCs only in small quantity. This experiment shows that the 
combined therapy can be used using the direct treatment method and is effective on cells 
that do not internalize nanoparticles. 
 
5.3.5.4 Comparison of the effects of the direct treatment on 
MCF-7 and U-87 cell lines 
The direct treatment method was shown to be quite effective on both U-87 and MCF-7 cell 
lines for the thermo-chemotherapy treatment. Mild hyperthermia at 40 °C resulted in 
synergistic effects of the combined therapy for both U-87 and MCF-7 cell lines. 
Hyperthermia at 42 °C resulted in synergistic effects of the combined therapy for U-87 cell 
line, while for MCF-7 cell line, only and sub-additive effects were observed. Hyperthermia 
at 44 °C resulted in sub-additive effects of the combined therapy for U-87 cell line, while 
for MCF-7 cell line, synergistic effects were obtained again. These results indicate that the 
hyperthermia and DOX chemotherapy can have both synergistic and sub-additive effects 
on a same cell line depending on the applied hyperthermia temperature, and therefore an 
appropriate thermal dose is critical for the synergy of the combined therapy. Similar results 
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were reported in vivo, where the amount of intracellular DOX taken up by the tumour with 
40 °C hyperthermia was increased by 80% relative to that at body temperature, but this 
effect was not observed at 43 °C hyperthermia.346  
 
These experiments also emphasize the importance of studying a particular cell line for a 
particular purpose. Indeed, tumours cells from different cell lines might behave differently. 
In this case the thermo-chemosensitisation effect was the highest at 40 °C, 48 h after the 
treatment for both cell lines, however the effects of the combined therapy at 42 °C and 
44 °C on MCF-7 cells are different from those obtained on U-87 cells. Depending on the 
cell line, the mechanisms responsible for the synergistic effect of the combined therapy 
might be more or less triggered at different applied hyperthermia temperature. 
 
 
 
5.4 Conclusion 
In summary, the MNCs were found to be biocompatible for concentrations up to 1 mg/mL. 
The quantification of MNCs cellular uptake with different cancer cell lines revealed 
significant variation of non-targeted cell loading. This affected the cytotoxicity of DOX-
MNCs on those cell lines, as shown by the IC50 values for the DOX-MNCs. Unlike free 
DOX, the DOX-MNCs are taken up through endocytosis that results in slow DOX delivery 
to the nuclei. The main components of endocytic pathway have an acidic pH that facilitates 
the release of the DOX from the nanoparticles. The thermo-chemotherapy experiments 
performed with the developed delivery system showed that the combinatorial treatment 
was more effective than both chemotherapy or magnetic hyperthermia individual 
treatments applied separately. Two different methods of treatment were studied. The direct 
treatment method involves subjecting the cells to the hyperthermia treatment immediately 
after putting them in contact with the nanoparticles. There is no nanoparticle internalized 
by the cells and thus only the temperature of the surrounding medium is involved in the 
magnetic hyperthermia treatment. The treatment after internalisation consists in incubating 
the cells with the nanoparticles for 24 h and subsequent washing of the cells before 
subjecting the cells to an AMF. Only nanoparticles taken up by cells were involved in the 
hyperthermia treatment and this experiment revealed that the MNCs retain the capability 
to perform as heat vectors upon internalisation by the cells. 
 
Cell death was found to be dependent on the method of treatment used. For a cell line that 
internalized the MNCs in a great extent such as the U-87 cell line, the thermo-
chemotherapy applied through the treatment after internalisation was found to be more 
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effective, the combined effects were found to be synergistic in nature and an almost 
complete cell death was achieved. However, positive results were also obtained for the 
direct treatment method for both U-87 and MCF-7 cells. These findings demonstrate that 
it is not necessary for tumour cells to internalize the nanoparticles for an efficient therapy, 
but is preferable. The study of the direct thermo-chemotherapy treatment at different 
hyperthermia temperature revealed the importance of the applied thermal dose. Indeed, 
both synergistic and sub-additive effects of the combined therapy were observed for a 
same cell line depending on the applied hyperthermia temperature. However, synergistic 
and sub-additive effects were found at different hyperthermia temperature depending on 
the cell line and thus emphasize the necessity to study each cell line independently for a 
particular treatment. The mechanisms responsible for the synergistic effect of the 
combined therapy might be more or less triggered depending on both the applied 
hyperthermia temperature and the cell line. 
 
Interestingly, the thermo-chemosensitisation effect was the highest at mild hyperthermia 
temperature of 40 °C for both cell lines. This result is of particular importance: if only a low 
hyperthermia temperature is necessary for the treatment, the quantity of nanoparticles 
necessary for the treatment can also remain low. The thermo-chemotherapy treatment 
allows for the reduction of both the chemotherapeutic dose and amount of nanoparticles 
needed which is a significant advantage for clinical use, in order to reduce toxicity and 
systemic effects to healthy tissues. 
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CHAPTER 6 
CELLULAR STUDIES ON CHEMOTHERAPY, 
MAGNETIC HYPERTHERMIA AND COMBINED 
THERMO-CHEMOTHERAPY FOR THERAPEUTIC 
APPLICATIONS USING THE BIOLUMINESCENCE 
IMAGING METHOD 
 
 
 
 
 
This work was performed during a short term scientific mission at the IMOTION laboratory 
(Imagerie Moléculaire et Thérapies Innovantes en Oncologie - Molecular Imaging and 
Innovative Therapies in Oncology), University of Bordeaux in collaboration with Dr. Franck 
Couillaud and Dr. Olivier Sandre.  A grant obtained from the EU-COST (European 
Cooperation in Science and Technology) TD 1402 Multifunctional Nanoparticles for 
Magnetic Hyperthermia and Indirect Radiation Therapy (RADIOMAG) facilitated this study. 
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6.1 Introduction 
In the previous chapter, the developed magnetic delivery system was tested for magnetic 
hyperthermia and drug delivery applications on two different human cancer cell lines. 
Overall, the MNCs developed in this work were found to have great potential for thermo-
chemotherapy applications and synergistic effects of combinatorial treatment were 
obtained under different conditions. Differences in cellular uptake of the MNCs, drug 
sensitivity and effects of the combined therapy were observed depending on the cell line 
studied, emphasising the importance to study each cell line individually. 
 
This chapter focuses on the suitability of the DOX-MNCs for the killing of another cell line 
by thermo-chemotherapy, a murine prostate cancer RM1 cell line model. This cell line was 
genetically modified to express the enzyme Firefly Luciferase, so that Luciferase activity could 
be used to evaluate the cell viability using the bioluminescence imaging method. The IC50 
values of DOX-MNCs were evaluated on the RM1 cell line for different incubation times. 
The effect of magnetic hyperthermia, chemotherapy and the combinatorial treatment was 
assessed using the same two different treatment methods as in the previous chapter so 
that the effect of nanoparticle internalisation and hyperthermia temperature in the 
synergistic effect of the combined therapy for the new cell line could be studied. While in 
chapter 5 magnetic hyperthermia was experimented on adherent cells in suspension due 
to restrictions linked to the MACH setup, in this chapter, a new device was used to subject 
the cells to magnetic hyperthermia that allowed for treatment directly on cell monolayers, 
the natural state of adherent cells. The application of magnetic hyperthermia directly on 
cell culture is more representative of the reality and can greatly enhance the assessment 
of hyperthermia and thermo-chemotherapy treatments. 
 
 
 
6.2 Bioluminescence imaging 
Bioluminescence, the production and emission of light by a living organism is a naturally 
occurring phenomenon. It is a form of chemiluminescence where the light is emitted as a 
result of a chemical reaction. Bioluminescence is a biological process that occurs widely 
in marine vertebrates and invertebrates and may be considered one of the most 
widespread form of communication on the planet. Bioluminescence also occurs in some 
funghi, microorganisms including bacteria, and invertebrates such as the firefly. The main 
chemical reaction responsible for the production of light involves the substrate luciferin and 
the enzyme luciferase. Luciferases are a wide range of enzymes that catalyse the 
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oxidation of luciferins in the presence of adenosine triphosphate, Mg2+ and oxygen. The 
oxidation reaction yields non-reactive oxyluciferin and the release of photons of light of 
dispersed wavelengths.347,348 
 
Bioluminescence imaging (BLI) is an optical imaging technique that is based on the 
sensitive detection of photons emitted during the bioluminescence reaction from 
bioreporter cells expressing luciferase. Currently, the firefly luciferase (LucF) and D-
luciferin are the most widely used luciferase and substrate for BLI.349 As of today, BLI has 
several limitations.350 Absolute quantification of the photons is usually not possible, and 
therefore simple quantification of light emission may not provide a true representation of 
the biological process studied. Indeed, the bioluminescent signal is dependent on several 
factors such as D-luciferin and co-factors availability, signal depth, and tissue absorption. 
Indeed, if the luciferin substrate and the co-factors are not abundantly present, light 
emission may not be a true representation of luciferase activity. Moreover, BLI is only a 
two-dimensional imaging technique, which can result in inaccurate deep tumour 
localisation. Finally, for transmission of light through animal tissue, there is approximately 
a 10-fold loss of photon intensity for each centimeter of tissue depth.351  
 
However, there are also many advantages to use LucF as a bioluminescent gene reporter. 
The inherent low background of bioluminescent markers as compared to fluorescent 
markers makes LucF a superior in vivo reporter.349 LucF light production has the highest 
quantum efficiency known for any chemiluminescent reaction endowing BLI a high 
sensitivity.352 The fast rate of LucF turnover in the presence of the D-luciferin substrate 
allows for real-time measurements, and the relationship between LucF concentration and 
photon emission in vitro is linear.353 The high sensitivity and the minimal background noise 
makes BLI an ideal technique for the detection of minor events in living animals. 
It is often used to study a wide range of molecular functions and ongoing biological 
processes in vivo, such as gene expression, cancer treatment, metastasis and disease 
progression.347,354 
 
LucF requires D-luciferin to be injected into the subject prior to imaging. The peak emission 
wavelength is about 560 nm. While the total amount of light emitted from bioluminescence 
is typically small and not detected by the human eye, an ultra-sensitive CCD camera can 
image bioluminescence (Figure 6.1). 
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Figure 6. 1 Examples of images obtained with the BLI method after subjecting cells 
genetically modified to express LucF to different treatments. 
 
 
6.3 Materials and methods 
6.3.1 Reagents 
Trypan blue solution (0.4%, sterile-filtered), was obtained from Sigma-Aldrich, France. 
Dulbecco’s phosphate buffered saline (DPBS, no calcium, no magnesium, sterile) and 
trypsin (0.5%, with ethylenediaminetetraacetic acid, sterile) were obtained from Gibco by 
Thermo Fisher Scientific. D-luciferin was obtained from Promega. 
 
Cell culture reagents: Dulbecco’s modified Eagle’s medium (DMEM, with 4.5 g/L D-
glucose, 0.11 g/L sodium pyruvate, L-glutamine, sterile), Fetal Bovine Serum (FBS, sterile-
filtered), and antibiotics Penicillin/Streptomycin (P/S, sterile) were obtained from Gibco by 
Thermo Fisher Scientific. Blasticidin was obtained from Euromedex. 
 
Unless stated, all reagents were used as purchased, without any further modifications. 
 
6.3.2 Cell culture media 
DMEM was supplemented with 1% penicillin/streptomycin used to prevent bacterial 
contamination of cell culture and 10% FBS. 
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6.3.3 Experimental methods 
6.3.3.1 In vitro hyperthermia of the magnetic nanocomposites 
Magnetic heating measurements were performed to assess the heating performances of 
the MNCs using the DM3 hyperthermia system (nB nanoscale Biomagnetics, Spain). 
Samples made of 0.5 mL of MNCs dispersed in water with a concentration of 3 mg/mL 
were placed in the middle of the coil and subjected to an AMF. The increase in temperature 
was continuously logged using fibres optic probes centred in the suspension. Two probes 
were used in order to limit possible errors coming from a non-homogeneous spatial heating 
of the suspension. The measurement was started when the temperature of the suspension 
was stabilised to room temperature, and the measurement time was limited to 10 min. 
Different frequency and field amplitude conditions were tested (Table 6.1), for each 
conditions the SAR and ILP were calculated. 
 
Table 6. 1 Frequencies and amplitudes of AMF used for heating measurements using the 
DM3 instrument. 
Frequency (kHz) 146 217 344.5 473.5 
Amplitude 
(kA/m) 
20 20 16 13 
 
6.3.3.2 Cell culture of RM1-CMV-LucF cell line 
The murine prostate carcinoma cell line genetically modified to express the Luciferase 
Firefly (LucF) RM1-CMV-LucF was cultured in 20 mL of complete DMEM medium in a T-
75 culture flask and incubated at 37 °C under 5% CO2 in a humidified atmosphere. When 
the cells reached 80% – 90% confluence, adherent cells were detached by trypsinization 
(see section 6.2.3.3) and seeded on a new tissue culture plate for subculture or used 
directly for experiments. 
 
6.3.3.3 Trypsinization of adherent cells 
The cell culture medium was discarded and the cell layer washed with DPBS. 2 mL of pre-
warmed trypsin at 37 °C was added to the cell layer. The culture flask was then returned 
to the incubator (37 °C, 5% CO2) for 3 min. To inactivate the trypsin, 8 mL of complete 
medium was added for a T-75 culture flask. The cells, now suspended in the medium, 
were centrifuged at 1200 rpm for 3 min to obtain a cell pellet. The supernatant was 
discarded and the cells were redispersed in 5 mL of fresh medium. The average number 
of viable cells in suspension was determined with the aid of a Malassez counting chamber 
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and the trypan blue exclusion method. The cell viability should be at least 90% for a healthy 
log-phase culture. After determining the number of cells/mL, the cells were either 
passaged and used directly for experiments, or returned to culture in a new culture flask 
with approximately 6.105 cells in 20 mL of complete medium for a T-75 flask. 20 µL of 
blasticidin at 10 mg/mL was added to the new culture flask. Blasticidin is an antibiotic often 
used in genetic engineering, to select transformed cells in a mammalian cell line that have 
been engineered to be blasticidin-resistant. Blasticidin has a fast mode of action causing 
rapid cell death at low antibiotic concentration by inhibiting termination step of translation 
and peptide bond formation by the ribosome. In this case, the cells that have been 
genetically modified to carry the resistance gene to blastidicin have also been engineered 
to carry the LucF gene. Therefore, blasticidin is used as a selection antibiotic, to make 
sure that only cells expressing the LucF gene grow in the new culture. 
 
6.3.3.4 Determination of the IC50 of DOX-MNCs in RM1-CMV-
LucF by bioluminescence imaging 
RM1-CMV-LucF cells were cultured as explained in section 6.2.3.2. After trypsinization, 
counting of the cells and confirmation that the cell viability was more than 90% by trypan 
blue exclusion as explained in section 6.2.3.3, cells suspended in 1 mL complete DMEM 
at a concentration of 2.5 104 cells/well were plated in 24 well, flat-bottomed culture plates. 
Cells were allowed to adhere and grow by incubation at 37 °C for 48 h before exposure to 
drug treatment. Briefly the medium was removed from each well, and the cells were 
exposed to 1 mL of complete DMEM containing various fixed concentration of DOX-MNCs 
for 24 h and 48 h at 37 °C in the 5% CO2 incubator. At the end of incubation, the cell 
viability was determined using the BLI method. Culture medium was removed and cells 
were rinsed with DPBS. Luciferase activity was used to evaluate the cell viability, by briefly 
adding 100 µL of D-luciferin solution in DPBS at 6.10-4 mol/L to each well. After 5 min of 
luciferin treatment, images were acquired by BLI using a IVIS Lumina LT (Perkin Elmer 
Inc., USA). The bioluminescence signal was analyzed using Living Image software. The 
percentage of viable cells for each concentration of DOX was determined based on the 
bioluminescence readings, and expressed as a percentage of the vehicle control. All 
assays were performed in triplicate. Data obtained were subject to median effect analysis 
using the CompuSyn® software to determine the half maximal inhibitory concentration 
values of DOX-MNCs on both RM1-CMV-LucF cell line for each incubation period. 
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6.3.3.5 In vitro anticancer studies by bioluminescence imaging 
For in vitro anticancer studies, the two same methods as in chapter 5 were employed: 
hyperthermia treatment after internalization of the nanoparticles in the cells and direct 
hyperthermia treatment. 
 
6.3.3.5.1 Treatment after internalization 
RM1-CMV-LucF cells were cultured, trypsinized and counted as explained in section 
6.3.3.2 and 6.3.3.3. Cells suspended in 3 mL of complete medium were seeded in 35 mm 
culture dish at a density of 100,000 cells/dish. Cells were incubated at 37 °C for 48 h before 
replacing the medium from each well with 3 mL of fresh complete DMEM only or containing 
MNCs or DOX-MNCs. The cells were then incubated for an additional 24 h at 37 °C. Six 
groups were formed: control- (media only, no AMF), control+ (media only, AMF), MNCs- 
(media containing MNCs, no AMF), MNCs+ (media containing MNCs, AMF), DOX-MNCs- 
(media containing DOX-MNCs, no AMF) and DOX-MNCs+ (media containing DOX-MNCs, 
AMF). Therefore, the group MNCs+ corresponds to hyperthermia treatment, DOX-MNCs- 
corresponds to chemotherapy treatment, and DOX-MNCs+ corresponds to thermo-
chemotherapy treatment. A nanoparticle concentration of 1 mg/mL was used for each 
group. After the 24 h incubation period, the three AMF positive groups (control+, MNCs+ 
and DOX-MNCs+ groups) were exposed to an AMF (H = 20.0 kA/m and f = 217 kHz) for 
30 min using the DM3 instrument. To that aim, the supernatant in each well was discarded 
and replaced with 2 mL of fresh complete DMEM to keep only the nanoparticles 
internalized or adsorbed on the cell surface. The cells in the three AMF negative groups 
(control-, MNCs- and DOX-MNCs- groups) were subjected to the same protocol, without 
being subjected to an AMF, in order to remove any environmental effect on cell death. 
After hyperthermia treatment, the cell culture dish was incubated at 37 °C for 24 h. At the 
end of incubation, the cell viability was determined using the BLI method. Culture medium 
was removed and cells were rinsed with DPBS. Luciferase activity was used to evaluate 
the cell viability, by briefly adding 1 mL of D-luciferin solution in DPBS at 6.10-4 mol/L to 
each well. 5 min post-luciferin treatment, images were acquired by BLI using a Lumina LT 
(Perkin Elmer Inc., USA). The bioluminescence signal was analyzed using Living Image 
software. The percentage of viable cells for each concentration of DOX was determined 
based on the bioluminescence readings, and expressed as a percentage of the vehicle 
control. Experiments were repeated at least three times. 
The combined effect of the thermo-chemotherapy treatment was evaluated by the 
Valeriote’s method as described previously in section 5.2.4.11.1.  
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6.3.3.5.2 Direct treatment 
RM1-CMV-LucF cells were cultured, trypsinized and counted as explained in section 
6.3.3.2 and 6.3.3.3. Cells suspended in 200 µL of complete medium were seeded in 16 
well, flat-bottomed culture plates, at a density of 2000 cells/well. These wells have the 
same size of the ones of 96 wells plate. These were chosen because they can fit in the 
DM3 setup and experiments can therefore be performed easily in triplicates. Cells were 
incubated at 37 °C for 48 h before replacing the medium from each well with 200 µL of 
fresh complete medium only or containing MNCs or DOX-MNCs. Again, six groups were 
formed as described in section 6.3.3.5.1. The concentration of nanoparticles in solution 
was chosen so that a temperature of 43 °C could be reached quickly (i.e. 0.5 mg/mL). The 
cells in culture plates were exposed to an AMF (f = 217 kHz) for 30 min using the DM3 
instrument and the temperature (either 42°C or 43°C) was adjusted by tuning the field 
amplitude H of the AMF. The field amplitude H started at 20.0 kA/m and decreased as 
appropriate to maintain the desired temperature. The cells in the three AMF negative 
groups (control-, MNCs- and DOX-MNCs- groups) were subjected to the same protocol, 
without being subjected to an AMF, in order to remove any environmental effect on cell 
death. After hyperthermia treatment, the cell culture plates were incubated at 37 °C for 24 
h. At the end of incubation, the cell viability was determined using the BLI method as 
described in section 6.3.3.5.1. Experiments were repeated at least three times. 
The combined effect of the thermo-chemotherapy treatment was evaluated by the 
Valeriote’s method as described previously in section 5.2.4.11.1.  
 
6.3.3.6 Statistical analysis 
Statistical analysis was performed using the Student’s t-test for unpaired data and the 
results are presented as mean ± standard deviations. Statistical significance was accepted 
at a level of p < 0.05. 
 
 
6.4 Results and discussion 
6.4.1 Magnetic heating measurements – DM3 
The field amplitude and frequency condition that gave the best heating potential were f = 
217 kHz and H = 20 kA/m, with a temperature increase from 22 °C to 55 °C in 10 min 
(Figure 6.2). It translates into a SAR of 280 W/g, equivalent to an ILP of 3 nHm²/kg. It is 
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worth noting that the Hf factor, here equal to 4.34 x 109 Am-1s-1 is below the limit 
recommended for safe application of an AMF of 5 x 109 Am-1s-1.65 
 
The staircase-like curve obtained is due to the DM3 software that did not save the 
temperature data with a decimal. This could not be fixed. 
 
 
Figure 6. 2 Typical heating curve of the MNCs dispersed in water with a concentration of 
3 mg/mL and subjected to an AMF (f = 217 kHz and H = 20.0 kA/m) using the DM3 instrument. 
 
6.4.2 Determination of the IC50 of DOX-MNCs in RM1-CMV-
LucF 
The concentration effect of DOX-MNCs as well as the exposure time on the cell viability 
were investigated by monitoring LucF activity at incubation time points of 24 h and 48 h. 
For each condition, the IC50 values were determined by constructing a dose-response 
curve according to the results obtained from the bioluminescence signal (Figure 6.3).  
 
 
Figure 6. 3 Dose response curves. Cell viability of RM1-CMV-LucF cells incubated with 
DOX concentrations DOX-MNCs for incubation period of 24 h and 48 h. 
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The cytotoxicity of the DOX-MNCs is dependent on concentration and exposure time, and 
increased with increasing DOX concentration and incubation period. The IC50 values after 
24 h and 48 h of incubation were found to be equivalent to a DOX concentration of 2.12 
µg/mL and 0.16 µg/mL, respectively. 
 
6.4.3 In vitro anticancer studies by bioluminescence 
imaging 
6.4.3.1 Initial considerations and preliminary experiments 
In this chapter, cell viability of a murine prostate carcinoma cell line genetically modified to 
express the luciferase firefly has been investigated by BLI. The two same methods of 
treatment as employed in Chapter 5 were also employed in this study: the direct treatment 
and treatment after internalization methods.  
 
In the previous chapter, the hyperthermia experiments had to be conducted on MCF-7 and 
U-87 cells suspended in their culture medium. Cells had to be detached before being 
subjected to the hyperthermia treatment and then taken back to culture to study the 
delayed response at different time point. This strategy was chosen because the MACH 
setup does not allow for a petri dish to be placed in the coil, however it may not reflect the 
complete cell response. The metabolism of live adherent cells can be altered when in 
suspension by changes in temperature, pH and cell aggregation in suspension. Thanks to 
the DM3 setup, it was possible to perform the hyperthermia treatment directly on cell 
monolayers. This is an important consideration as it is the natural state of adherent cells. 
Thus, the application of magnetic hyperthermia directly on cell culture is more 
representative and can greatly enhance the assessment of hyperthermia treatments. 
 
The same initials considerations as for U-87 and MCF-7 cells were made for RM1-CMV-
LucF cells. Experiments with a lower DOX concentration were performed by mixing the 
MNCs with DOX-MNCs to obtain the desired nanoparticle concentration and the desired 
DOX concentration. Using the IC50 values of DOX-MNCs for RM1-CMV-LucF cells 
obtained from the dose-response curves determined by the BLI method in section 6.4.3 a 
DOX concentration of 0.18 µg/mL was chosen for the current study. At this concentration, 
cell viability was shown to remain above 90% 24 h after the treatment. 
 
Preliminary experiments of hyperthermia, chemotherapy and the combined thermo-
chemotherapy at different hyperthermia temperature using the direct treatment methods 
were realised on RM1-CMV-LucF cells. These experiments revealed that mild 
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hyperthermia temperature of 42 °C was more efficient for the combined therapy than 
hyperthermia at 40 °C or 44 °C for this specific cell line. As a consequence, hyperthermia 
temperatures of 42 °C and 43 °C were studied in this chapter. 
 
6.4.3.2 In vitro anticancer studies, direct treatment and 
treatment after internalisation 
Hyperthermia, chemotherapy and the combined thermo-chemotherapy using the direct 
treatment and the treatment after internalisation were experimented on RM1-CMV-LucF 
cells. The concentration in DOX was kept constant at 0.18 µg/mL by mixing MNCs and 
DOX-MNCs (ratio 399:1 w/w and 199:1 w/w for the treatment after internalisation and for 
the direct treatment, respectively) to obtained the desired final concentration in DOX and 
in nanoparticles. The obtained cell viabilities 24 h after treatment are presented in Figure 
6.4. 
 
 
Figure 6. 4 Cell viabilities of RM1-CMV-LucF cells 24 h following A) treatment after 
internalisation with or without a 30 min exposure to an AMF (f = 217 kHz and H = 20.0 kA/m) 
and B) direct treatment with or without a 30 min exposure to an AMF (f = 217 kHz and H varies 
to maintain the desired temperature, Hmax = 20.0 kA/m) with media alone (control cells), MNCs 
or DOX-MNCs containing 0.18 µg of DOX. The asterisks refer to significant levels compared 
to the corresponding control experiment or the combined therapy; p < 0.05 (*), p < 0.01 (**) 
and p < 0.001 (***). 
 
The application of the AMF alone does not have any detrimental effect on the RM1-CMV-
LucF viability. For the treatment after internalisation, the relative cell viabilities 24 h after 
treatment were 65% (p < 0.01) for hyperthermia, 82% for chemotherapy and 44% (p < 
0.01) for thermo-chemotherapy. For the direct treatment, the relative cell viabilities 24 h 
after treatment were 93% for chemotherapy, 89% for hyperthermia and 57% (p < 0.01) for 
thermo-chemotherapy at 42 °C; 70% (p < 0.05) for hyperthermia and 26% (p < 0.001) for 
thermo-chemotherapy at 43 °C. 
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The RM1-CMV-LucF cell line is quite sensitive to heat released from nanoparticles 
internalised in the cells, as observed from the resulting cell viability of 65%, but is not too 
sensitive to the heating of the surrounding medium at temperature below 43 °C (cell 
viability of 89% 24 h after treatment at 42 °C). 
 
Cell viabilities obtained 48 h after the different treatments are not shown. Indeed, one 
major problem encountered working with the RM1 cell line was a very important cell 
detachment, especially at high confluency. As a consequence, this phenomenon 
happened in a greater extent for control cells or cells that were not affected by the received 
treatment, and bioluminescence intensity values obtained could not be trusted to represent 
accurate values of the cell viabilities. 
 
The cytotoxic effect of the combinatorial treatment achieved with the developed delivery 
system after cellular uptake of the nanoparticles was found superior to either hyperthermia 
(p < 0.05) or chemotherapy (p < 0.01) applied separately.  
 
For each hyperthermia temperature, the cytotoxic effect of the combinatorial treatment 
achieved with the developed delivery system using the direct treatment method was also 
found superior to each of the two treatments applied separately. 
 
For both methods, an evaluation using Valeriote’s formula showed that the combined 
effects were synergistic in nature (Table 6.2). 
 
Table 6. 2 Evaluation of the combined effects of the thermo-chemotherapy treatment after 
nanoparticle internalisation and of the direct thermo-chemotherapy treatment at different 
hyperthermia temperatures with 0.18 µg of DOX for RM1-CMV-LucF cell line according to 
Valeriote’s formula. 
  (A)*(B)/100 (%) (A+B) (%) Effect 
Treatment after 
internalisation 
/ 53 44 Synergistic 
Direct 
treatment 
42 °C 83 59 Synergistic 
43 °C 64 27 Synergistic 
 
 
6.5 Conclusion 
In summary, the heating performance of the MNCs were assessed again with the DM3 
machine and were found to yield an ILP of 3 nHm²/kg under the field conditions of f = 217 
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kHz and H = 20 kA/m. The IC50 values of the DOX-MNCs for the RM1-CMV-LucF cell line 
were evaluated for different incubation time before proceeding to the in vitro thermo-
chemotherapy experiments. 
 
Monitoring the luciferase activity by the BLI method was found to be a precise and simple 
tool for evaluation of the cell viability. Such as in chapter 5, cell death was found to be 
dependent on the method of treatment used. For both treatment methods, an evaluation 
using Valeriote’s formula showed that the combined effects were synergistic in nature. 
However, while for the two cell lines studied in chapter 5 the thermo-chemosensitisation 
effect using the direct treatment method was the highest at mild hyperthermia temperature 
of 40 °C, it was found for the RM1 cell line to be more effective at hyperthermia temperature 
of 43 °C. This finding highlights again the cell line dependency and emphasizes the 
necessity to study each cell line independently for a particular treatment. 
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CHAPTER 7  
CONCLUSIONS AND FUTURE WORK 
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CONCLUSION 
 
Superparamagnetic iron oxides are the most commonly used nanoparticles for 
applications in biomedicine, because of their numerous advantages, but their heating 
potential for hyperthermia applications is limited because of their low saturation 
magnetisation and magnetic anisotropy. Pure metal nanoparticles such as iron have the 
highest saturation magnetisation, but have limited use in biomedical applications due to 
their inherent toxicity and poor chemical stability, mainly their quick oxidation process. A 
core/shell structure can be adopted with an appropriate coating able to prevent oxidation 
of the metallic core. Gold has been one of the most popular metallic coating materials for 
iron owing to its chemical inertness that protect iron against oxidation and its 
biocompatibility.355 Similar to gold, bismuth is chemically inert and can be used as CT-
imaging agent. Bismuth even possesses a larger X-ray attenuation coefficient, has low 
toxicity and is less expensive. For those reasons, bismuth was chosen as a coating for 
iron nanoparticles. Thermal decomposition of iron precursors followed by reduction of 
bismuth precursors was chosen as a synthetic route. As desired, iron nanoparticles were 
found to be highly magnetic. However, this caused issues in the stabilization of the 
nanoparticles due to strong magnetic interactions between the nanoparticles. Observation 
of the obtained nanoparticles with TEM was greatly hindered due to the highly aggregated 
state of the particles and made the interpretation of the results challenging. The 
stabilization of the particles could only be addressed by a long and tedious post-synthetic 
process with several cycles of oleylamine addition, sonication and washing of the particles.  
After stabilization and observation of well-separated particles on a TEM grid, only one type 
of core/shell nanoparticles could be observed. However, due to the grain size obtained 
from XRD patterns, EDS analyses and elemental mapping of single particle, it was 
concluded that bismuth did not seem to nucleate on the surface of the already formed iron 
nanoparticle but rather grow as separate particles. The bismuth nanoparticles might have 
been lost in the stabilization process. Despite different attempts varying the synthetic 
conditions, the separated growth of bismuth could not be suppressed and the synthesis of 
core@shell Fe@Bi nanoparticles was found unsuccessful. 
 
As a consequence, core@shell Fe@Bi nanoparticles could not be used in the 
development of a magnetic nanocarrier for hyperthermia therapy and drug delivery 
applications. Iron oxide nanoparticles were chosen as substitute. Despite their lower 
saturation magnetisation, their ease of synthesis made them ideal candidates for 
investigation. Iron oxide nanoparticles were synthesised using a microwave-assisted co-
precipitation method. This highly reproducible synthesis yielded highly crystalline naked 
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IONPs that were subsequently functionalised with a thermo-responsive polymer. The 
nanoparticles were superparamagnetic at room temperature with a high average 
saturation magnetisation of 78 emu/g. The thermo-responsive polymer p(DEGMA-co-
PEGMA-b-[TMSPMA-co-VBA]), synthesized by RAFT polymerisation, was composed of 
four mains blocks each having a specific utility. The LCST, that could be tuned by varying 
the DEGMA:PEGMA molar ratio, was chosen around 40 °C to be above physiological 
temperature and easily reached via magnetic hyperthermia. Under appropriate conditions, 
the functionalisation of the nanoparticles resulted in highly stable aqueous suspensions 
exhibiting good heating performances with an ILP of 2.1 nHm²/K, 3.5 nHm²/K if only the 
mass of iron is considered.  
 
High encapsulation of the anticancer drug DOX in the MNCs was achieved through 
formation of heat- and acid-labile Schiff base bonds. The dual temperature-and pH-
responsive behaviour of the nanocarrier is an important feature that gives rise to spatial 
and temporal control over the release of the drug. High temperature and acidic pH were 
shown to act as triggers for the release of the drug. A burst release of the drug is achieved 
under application of an AMF and tumour acidic pH conditions, with almost 90% of drug 
being released after 1 h. At physiological pH and temperature, the amount of released 
drug is low; that is the DOX is correctly retained in the nanocarrier, which is desirable in 
clinical applications to limit distribution of the drug to healthy tissues and unwanted side 
effects. 
 
The developed MNCs were then used for in vitro experiments on human glioma U-87 and 
breast cancer MCF-7 cell line models to demonstrate their potential as thermo-chemo 
therapeutic agent for the treatment of cancer. The MNCs were found to be non-toxic to 
cells at concentration up to 1 mg/mL. The cellular uptake of the MNCs was dependent on 
the nanoparticle concentration and the cell line. This cell line dependency was reflected in 
the study of DOX-MNCs cytotoxicity. U-87 cells internalised the MNCs in a great extent, 
which resulted in a more acute cytotoxicity of DOX-MNCs towards U-87 cells compared to 
MCF-7 cells. Study of drug intracellular distribution revealed the quick accumulation in the 
cell nuclei of free DOX through permeation of cellular and nuclear membrane by passive 
diffusion. In contrast, DOX-MNCs were shown to be taken up by malignant cells through 
endocytosis, followed by some extent of drug release in the cytoplasm due to acidic pH of 
endosomes/lysosomes organelles and subsequent DOX diffusion to the nucleus. Such a 
delivery system is particularly interesting to overcome drug resistance in drug resistant 
cancer and to reduce the amount of available drug molecules present in the extracellular 
environment therefore reducing unwanted side effects. 
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For thermo-chemotherapy experiments, two different methods of treatment were studied. 
The direct treatment method involved subjecting the cells to an AMF immediately after 
putting the nanoparticles together with the cells. There is no time for cell uptake of the 
particles and consequently only nanoparticles in the extracellular environment participate 
to the hyperthermia treatment. The treatment after internalisation consists in incubating 
the cells in culture with the nanoparticles for 24 h, and then remove the nanoparticles in 
the extracellular environment by replacing the media with fresh media before subjecting 
the cells to an AMF. Only nanoparticles internalised in the cells are involved in the 
hyperthermia treatment. This experiment revealed that the MNCs retain their heating 
capability in some extent upon internalisation by the cells. For both methods, the 
combinatorial treatment was more effective than chemotherapy or magnetic hyperthermia 
as individual treatments.  
 
The method of treatment used was found to influence the resultant cell killing. For a cell 
line that internalized the MNCs in a great extent such as the U-87 cell line, the thermo-
chemotherapy applied through the treatment after internalisation method was found to be 
more effective, the combined effects were found to be synergistic in nature and an almost 
complete cell death was achieved. However, encouraging results were also obtained for 
the direct treatment method for both U-87 and MCF-7 cells. These findings demonstrate 
that it is not necessary for tumour cells to internalize the nanoparticles for an efficient 
therapy, but is preferable. The importance of the applied thermal dose was emphasized 
through the study of the direct thermo-chemotherapy treatment at different hyperthermia 
temperature. Both synergistic and sub-additive effects of the combined therapy were 
observed depending on the applied hyperthermia temperature. However, synergistic and 
sub-additive effects were found at different hyperthermia temperature depending on the 
cell line which again showed the necessity to study each cell line independently for a 
particular treatment. The mechanisms responsible for the synergistic effect of the 
combined therapy might be more or less triggered depending on whether nanoparticles 
have been internalized, the applied hyperthermia temperature and the cell line. The 
mechanisms responsible for the synergy of the combined therapy generally involve an 
inhibition of DNA repair, acceleration of the cytotoxic chemical reaction rate and an 
improve intracellular uptake of nanoparticles or drug molecules in heated tumour as 
compared to non-heated tissues. The latter seems to be particularly relevant in the case 
of the direct treatment. Finally, because the MNCs are pH- and thermo-sensitive, a 
maximized drug release is obtained when both stimuli are applied at the same time, and 
therefore a better synergism of the combined therapy. This is the case for internalised 
DOX-MNCs. Nonetheless, in vivo, tumour extracellular environment is often more acidic 
than normal tissue, with a pH ranging from 5.7 to 7.8,344 that would facilitate the release of 
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the drug from MNCs that have not been yet internalised, and subsequent quick 
accumulation of available released DOX molecules in the cell nuclei through cellular 
membrane diffusion. 
 
Finally, monitoring the luciferase activity using the BLI method was used for the evaluation 
of the cell viability of a third cell line, a murine prostate carcinoma RM1 cell line genetically 
modified to express the Luciferase Firefly. It was found to be a simple but precise and 
reliable tool for the study of cell death after magnetic hyperthermia, chemotherapy or the 
combined treatment. The assessment of hyperthermia and thermo-chemotherapy 
treatments was enhanced as compared to the study carried out in chapter 5, because 
hyperthermia treatment could be applied directly on cell monolayers. For both treatment 
methods, the combined effects were found to be synergistic in nature. 
 
To conclude, each cell line studied in this work was found to behave differently from one 
another and to respond differently to thermo-chemotherapy treatment, highlighting the 
necessity to study each cell line independently for a given treatment. However, the 
developed delivery system was shown to be an effective and promising tool for multi-modal 
cancer therapy, and especially for thermo-chemotherapy applications. Synergistic effects 
of the combinatorial treatment were observed for the three cell lines used in this work in 
almost every studied conditions. No matter the cell line, cell recovery 48 h after thermo-
chemotherapy treatment was never observed, which is important to avoid tumour 
recurrence. This study also highlighted the difference in cell death that can be obtained 
depending on the method of treatment adopted for application of magnetic hyperthermia 
and thermo-chemotherapy, i.e. whether nanoparticles are situated in the intracellular or 
extracellular environment. 
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FUTURE WORK 
 
The DOX-loaded dual pH- and thermo-responsive magnetic nanocarrier developed in this 
work as well as the in vitro studies constitute a step forward towards the generation of 
nanosystem that could be designed and envisioned for clinical applications. Next steps 
would involve more in depth in vitro studies such as cell death mechanisms (apoptosis or 
necrosis) depending on the method of treatment, chemotherapeutic and thermal dose 
applied. Investigating the effect of thermo-chemotherapy with the developed delivery 
system on a greater number of cell lines, including drug-resistance cell lines, would also 
be useful to provide a bank of results concerning both the response of a particular cell line 
to the combinatorial treatment and the compatibility of this particular developed delivery 
system for different type of cancer. Furthermore, it would be interesting to study and 
quantify the uptake of the MNCs by macrophages in order to evaluate whether the MNCs 
would be rapidly cleared by the reticulo-endothelial system or have a long blood circulation 
time. 
 
Moreover, because in vitro studies showed the cell line dependency of cellular uptake of 
the non-targeted MNCs, and their different behaviour in response to thermo-chemotherapy 
treatment, further surface functionalisation of the MNCs for active targeting, improved 
specificity and therapeutic response with specific ligands or antibodies would be highly 
desirable. The carboxylic end group of the polymer offers an excellent platform for further 
functionalisation with targeting moieties. 
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Appendix I: Publications and participation to conferences 
 
Publications 
 
 
- A. Hervault and NTK. Thanh, Magnetic nanoparticle-based therapeutic agents for 
thermo-chemotherapy treatment of cancer, Nanoscale, 2014, 6, 11553-11573. 
Invited Featured article 
 
- R. Hachani, M. Lowdell, M. Birchall, A. Hervault, D. Mertz, S. Bégin-Colin and NTK. 
Thanh, Polyol synthesis, functionalisation and biocompatibility studies of 
superparamagnetic iron oxide nanoparticles as potential MRI agents, Nanoscale, 
2016, 8, 3278-3287. 
 
- A. Hervault, A.E. Dunn, M. Lim, C. Boyer, D. Mott, S. Maenosono and NTK. Thanh, 
Doxorubicin loaded dual pH- and thermo-responsive magnetic nanocarrier for 
combined magnetic hyperthermia and targeted controlled drug delivery 
applications, Nanoscale, 2016, 8, 12152-12161. Cover paper 
 
 
 
 
 
 
 
Conferences 
 
 
- July 2014, UK colloids 2014, London (UK), attendance only 
 
 
- September 2014, Faraday Discussion 175: Physical chemistry of functionalised 
biomedical nanoparticles, Bristol (UK). Poster presented by A. Hervault: 
A. Hervault and N.T.K. Thanh, Functionalisation and characterisation of 
magnetic nanoparticles for applications in thermo-chemotherapy of cancer. 
 
 
- March 2015, The 95th annual meeting 2015 of Chemical Society of Japan, Tokyo 
(Japan). Talk presented by A. Hervault: 
A. Hervault, M. Lim, A. Dunn, C. Boyer, T. Taniike, D. Mott, S. Maenosono 
and N.T.K. Thanh, Functionalisation and characterisation of magnetic 
nanoparticles for applications in thermo-chemotherapy of cancer. 
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- September 2015, CSEJ 47th spring meeting, Kagoshima (Japan). Talk presented 
by A. Hervault: 
A. Hervault, M. Lim, A. Dunn, C. Boyer, T. Taniike, D. Mott, S. Maenosono and 
N.T.K. Thanh, Development of a dual pH- and thermo-responsive magnetic 
nanocarrier for application in thermo-chemotherapy of cancer. 
 
 
 
- November 2015, 2015 EU-Japan collaborative workshop on Next-Generation 
Nanomagnetic Medicine, Kanazawa (Japan). Talk presented by A. Hervault: 
A. Hervault, M. Lim, A. Dunn, C. Boyer, T. Taniike, D. Mott, S. Maenosono and 
N.T.K. Thanh, Doxorubicin loaded dual pH- and thermo-responsive magnetic 
nanocarrier for application in thermo-chemotherapy of cancer. 
 
 
 
- December 2015, PACIFICHEM The international chemical congress of Pacific 
Basin Societies 2015, Honolulu (Hawaii, USA). Talk and poster presented by A. 
Hervault: 
A. A. Hervault, M. Lim, A. Dunn, C. Boyer, T. Taniike, D. Mott, S. Maenosono 
and N.T.K. Thanh, Development of a dual pH- and thermo-responsive 
magnetic nanocarrier for application in thermo-chemotherapy of cancer 
(talk). 
B. A. Hervault, M. Lim, A. Dunn, C. Boyer, T. Taniike, D. Mott, S. Maenosono 
and N.T.K. Thanh, Synthesis and characterization of a composite magnetic 
nanosystem for application in thermo-chemotherapy of cancer (poster). 
 
 
- April 2016, EU COST Meeting, Synthesis and functionalisation of magnetic 
nanoparticles for magnetic hyperthermia and radiotherapy, London, (UK). Talk 
presented by A. Hervault: 
A. Hervault, M. Lim, A. Dunn, C. Boyer, T. Taniike, D. Mott, S. Maenosono and 
N.T.K. Thanh, pH- and thermo-responsive magnetic nanocarrier for thermo-
chemotherapy of cancer. 
 
 
- May 2016, 2016 EU-Japan collaborative research on Next Generation 
Nanomagnetic Medicine, London (UK). Attendance only. 
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- June 2016, The 11th International Conference on the Scientific and Clinical 
Applications of Magnetic Carriers, Vancouver (Canada). Talk presented by A. 
Hervault: 
A. Hervault, M. Lim, A. Dunn, C. Boyer, T. Taniike, D. Mott, S. Maenosono and 
N.T.K. Thanh, Doxorubicin-loaded dual pH- and thermo-responsive magnetic 
nanocarrier for combined hyperthermia and controlled drug delivery 
applications. 
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